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Abstract 
 
The importance of inflammation in cancer is well established, with 
cytokines/chemokines playing an important role in carcinogenesis. IL-33 was recently 
identified as the ligand for ST2. ST2 is a member of the toll-like receptor/IL-1 receptor 
family. Three isoforms of ST2 exist: a trans-membrane receptor (ST2L), a secreted 
soluble form (sST2), and a variant form (ST2V). The IL-33/ST2 pathway has been 
implicated in inflammatory bowel disease, a major risk factor for colon cancer. The aim 
of the first part of my thesis was to investigate the role of IL-33 and ST2 in colon 
cancer. CT26 and HT29 colon cancer cells were found to express ST2 and IL-33 in 
vitro, with expression increased by inflammatory mediators (LPS, TNF-α and PGE2). 
Stimulation with IL-33 increased the migration, but not proliferation, of colon tumour 
cells. Functional analyses showed that stimulation with IL-33 induced the expression of 
CXCL-1 by CT26 and CCL2 expression by HT29 cells. To investigate the role of ST2 
in vivo, ST2 knockdown cells were generated using ST2-specific shRNA (CT26 
ST2shRNA
) and injected subcutaneously into BALB/C mice. Knockdown of ST2 in colon 
tumours resulted in enhanced tumour growth (2.3 fold increase compared to CT26 
scrshRNA
) in vivo. This was associated with alterations in immune cell infiltration, 
including an increase in macrophage infiltration. In contrast, characterisation of human 
colon tumours revealed that ST2L expression was increased in tumour cells relative to 
adjacent non-tumour cells, with no change in expression of total ST2. These results 
indicate that the IL-33/ST2 signalling axis may play an important role in colon 
carcinogenesis and merits further investigation.  
The role of the IL-36R, a second IL-1R family member, in colon cancer was 
investigated in the second part of my thesis. Characterization of human colon tumours 
x 
 
ex vivo showed significantly increased expression of the IL-36 ligands, IL-36α and IL-
36γ, compared to adjacent non-tumour tissue. In vitro colon cancer cell lines HT29 and 
SW480 were shown to express the IL-36R and IL-36 ligands. IL-36α and IL-36γ 
stimulation of HT29 cells also increased the expression of the chemokines CXCL-1, 
CCL2, CCL20, and IL-8. This suggests that IL-36 signalling may promote tumour-
derived immune cell recruitment. This field requires further study to determine if the 
recruitment of immune cells by IL-36 signalling could be utilised to break tolerance 
against tumour antigens. This thesis has laid the basis for further studies to explore the 
role of IL-36 signalling in colon cancer.  
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1.0 Introduction 
 
1.1 Cancer  
Carcinogenesis is a multi-step process that develops through epigenetic changes and 
mutation of multiple genes, including loss of function of tumour suppressor genes 
and gain of function of oncogenes. These genetic changes in normal cells can each 
contribute a growth advantage, leading to the transformation of cells into cancer cells 
[1]. In 2000, Hanahan and Weinberg described a series of 6 biological capabilities or 
‘hallmarks’ acquired by most types of cancers during the multi-step development of 
cancer  (Figure 1). They are as follows; ‘sustaining proliferative signalling’, ‘evading 
growth suppressors’, ‘activating invasion and metastasis’, ‘inducing angiogenesis’, 
‘resisting cell death’ and ‘enabling replicative immortality’ [2]. 
In 2011, Hanahan and Weinberg went on to describe two additional ‘hallmarks’ of 
cancer. These were ‘deregulating cellular energetics’ and ‘avoiding immune 
destruction’ (Figure 1). Acquisition of these capabilities is enabled by genomic 
instability, that is important for the generation of the genetic diversity that promotes 
their acquisition [3]. As well as genetic instability, a second enabling characteristic is 
tumour-promoting inflammation, which refers to the ability of the tumour to harness 
the inflammatory response to promote tumorigenesis. 
 
1.1.1 Colon cancer 
 
Adenocarcinoma of the colon and rectum (colorectal cancer (CRC)) is the third most 
common cancer worldwide, with over 1.4 million people diagnosed each year [4]. 1 
in 5 CRCs have a familial or congenital gene mutation that compounds colon cancer  
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Figure 1: The ‘hallmarks’ of cancer. The hallmarks of cancer are biological 
functions acquired during the development of tumours. They include; sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis and activating invasion and 
metastasis. The two most recently described hallmarks of cancer are reprogramming 
of energy metabolism and evading immune destruction. Enabling characteristics 
such as genomic instability allow cancer cells to generate mutations that enhance 
tumour progression. The immune response used to protect against pathogenic insult 
can facilitate tumour promotion by activating proliferation and metastasis. Figure 
adapted from D Hanahan and R. Weinberg, Hallmarks of cancer: the next 
generation, Cell 2011. 
 
Evading 
Growth 
suppressors 
 
 
Sustaining 
proliferative 
signalling 
 
 
Inducing 
angiogenesis 
 
 
 
Activating 
invasion & 
metastasis 
 
 Replicative 
immortality 
 
 
 
Resisting cell 
 death 
 Genome 
instability and 
mutation 
  
 
Tumour- 
promoting 
Inflammation 
 
Avoiding immune 
destruction 
 
 
Deregulating 
cellular 
 energetics 
 
3 
 
risk and these cancers usually become established at a young age. Hereditary non-
polyposis colorectal cancer (HNPCC) accounts for approximately 5% of these cases 
and familial adenomatous polyposis (FAP) accounts for ~1%. The genetic mutations 
responsible for these two conditions lie in the mismatch repair genes and in the 
adenomatous polyposis coli (APC) gene, respectively. The remaining ~80% are 
sporadic, with no clear genetic origin. They usually occur at an advanced age. This 
suggests that environmental factors may cause genetic mutations that accrue over 
time.  
The risk of developing cancer depends on many factors. Those with a parent, sibling 
or child with the disease have a 2-fold increased risk of developing the disease [5]. 
Other risk factors include family history, increasing age, the presence of colonic 
polyps, inflammatory bowel disease (IBD) and a previous history of colon, ovarian 
or breast cancer. Environmental factors such as smoking, alcohol, viral exposure, 
exogenous oestrogens, a low fibre diet and physical inactivity have also been 
identified as important risk factors for developing colon cancer.  
1.1.2 Colon cancer development 
Colon cancer development normally follows a measured gradient process, in which 
various genetic mutations gradually accumulate over time, inducing the 
transformation of healthy cells into cancerous cells. In the majority of cases, this 
malignant disease begins as a benign adenomatous polyp, which then develops into 
an advanced adenoma with high grade dysplasia. This is followed by progression to 
carcinoma and ultimately to metastasis (Figure 2). This process normally takes  
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Initially, small adenomas form. Once severe dysplasia occurs, this marks the progression 
from early to late adenoma. The next sequential step is the progression from late adenoma 
to malignant carcinoma. During this transition increased vascularization and recruitment of 
immune cell populations are observed. This is followed by metastasis. Common alterations 
in genes and pathways associated with each stage of the transformation of normal 
epithelium to carcinoma are illustrated.  
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decades (Figure 2) [6]. Different genetic mutations have been shown to be associated 
with the various stages of colon cancer development (Figure 2). One of the earliest 
changes associated with CRC development is inactivation of the adenomatous 
polyposis coli (APC) tumour suppressor gene. APC is inactivated in the majority of 
sporadic CRCs, and is the genetic mutation responsible for colon tumour 
development in FAP [7]. Silencing of APC drives genomic instability and promotes 
cell growth as the cells are no longer bound by normal cell cycle checkpoints [8]. In 
many cancers, the RAS-GTPase family proto-oncogene K-RAS also becomes 
activated. This is usually linked with the transition from early to intermediate 
adenoma. The gene called deleted in colon cancer (DCC) can also be lost. This 
commonly occurs in the transition from intermediate adenoma to late adenoma. 
Mutations of the tumour suppressor p53 are associated with the development of 
carcinoma. Loss of chromosome 8p is associated with carcinoma to metastasis 
transition [9]. Other genes or pathways that are frequently mutated in CRC include 
the cyclooxygenase (COX) signalling pathway, the signal transducer 
phosphatidylinositol 3-kinase (PI3K), the Wnt/beta-catenin signal transduction 
pathway and the transforming growth factor (TGF)-β-signalling pathway [10-12].  
1.1.3 CRC Staging 
 
Clinical staging of CRC is used to determine the extent of the cancer and involves 
the use of the Tumour/Node/Metastasis (TNM) staging system. The TNM system 
classifies the stages of colon cancer under the following headings: T-the degree of 
invasion of the intestinal wall; N-the degree of lymphatic node involvement; and M-
the degree of metastasis. Stage I refers to CRCs confined to the mucosa or indicates 
lymph node metastasis and stage IV cancers are those that have metastasized to 
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distant organs. The liver and the lung are the two most common sites of CRC 
metastasis [13].  
1.1.4 CRC Treatment 
 
 Surgery alone is used to treat individuals with stage I or stage II CRC. Radiation 
therapy or chemotherapy may be recommended in stage III post-surgery. Most 
commonly 5-Fluorouracil (5-FU), lucovorin and oxaliplatin combined, or 
cappecitabine and oxaliplatin combined chemotherapy regimens are employed. In 
stage IV disease, chemotherapy may be employed pre-surgery to shrink tumours and 
also post-surgery to remove any remaining cancer cells not removed by surgery. At 
this stage, targeted therapies may be employed alone or in combination with the 
previously mentioned chemotherapy regimens. Targeted therapies include 
Cetuximab and Regorafenib which target the EGFR and VEGFR respectively. 
Radiation therapy is also used in Stage IV to relieve symptoms [14]. The 5-year 
survival rate for patients with stage I colon cancer is approximately 92% and this 
drops dramatically to ~11% for patients with state IV or metastatic disease [15].  
1.2 Inflammation and cancer 
 
The link between inflammation and cancer is well established, with inflammation 
highlighted as one of the enabling characteristics in cancer development [3]. As early 
as 1863, Virchow indicated that cancer tended to occur at sites of chronic 
inflammation. Indeed many cancers are associated with chronic inflammation. 
Patients with chronic hepatitis caused by Hepatitis B and C infection are at increased 
risk of developing hepatocellular carcinoma [16], while infection with human 
papilloma virus (HPV) is linked to the development of cervical cancer [17, 18]. In 
the colon, inflammatory bowel disease (IBD)-associated inflammation increases the 
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risk of developing CRC [19]. Inflammatory bowel diseases (IBDs) are inflammatory 
disorders of the gastrointestinal tract that can be subdivided into two major 
disorders: ulcerative colitis (UC) and Crohn’s disease (CD). Indeed, the extent and 
the duration of UC was found to directly correlate with the risk of CRC development 
[20]. Mortality is also increased in patients who develop CRC following UC [21], 
suggesting that the inflammatory processes observed in this disease may result in a 
more aggressive tumour phenotype.  
1.2.1 The Inflammatory component of tumours 
 
Tumours are composed of both tumour cells and non-tumour cells, with the tumour 
microenvironment describing the non-cancerous cells present in the tumour. In this 
microenvironment tumour cells interact with surrounding cells, including cancer-
associated fibroblasts, endothelial cells, adipocytes and immune cells. Immune cells 
present in the tumour microenvironment have been shown to have wide ranging 
effects. They can influence cellular proliferation signals, angiogenesis and tissue 
remodelling in ways that can either promote or suppress tumour progression (Figure 
3) [22].  
Immune cells are recruited into the tumour microenvironment by soluble chemo-
attractants produced by cancer cells and stromal cells [23-25]. Chemokines are small 
(8-11 kDa), secreted proteins that regulate the number and the phenotype of immune 
cells recruited by tumours. However, chemokines can also be exploited by the 
tumour to promote tumour growth, survival, angiogenesis and tumour cell migration 
[26, 27]. For instance, the chemokine CXCL1 can function as both a growth factor  
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Figure 3: Tumour-infiltrating immune cells and tumorigenesis. Upon 
recruitment to tumours, immune cells are exposed to various tumour- or immune-
derived factors. These factors can skew the function of the immune cell towards an 
anti-tumour or pro-tumour response. Immune cells associated with pro-tumour 
activities include M2 macrophages, N2 neutrophils, myeloid-derived suppressor 
cells (MDSCs) and T-reg cells. Immune cells associated with tumour rejection 
include M1 macrophages and N1 neutrophils. Anti-tumour activity is also displayed 
by various lymphocyte subsets, such as NK cells, CD8
+ 
T cells, γδ1 T cells and Th1 
cells. These leukocytes are usually cytotoxic and produce cytokines that can 
promote tumour rejection. 
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for cancer cells and as an angiogenic factor that regulates angiogenesis, which is 
critical for tumour growth and progression [28, 29]. 
Cytokines are low molecular weight protein mediators that facilitate cell-to-cell 
communication. Multiple cell types in the tumour microenvironment express these 
inflammatory mediators, including immune cells and stromal cells such as 
fibroblasts and endothelial cells. Cytokines perform numerous functions including 
the regulation of cellular proliferation, migration and cell death as well as immune 
cell activation.  Depending on the tumour microenvironment, cytokines can promote 
a pro- or anti-tumour immune response. This is dependent on a number of factors, 
including the balance of pro- and anti-inflammatory cytokines, their comparative 
concentrations and cytokine receptor expression by the immune cells [30].  
1.2.2 Tumour associated macrophages  
 
Macrophages are key components of the immune infiltrate found in tumours [31]. 
Two main macrophage phenotypes have been identified (Figure 4) [32]. Classically 
activated M1 macrophages are regarded as anti-tumorigenic, while M2 macrophages 
are pro-tumorigenic (Figure 4) [33, 34]. M1 macrophages can stimulate an anti-
tumour immune response via production of pro-inflammatory cytokines such as IL-
12, IL-23 and TNFα [35]. M2 macrophages promote an immunosuppressive 
microenvironment  by production of cytokines such as IL-10, can be 
immunosuppressive and inhibit the activity of Th1 cells and NK cells [36]. 
Moreover, this immune suppressed environment can be exploited by the tumour to 
invade surrounding tissue and metastasize to distant organs [37]. M1 and M2 
chemokine profiles can vary significantly, resulting in the recruitment of distinct 
immune cells. M1 macrophages are known to chiefly produce CXCL9 and CXCL10,  
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Figure 4: M1 versus M2 macrophages in tumorigenesis. Upon recruitment to the 
tumour, macrophages are exposed to factors derived from the tumour 
microenvironment that can skew their function. TAMs polarized towards an M1 
phenotype play a vital role in tumour rejection, while TAMs polarized towards an M2 
phenotype can drive tumour progression. M1 macrophages stimulate a tumour 
suppressing response via production of immunosuppressive cytokines, such as IL-1, 
IL-12 and TNFα. M2 macrophages activate a tumour promoting response by 
promoting angiogenesis, metastasis and invasion via a Th2 response. M2-polarized 
macrophages also produce potent pro-survival molecules. These molecules regulate 
gene expression in neoplastic cells by altering cell-cycle progression and increasing 
tumour cell survival. Together these processes circumvent immuno-surveillance and 
tumour-reactive immunity. 
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which are chemotactic factors for T-helper 1 (Th1) and cytotoxic T-cells (CTLs), 
while M2 macrophages mainly secrete CCL17 and CCL22, which recruit regulatory 
T cells (T-reg) and T-helper type (Th2) subsets [38, 39]. Studies have shown that 
tumour associate macrophages (TAMs) are phenotypically more like M2 
macrophages [40, 41]. M2 TAMs can contribute to tumorigenesis through several 
mechanisms, such as release of PGE2 and IL-10 which suppresses the anti-tumour 
immune response [42]. Alternatively activated TAMs facilitate tumour growth by 
secreting pro-angiogenic factors [43]. Although TAMs are predominantly associated 
with poor prognosis in many cancers, the role of TAMs in CRC still remains unclear. 
Indeed, numerous studies have shown that TAMs can positively influence CRC 
patient survival [44-46].  
1.2.3 Tumour associated Neutrophils 
 
Although not as well studied as TAMs, tumour associated neutrophils (TANs) can 
have either a pro-tumorigenic (N1) or an anti-tumorigenic (N2) phenotype.  N1 
neutrophils are cytotoxic to tumour cells and express increased levels of the pro-
inflammatory cytokines IL-12, VEGF, TNF-α, and IL-1β [199]. N1 TANS also 
produce tumouricidal factors such as proteases [47], while N2-neutrophils secrete 
arginase to suppress T cell effector functions, comparable to M2 like TAMs. N2 
TANS can also influence angiogenesis [48] through the production of mediators 
such as oncostatin M, which stimulate the production of  VEGF by malignant cells 
[49].  
1.2.4 Myeloid-derived suppressor cells 
 
Myeloid-derived suppressor cells (MDSCs) are CD11b
+
Gr1
+
 immature myeloid cells 
that have been shown to be capable of suppressing immune responses. In addition, 
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these cells become pathologically activated and can directly support tumour 
progression. MDSCs suppress immune function in a number of ways including the 
expression of arginase, inducible NOS (iNOS) and COX2 [50]. 
 
1.2.5 Tumour infiltrating lymphocytes  
 
Low numbers of lymphocytes are found in tumours, these cells predominantly 
localize to the invasive margin [51]. T cells can express either CD8 glycoprotein and 
are called CD8
+
 T cells (cytotoxic) or CD4 glycoprotein and are called CD4 cells, 
but are also known as T helper (Th) cells. The two main subsets of CD4
+
 cells are 
Th1 and Th2 cells. These cells differ in their cytokine secretion patterns and 
functions [52]. Th1 cells are involved in the maturation of B cells and the activation 
of macrophages. Th2 cells play a key role in immunological tolerance [53]. Although 
both CD4
+
 and CD8
+
 T cells can infiltrate tumours, CD4
+
 T-cells are unable to 
recognise cancer cells directly [54], as opposed to CD8
+
 T cells, which can directly 
kill cancer cells. Indeed, intraepithelial CD8
+
 TILs were found to be a positive 
predictor of survival in CRC [55, 56]. Similarly low CD8
+
 T cell infiltration is 
indicative of therapy resistance and poor prognosis in many human malignancies 
[57, 58].  
1.2.6 Regulatory T cells 
 
Regulatory T cells (T-regs) are CD4
+
CD25
+
Foxp3
+
 cells involved in maintaining 
self-tolerance [59]. One of the ways in which they promote immune suppression in 
CRC is through production of TGF-β and IL-10. [60]. TGF-β can directly suppress 
effector T cell signalling [61]. However, the role of T reg cells in CRC is 
13 
 
controversial as numerous studies have shown that increased T reg cells are 
indicative of an improved prognosis [60, 62]. 
1.2.7 Natural killer cells 
 
Natural killer (NK) cells are cytotoxic cells that target and kill both virally infected 
cells and cancer cells [63]. NK cells initiate the innate immune response [64] and can 
promote powerful anti-tumour cytotoxicity in vitro. Their cytotoxicity is dependent 
on the level of activation of the NK cells by the presence of surface markers, as 
tumours express both activating and inhibiting receptors [65]. Transformed cells may 
express reduced levels of MHC class I molecules in combination with other ligands. 
This enables them to evade being targeted by CD8
+
 T cells and CTLs. However, this 
makes them more vulnerable to attack by NK cells [66].  
1.3 The IL-1 cytokine 
 
The cytokine, IL-1, has been the subject of copious research since it was first 
identified. This pro-inflammatory cytokine is known to play a dichotomous role in 
disease by inducing pathogenesis of auto-inflammatory disorders, while 
simultaneously defending against invading pathogens [67]. IL-1 is implicated in the 
development of numerous inflammatory diseases including ulcerative colitis [68]. 
This has resulted in the mechanism behind IL-1 signalling becoming the subject of 
much interest. Likewise, novel members of both the IL-1 family of cytokines and the 
IL-1 receptor (IL-1R) family are also the focus of intense research in order to 
determine their involvement in the host response to disease. I will now discuss these 
cytokines and receptors in more detail, focusing specifically on the IL-33/ST2 and 
IL-36/ IL-36R pathways as these are the subject of this thesis.  
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1.3.1 IL-1 and IL-1R family members 
 
The IL-1R/ toll-like receptor (TLR) superfamily consists of two subgroups: the IL-
1R family whose members contain three extracellular immunoglobulin domains (Ig) 
and the Toll-like receptor subgroup whose members contain extracellular leucine-
rich repeats. All family members share a similar intracellular Toll-IL1R (TIR) 
domain, which is required for binding of adaptor proteins. The IL-1 family is divided 
into three subfamilies based on the length of the N-terminal domain (Table 1). The 
IL-1 subfamily consists of IL-1α, IL-1β, IL-1Ra and IL-33. The IL-18 subfamily is 
composed of IL-18 and IL-37, and finally the IL-36 subfamily contains IL-36α, IL-
36β, IL-36γ, IL-36RN and IL-38.   
The IL-1R family members are as follows; the type I IL-1 receptor (IL-1R1) [69], 
which binds IL-1α and IL-1β and was the first member of the family to be identified, 
the type II IL-1 receptor (IL-1R2) which is a decoy receptor [70], ST2 (IL-1RL1) 
which binds IL-33 [71-74], and the IL-1Rrp2 (IL-36R), which binds three agonistic 
ligands, IL-36α, IL-36β and IL-36γ (Figure 5) [75]. Other IL-1R family members 
include the IL-1 receptor accessory protein (IL-1RAcP) [76], which acts as a co-
receptor for IL-1R, ST2 and IL-36R, the IL-18 receptor (IL-18Rα) [77, 78] and its 
accessory protein (IL-18Rβ), and TIGIRR-2 (IL-1 receptor accessory protein like) 
[79, 80] and the three Ig domain-containing IL-1 receptor-related (TIGIRR-1) [79, 
81] . Single Ig-domain containing Il-1 receptor related (SIGIRR) [82] is also a family 
member although it only possesses one Ig-domain extracellularly, similar to the IL- 
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Previously 
 called 
Name Receptor/ 
coreceptor 
Property Synthesized as 
precursor 
Processing 
required 
for activity 
IL-1F1 IL-1α IL-1R1/ 
IL-1RAcP 
Proinflammatory Yes No 
IL-1F2 IL-1β IL-1R1/ 
IL-1RAcP 
Proinflammatory Yes Yes 
IL-1F3 IL-1Ra IL-1R1 Antagonist for IL-
1α,β 
No No 
IL-1F4 IL-18 IL-18α/ 
IL-18β 
Proinflammatory Yes Yes 
IL-1F5 IL-
36Ra 
IL-1Rrp2 Antagonist for IL-
36 
Yes Yes 
IL-1F6 IL-36α IL-1Rrp2/ 
IL-1RAcP 
Proinflammatory Yes Yes 
IL-1F7 IL-37 IL-18Rα,IL-
18BP 
Anti-inflammatory Yes Yes 
IL-1F8 IL-36β IL-1Rrp2/ 
IL-1RAcP 
Proinflammatory Yes Yes 
IL-1F9 IL-36γ IL-1Rrp2/ 
IL-1RAcP 
Proinflammatory Yes Yes 
IL-1F10 IL-38 IL-1Rrp2 ?Antagonist Yes ?No 
IL-1F11 IL-33 ST2/IL-
1RAcP 
Proinflammatory Yes No 
 
 
 
 
 
 
Table 1: IL-1 family ligands and receptors The IL-1 family is divided into three 
subfamilies based on the length of the N-terminal pro-pieces. The IL-1 subfamily 
shown in green consists of IL-1α, IL-1β, IL-1Ra and IL-33. The IL-18 subfamily is 
composed of IL-18 and IL-37 shown in blue, and finally the IL-36 subfamily contains 
IL-36α, IL-36β, IL-36γ, IL-36Ra and IL-38 (purple). The TIR domain of each 
receptor chain comes together and recruits MyD88. IL-36Ra binds to IL-1Rrp2 but 
fails to form a complex with IL-1RAcP. Thus, IL-36Ra prevents the binding of IL-
36α, IL-36β, or IL-36γ to IL-1Rrp2, and thus is the natural IL-36R antagonist. 
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18BP  [83]. SIGIRR is considered an orphan receptor, and it also has regulatory 
activity [84].The IL-1 family of cytokines share a core tetrahedron-like structure 
composed of 12 β-strands [85]. This family consists of 11 members, of which seven 
are agonistic (i.e. IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, and IL-36γ) and four 
are antagonistic (IL1Ra, IL-36Ra, IL-37 and IL-38). The genes encoding the IL-1 
family cytokines cluster on human chromosome 2, with the exception of IL-33 and 
IL-18, which are located on chromosome 9 and 11, respectively [86]. IL-1 family 
members form heterodimeric transmembrane receptor complexes and trigger 
signalling pathways that include the adaptor molecule MYD88, IRAK kinase family 
members and the ubiquitin ligase TRAF6. 
1.3.2 IL-1R family signalling 
 
The receptor complex for each IL-1 family cytokine is a heterodimer with a specific 
receptor and a common subunit, usually the IL-1RAcP. Once the complex is formed, 
following interaction with its cognate ligand, the TIR domain of each receptor chain 
come together and recruit MyD88, followed by phosphorylation of IL-1R–associated 
kinases (IRAKs) and activation of TRAF6 (Figure 5). This pathway diverges to 
activate mitogen activated protein kinases (MAPKs) such as ERK, JNK and p38 or 
to activate TAK1, which subsequently results in the translocation of NF-κB to the 
nucleus. However, not all IL-1 family receptors activate these pathways; e.g. 
SIGIRR is an inhibitory receptor, inhibiting IL-1, IL-18 and IL-33 signalling [87].  
1.3.3 IL-1α, IL-1β and the IL-1R complex 
 
The IL-1R1 is the best characterised receptor in the IL-1R superfamily. This 80kDa 
glycoprotein binds the agonists IL-1α and IL-1β, which have similar biological 
properties. However, there are some differences between these cytokines. The IL-1α  
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Figure 5: IL-1R family signalling activates MAPK and NF-κB. The IL-1 
subfamily consists of IL-1α, IL-β, IL-1Ra, and IL-33. The IL-18 subfamily is 
composed of IL-18 and IL-37. While IL-36α, IL-36β, IL-36γ, IL-36Ra and IL-38 all 
belong to the IL-36 subfamily. The receptor for each IL-1 family cytokine is a 
heterodimer composed of a specific receptor and a common co-receptor. The TIR 
domain of each receptor chain align and recruit MyD88, followed by phosphorylation 
of IL-1R–associated kinases (IRAKs), activation of TRAF6, and this pathway 
activates mitogen activated protein kinases (MAPKs). TAK1 can also be activated 
this results in the translocation of NF-κB to the nucleus. However, not all IL-1R 
family members activate these pathways. SIGIRR contains an altered TIR domain 
and inhibits IL-18 signalling.  
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precursor is fully active and found in epithelial layers throughout the gastrointestinal 
tract. It is released upon necrotic cell death to function as a cellular “alarmin” [88, 
89]. IL-1α also contains a nuclear localization signal and localizes to the nucleus. In 
contrast, IL-1β is produced by haematopoietic cells such as macrophages and must 
be cleaved by caspase 1 to become active. Moreover, it has never been observed in 
the nucleus. In tumorigenesis another variation between IL-1α and IL-1β has been 
observed. IL-1β-deficient mice develop fewer tumours compared to IL-1α-deficient 
mice [90]. IL-1β has also been shown to induce angiogenesis and enhance metastatic 
spread [91]. The IL1R antagonist (IL-1Ra) functions to block both IL-1α and IL-1β 
activity. The type II IL-1 R contains a truncated cytoplasmic domain lacking the TIR 
domain and therefore is unable to transduce a signal upon IL-1 ligation. It functions 
as a decoy receptor to negatively regulate IL-1 signalling [92]. 
1.3.4 The IL-18 subfamily 
 
The cytokine IL-18 was first recognised in 1995 as a potent inducer of IFN-γ [93]. 
The receptor for this cytokine, the IL-18R, was identified as a member of the IL-1R 
family due to its homology to the IL-1R1, IL-1RAcP and ST2 [77]. The IL-18R 
shares the common conserved sequences found in all members of the IL-1R family. 
Similar to IL-1β, IL-18 is synthesized as an inactive precursor and requires 
activation by caspase-1 cleavage. The IL-18 precursor is constitutively expressed in 
most human and murine cells [94]. Once activated, IL-18 binds to the IL-18 α-chain 
(IL-18Rα) forming a signalling complex. The accessory protein IL-18R β-chain (IL-
18Rβ) then associates to form a heterodimeric complex. The IL-18 binding protein 
(IL-18BP) is located in the extracellular compartment and regulates IL-18 activity by 
binding to mature IL-18 and preventing it from activating the IL-18R. IL-37 is also a 
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member of the IL-18 family. The IL-18 precursor is structurally similar to the IL-37 
precursor and IL-37 also binds to the IL-18R to inhibit signalling. IL-37 is an anti-
inflammatory cytokines, similar to IL-10. IL-37 suppresses innate inflammation and 
immune responses in a number of ways, including by inhibiting DC activation at the 
cellular level [95].   
1.4 ST2, a member of the IL-1R subfamily 
 
ST2 is a member of the IL-1R subfamily and was identified in 1989 [72, 73, 96]. The 
ST2 gene is located on chromosome 2q12 in humans and contains 13 introns and 
spans 40 kilobases (kb) [97]. In humans three splice variants exist, ST2L, sST2 and 
ST2V (Figure 6a). ST2L is a transmembrane bound receptor and as such specifically 
belongs to the Toll/IL-1R (TIR) superfamily and shows homology to the intracellular 
domain of IL-1R1 [97-99].  sST2 is a soluble protein with no transmembrane 
sequence, it is excreted extracellularly and binds to IL-33. Both ST2L and sST2 
contain three identical Ig extracellular domains, although sST2 lacks the 
transmembrane sequence. Instead sST2 contains an additional 9 amino acids at the C 
terminus. sST2 is thought to act as a decoy receptor sequestering IL-33 away from 
the transmembrane bound receptor ST2L [100]. ST2V is a membrane-bound 
receptor that contains a hydrophobic tail [101]. It contains two Ig domains and is 
expressed in the gut [102]. The function of ST2V has not been fully elucidated [103].  
1.4.1 Regulation of ST2 expression 
 
All ST2 isoforms are produced from the IL-1RL1 gene as a result of alternative 
splicing under the control of two distinct promoters, the distal and the proximal 
promoter (Figure 6b) [104, 105]. Early ST2 expression studies were carried out on  
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Figure 6: There are three human ST2 isoforms- ST2L, sST2 and ST2V. ST2 
is encoded by the IL1RL1 gene. In humans three splice variants exist, ST2L, 
sST2 and ST2V. (a) ST2L is a transmembrane receptor that binds to IL-33. sST2 
is a soluble protein with no transmembrane sequence and can also bind to IL-33. 
ST2V is a membrane-bound receptor that contains two Ig domains and a 
hydrophobic tail. (b) All ST2 isoforms are produced from the IL-1RL1 gene as a 
result of alternative splicing under the control of two distinct promoters, i.e. the 
distal and the proximal promotor.  
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the rat ST2 gene, known as Fit1. The ST2 gene contains two discrete promoters. It 
was originally suggested that the sST2 and ST2L mRNA isoforms were transcribed 
from different promoters resulting in alternative splicing to generate two discrete 3’ 
coding sequences [106]. Further investigations demonstrated that both the human 
and murine ST2 genes similarly contain both promoters, a distal and a proximal 
promoter [104]. However, in contrast to the initial study, it was shown that the two 
isoforms can be transcribed from either promoter, with the choice of promoter 
governed by the cell type. For instance, the human leukaemic cell line, UT-7 can 
transcribe both ST2 isoforms using either the distal or proximal promoter, but 
predominantly use the distal promoter. In contrast, most ST2 expression in the 
human TM12 fibroblastic cell line is initiated from the proximal promoter [105]. 
Similarly, it was found that mast cells utilised the distal promoter, while fibroblasts 
employed the proximal promoter, suggesting that promoter usage is dependent on 
the cell type and is not transcript specific [104].  
The distal ST2 promoter contains two GATA consensus sites which enable binding 
of the transcription factors GATA1 and GATA2, both of which are involved in the 
regulation of ST2 gene expression. These transcription factors bind upstream of the 
transcription start site and regulate ST2 gene transcription. The ST2 promoter is 
transactivated by GATA-2 and repressed by GATA-1 in mast cells and basophils 
[107]. In mast cells and Th2 cells, ST2L expression is regulated by transcription 
factors GATA-3 and STAT5 [108, 109], while the transcription factor Gfi1 was 
found to upregulate surface expression of ST2L in innate lymphoid cells [110]. IL-
33, the ligand for ST2, has been found to downregulate sST2 and ST2L mRNA in 
pancreatic cancer cells [111]. 
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1.4.2 Expression of ST2 
 
The kidney, lung, placenta and stomach all express high levels of sST2 and ST2L. In 
addition, many endothelial cells from lung, bronchus, coronary artery and umbilical 
cord express both ST2L and sST2 mRNA [112]. The expression levels of the 
isoforms vary, with ST2L expression found to be higher in the spleen, heart, testis 
and colon than sST2, whilst sST2 expression levels are higher in the brain and liver 
[97]. sST2 is induced by serum. ST2L is also expressed on the surface of fibroblasts 
and hematopoietic cells such as T helper type 2 (Th2) lymphocytes and mast cells 
[113, 114], and has recently been found to be expressed by Th1 cells, CD8
+
T cells, 
NK cells and NKT cells [115-118]. 
1.4.3 IL-33, the ligand of ST2L 
 
IL-33 was originally named nuclear factor from high endothelial venules (NF-HEV), 
as it was first found to be expressed in the nucleus of quiescent endothelial cells 
[119-121]. Later, in 2005, IL-33 was identified as a member of the IL-1 family of 
cytokines and as the ligand for ST2L [122]. Unlike other IL-1 family members, 
which are located on chromosome 2, the IL-33 gene is located on chromosome 9 at 
9p24.1. It spans ~16 kb and contains seven exons and contains two alternative 
promoters. Human IL-33 comprises 270 amino acids (aa), while murine IL-33 
consists of 266 aa [85]. 
1.4.4 Processing of IL-33 
 
Different IL-33 splice variants have been observed in human tissues. IL-33 is 
generated as a full-length protein [123-127], and contains a caspase-1 cleavage site 
[122]. It was originally proposed that full-length IL-33 required cleavage by caspase-
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1 [123, 125], similar to IL-1β and IL-18, to generate the mature biologically active 
form of the cytokine [125-127]. However, further studies demonstrated that full-
length IL-33 does not require activation by caspase-1 to be active [128]. Although 
IL-33 is not activated by caspase-1, IL-33 can be processed by caspase-3 and 
caspase-7 to yield biologically inactive fragments [125-127].   
Processing by proteolytic enzymes may play a vital part in modulating IL-33 activity 
during inflammation. Un-cleaved full-length IL-33 is released from the nucleus of 
barrier tissue during necrosis and functions as a danger signal or ‘alarmin’. However, 
the alarmin signal can be amplified by cleavage of macrophage, neutrophil, or mast 
cell-derived proteases, such as elastase, which cleaves full-length IL-33 into the IL-
3395-270, IL-3399-270, and IL-33109-270 mature forms. These isoforms are between 18 
and 21 kDa in human and 20 kDa in mouse, i.e. IL-33102-266. These mature forms of 
IL-33 have up to 30-fold increased biological activity compared to the full length 
uncleaved, IL-33 [129]. In this way a small number of alarmin molecules can have a 
potent local effect upon proteolytic cleavage of the N-terminus. Bioactivity is lost 
upon cleavage of the core IL-1 family structure by chymase or other proteases 
secreted by mast cells, thus silencing the alarmin signal [130]. A second mechanism 
of silencing IL-33 has also been documented. This involves the formation of two 
disulphide bridges, which inhibits binding of IL-33 to ST2L, thus abrogating the 
ability of IL-33 to transduce a signal [131]. 
1.4.5 IL-33 expression 
 
IL-33 is expressed by a diverse range of cells in many organs, such as activated 
leukocytes, especially innate immune cells (e.g. mast cells, macrophages and DCs), 
endothelial cells, epithelial cells, keratinocytes, fibroblasts, fibrocytes and smooth 
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muscle cells [132]. IL-33 can be induced by immune stimuli. For instance, pro-
inflammatory stimuli or pathogen recognition receptor (PRRs), especially TLRs, 
induce IL-33 expression in immune cells [133]. Similarly, in human keratinocytes 
IL-33 expression is constitutively weak but is strongly induced during inflammation 
[134]. In contrast, although IL-33 is also constitutively expressed in mouse epithelial 
cells of various origins, expression is lost during acute inflammation [134]. 
However, this is thought to be due to its release to perform its alarmin function. 
IL-33 exhibits two diverse functions. IL-33 can function as a cytokine that binds to 
ST2L and regulates the immune response, epithelial repair and activates Th2 cells. 
IL-33 can also function as a nuclear factor involved in maintaining barrier function 
through gene regulation. However, once the barrier is breached, IL-33 is released 
and functions as an ‘alarmin’. The structure of IL-33 is vital to its multiple functions. 
IL-33 shares the IL-1 family C-terminal core tetrahedron structure, and similar to 
other IL-1 cytokine members, IL-1β and IL-18, IL-33 is translated without a signal 
sequence for secretion [135].  
1.4.6 Nuclear IL-33 regulates gene expression 
 
Under homeostatic conditions IL-33 predominantly localizes to the nucleus as it 
possesses a nuclear localization signal within its N terminus [136]. Here it functions 
as a nuclear factor, binding directly to chromatin in the nucleus. Chromatin 
interaction is enabled by a conserved homeodomain-like helix-turn-helix motif 
located in the N-terminal domain [136, 137]. Nuclear IL-33 regulates gene 
expression in numerous ways. IL-33 binds to the nucleosome acidic patch in histone 
H2A-H2B dimers and regulates chromatin structure and by default, gene expression 
[136-138].  IL-33 also activates histone deacetylase-3 (HDAC3) activity, indicating a 
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potential role for IL-33 in modulating epigenetic regulation [139]. IL-33 may also 
bind to the transcriptional repressor, histone methyltranserase SUV39H1 [136]. 
Additionally, nuclear IL-33 has been reported to directly bind to NF-κB, suppressing 
its activity [140]. IL-33 has been shown to alter expression of the p65 NF-κB subunit 
by binding to the p65 promoter [141]. 
1.5 IL-33/ST2 signalling  
 
IL-33 functions as a cytokine once it has been secreted into the extracellular 
environment. Similar to other IL-1 family members, it binds to its specific plasma 
membrane receptor, ST2L. Once IL-33 has bound to ST2L, the receptor undergoes a 
conformational change, recruiting the IL-1RAcP, thus bringing the two intracellular 
TIR domains together [85]. Signalling occurs as previously described in section 1.2 
(IL-1 family signalling). Similar to other IL-1 signalling pathways, IL-33 signal 
transduction may result in the phosphorylation of extracellular signal-regulated 
kinase (ERK) 1/2, p38 MAPK and  JNKs (Figure 7) [122]. IL-33 may therefore also 
activate the transcription factor AP-1 independently of NF-κB activation [142]. 
Indeed, although TRAF6 appears to be required for IL-33-mediated NF- B 
activation, IL-33-mediated ERK activation may be TRAF6-independent [143]. This 
indicates a level of variation between the IL-33/ST2 pathway and other IL-1R 
signalling pathways. 
In certain cells, such as mast cells, IL-33/ST2L signalling appear to be more 
complex as the IL-1RAcP has been shown to be complexed to c-Kit, a receptor 
tyrosine kinase (RTK). ST2L cross-activates c-Kit, and this RTK regulates IL-33 
signalling in mast cells [144]. c-Kit is activated by its ligand, stem cell factor (SCF). 
As well as mast cells, c-Kit is also expressed by haemopoiectic stem cells, progenitor  
26 
 
 
 
 
 
Figure 7: IL-33/ST2 signalling in immune cells. IL-33 binds to the ST2L receptor and 
once the IL-1RAcp is recruited, the TIR domain of IL-1RAcp aligns with the ST2L TIR 
domain. The heterodimeric complex acts as a scaffold for the recruitment of MyD88, 
IRAK-1 and IRAK4. This results in the phosphorylation of IκB which activates the 
transcription factor NF-𝜅�B. AP-1 has also been shown to be activated through 
phosphorylation of the MAPK signalling pathway. This activates a pro-inflammatory 
response via the induction of cytokines and chemokines such as IL-6, IL-1β, TNF and 
CCL5.  
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cells, innate lymphoid cells and neoplastic cells. It is unclear whether other RTKs 
associate with the IL-33/ST2L complex, and are involved in attenuating IL-33 
responses [145].  
Downstream of IL-33 signalling, activation of this pathway has been shown to have 
far reaching effects in many different cell types. The number of genes or proteins 
modified varies depending on the cell type being examined. In RAW 264.7 murine 
macrophages, IL-33 stimulation altered the expression of over 670 proteins [146]. In 
CCD-18Co, a subepithelial myofibroblast cell line, IL-33 upregulated 700 transcripts 
and downregulated 650 transcripts [147]. In human umbilical vein endothelial cells 
(HUVECs), IL-33 regulated over 300 genes [148]. Further research on the response 
of cells to stimulation with IL-33 alone and combined with other cytokines may 
provide an insight into the in vivo crosstalk which occurs during inflammation. 
1.5.1 Regulation of ST2L signalling 
 
Given the potent immune reactions that occur following IL-33-induced ST2 
signalling it is essential that this pathway is tightly regulated. Activation of ST2L by 
IL-33 results in activation of focal adhesion kinase (FAK) and glycogen synthase 
kinase-3β (GSK-3β) (Figure 8) [149]. Activated GSK-3β binds to ST2L at Ser446 
and phosphorylates it at Ser442. This results in the swift internalization of ST2L 
[150]. Transmembrane emp24 domain- containing (TMED1) is a protein involved in 
the vesicular trafficking of proteins. TMED1 co-precipitates with ST2L [151]. Once 
internalized, ST2L is polyubiquitinated by the E3 ubiquitin ligase FBXL19, [149], 
leading to  proteasomal degradation of ST2L. IL-33 and ST2L signalling can also be 
regulated in other ways. Unlike other IL-1 family members, there is no known  
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Figure 8: Degradation of the IL-33 signalling complex.. Internalization and 
degradation of the IL-33 signalling complex occurs through the activation of 
FAK, which in turn activates GSK-3β. GSK-3β phosphorylates ST2L and 
once labelled ST2L is rapidly internalized. The IL-33R complex is 
internalized and extracellular regions are digested. The cytoplasmic region of 
ST2L is polyubuitquitinated and sent for proteasomal degradation. This figure 
was adapted from N. Martin et al., IL- 33 is a guardian of barriers and a local 
alarmin, 2015. 
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antagonistic ligand for ST2L. However, SIGIRR is an IL-1R family member that 
associates with ST2L. It is known to negatively regulate IL-1R-mediated immune 
responses [152], and may interact with ST2L to inhibit IL-33/ST2L signalling. 
Evidence of this comes from SIGIRR-/- mice where IL-33 has been shown to induce 
a greater inflammatory response in the absence of SIGIRR [153, 154]. The 
heterodimer IL-1RAcP that makes up the IL-33/ST2 signalling complex is 
constitutively expressed at low levels and does not appear to be subject to notable 
modulation.  
1.6 A physiological role for IL-33 
 
1.6.1 A role for IL-33 in barrier function and epithelial wound healing   
 
IL-33 is constitutively expressed by cells involved in the maintenance of mechanical 
barriers, including keratinocytes, lung and gut epithelial cells, fibroblasts and smooth 
muscle cells [145]. In these cells IL-33 is localized to the nucleus and mediates gene 
transcription. IL-33 is believed to maintain a quiescent state as it is only produced in 
barrier cells when they are senescent. Indeed, downregulation of IL-33 has been 
linked to the initiation of cellular proliferation in barrier cells [145]. Once a barrier is 
breached, nuclear IL-33 is released and functions as an “alarmin” or damage 
associate molecular pattern (DAMP) [155]. This extracellular IL-33 binds to ST2L 
expressing cells, such as mast cells, DCs, macrophages or group 2 innate lymphoid 
cells to activate a primary acute immune response. Th2 and mast cells constitutively 
express ST2L on the surface and rapidly respond to IL-33 [156]. Mast cells secrete 
pro-inflammatory cytokines, typically resembling a Th2 response (i.e. IL-4 and IL-
5), thus promoting the migration of basophils and eosinophils to the site of the 
barrier breach. Proteases are also secreted which disrupt connective tissue to allow 
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the influx of immune cells. These enzymes cleave the full-length IL-33 alarmin into 
N-terminally truncated forms, which can amplify the bioactivity up to 30-fold [131, 
157, 158]. Activated mast cells also actively secrete IL-33, leading to high local 
levels of IL-33.  
At the same time, recent data has shown IL-33 can trigger wound healing responses, 
to rapidly repair the damaged barrier by directly activating surrounding fibroblasts 
[159-161]. DCs are activated in this inflammatory environment and phagocytose 
pathogens. The pathogenic antigens are transported to nearby lymph nodes to 
activate naïve T helper cells, thus activating the appropriate immune response. 
Eventually, IL-33 bioactivity is extinguished upon destruction of the IL-1 family 
core structure, by chymase produced by activated mast cells [130, 158].  
Consistent with its role in maintaining barrier function, IL-33 is emerging as a 
significant mediator of colonic mucosal wound healing. Indeed, administration of IL-
33 was shown to promote wound healing in a surgical incision model by increasing 
re-epithelialisation and extracellular matrix (ECM) deposition [162]. Following 
damage to the intestinal barrier, an initial inflammatory phase occurs. IL-33 is 
significantly upregulated during this phase. The increased levels of IL-33 activate 
local innate immune cells. Subsequently, a proliferative phase occurs, during which 
collagen is laid down and angiogenesis occurs. This is followed by a remodelling 
stage. During this time, inflammation is reduced and intestinal homeostasis is re-
established. Finally, fibrosis takes place [163].  
1.6.2 The role of IL-33/ST2 in immune cells  
 
Given the high level of expression of ST2 on Th2 cells, a vast amount of literature 
has explored the role of IL-33/ST2 signalling in these cells and the effects of this 
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pathway on the cell populations. ST2L modulates effector functions in infectious, 
allergic and autoimmune disorders [164]. ST2L is expressed by polarized Th2 cells 
and can induce production of Th2 cytokines such as IL-4, IL-5 and IL-13 [122]. This 
is in contrast to Th1 cells, which produce mainly interferon (IFN)-γ, IL-2 or TNF-β 
[113]. Treatment of mice with recombinant IL-33 induced a Th2-mediated immune 
response. Increased IL-5, IgE and eosinophil recruitment was also observed, 
accompanied by goblet cell hyperplasia and increased mucus production [165].  
Recently innate lymphoid cell (ILC) populations have been shown to strongly 
express ST2 and as such, much recent focus concerns this pathway in ILC2s. 
Increased ILC populations are found at barrier surfaces such as the skin, lung and gut 
[166, 167]. ILCs are involved in regulating the immune response from initiation to 
resolution of inflammation. These cells produce many pro-inflammatory and 
immunoregulatory cytokines in response to cytokine or microbial stimuli [166-168]. 
This cell population can be divided into three groups depending on their expression 
of surface markers, transcription factors and cytokines [167]. Group 2 ILCs (ILC2s) 
respond to IL-33, as well as thymic stromal lymphopoietin (TSLP) and IL-25. In the 
lung, following damage to the epithelial barrier, the ‘alarmin’ IL-33 is released and 
ILC2s become activated [169]. Depletion of ILC2s in mice reduced repair of the 
airway epithelium in influenza infected mice. [169]. In an intestinal murine model, 
ILC2s were shown to support eosinophil development and survival in the intestine 
via IL-5 production. These cells also modulate tissue-resident eosinophils by 
secretion of IL-13 and subsequent eotaxin production [170]. As well as regulating 
innate immunity, ILCs have also been implicated in the regulation of adaptive 
immunity [166-168], as studies have suggested that ILC2s may be involved in 
crosstalk with other cells expressing ST2L, such as T-regs [171-173].  
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1.7 The Pathological functions of IL-33/ST2 
 
As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that 
dysregulation of the pathway has been linked to the pathogenesis of several 
autoimmune disorders. In asthma, IL-33 was shown to be a key driver of lung 
inflammation, as lymphocyte and eosinophil recruitment and general lung 
inflammation were reduced in the absence of IL-33. This suggests that  the IL-
33/ST2 axis could be a potential therapeutic target in asthma [174]. IL-33 is also 
implicated in rheumatic diseases. Indeed, IL-33 was detected in the serum of 
rheumatoid arthritis (RA) patients, while being completely absent in healthy controls 
[175]. The level of circulating IL-33 correlated with IgM and RA-related antibodies. 
Research to date also suggests that IL-33 has a pro-inflammatory effect in various 
rheumatological diseases, activating synovial fibroblasts and mast cells in the joints 
[153]. IL-33 was also increased in the skin lesions of patients with atopic dermatitis 
compared to non-inflamed skin [176], thus indicating a role for IL-33 in psoriatic 
pathology. 
1.7.1 IL-33/ST2 in inflammatory bowel disease 
 
IL-33 and ST2 are also implicated in the pathogenesis of inflammatory bowel 
disease (IBD). Both IL-33 mRNA and protein were found to be upregulated in 
inflamed ulcerative colitis (UC) and Crohn’s disease (CD) [177, 178]. It has been 
reported that IL-33 expression was increased in the epithelium of mild to moderate 
UC. As the intestinal epithelium becomes damaged and mucosal lesions form in 
severe UC, IL-33 becomes increased in myofibroblasts, where it functions as an 
alarmin [179, 180]. The expression pattern of ST2 was also altered in IBD. ST2 
expression becomes depleted in intestinal epithelial cells (IECs), and is prominent in 
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the lamina propria of IBD patients. The expression of ST2 isoforms is also altered in 
UC, ST2L becomes reduced [177], while sST2 is increased compared to CD and 
control tissue [177, 181]. Circulating levels of both IL-33 and sST2 were also 
increased in UC patients compared to controls [177]. Expression of IL-33 and ST2 
were found to be regulated by TNF, as anti-TNF therapy reduced IL-33 levels and 
increased sST2 expression in UC patients [177]. 
Mouse models of IBD have shown a complex role for IL-33 [177, 182] and ST2 
[183] in this disease. Loss of IL-33 or ST2 improved symptoms and reduced 
intestinal inflammation in the early stage of dextran sodium sulphate (DSS) induced 
colitis. Contrastingly, however, a further study reported delayed resolution of DSS 
dependent tissue damage in IL-33
-/- 
mice [174]. Consistent with this finding, 
treatment with exogenous IL-33 ameliorated chronic DSS colitis [184]. Therefore, 
IL-33 may have dual roles in intestinal pathology as well as in the maintenance of 
intestinal homeostasis.  
1.8 ST2 as a positive prognostic indicator 
 
ST2 has been investigated in many diseases including obesity, atherosclerosis, and 
cardiovascular disease. Studies to date indicate that sST2 may be useful as a possible 
prognostic biomarker in cardiovascular disease [185-187], as sST2 levels are 
associated with heart failure severity and poor outcome [185, 188]. Circulating levels 
of sST2 also appear to decline with improved prognosis in patients with heart failure 
[189, 190]. Thus, sST2 was recently included in current AHA guidelines for 
determining risk in acute and chronic heart failure patients [191]. However, concerns 
were raised regarding the specificity of sST2 as it is also increased in other disease 
types such as autoimmune disorders.  
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1.9 IL-33/ST2 in cancer 
 
A link between the IL-33/ST2 signalling axis and tumorigenesis has recently been 
identified. Immune infiltrates within tumours can positively or negatively influence 
patient mortality by altering angiogenesis, metastasis and response to therapeutics [3, 
192]. Therefore, it is vital to determine the effect of specific cytokines on 
tumorigenesis. Initially the link between IL-33/ST2 and cancer was identified in 
breast cancer and most research to date has focused on this cancer type. Early studies 
utilising ST2
-/-
 mice demonstrated that ST2 deletion inhibited breast cancer 
progression and increased the intra-tumoural accumulation of both innate i.e. NK 
cell and acquired immune cells i.e. CD8
+
 T-cells and Th1/Th17 cytokines [193], 
indicating a lack of IL-33 signalling through ST2L promotes a Th1 response. In 
addition, suppressing sST2 reduced ErbB2-induced cell motility in breast cancer 
cells. Moreover, breast cancer patients with metastatic disease showed increased 
levels of circulating sST2 compared to patients with primary tumours [194]. Further 
studies in breast cancer also showed significantly higher levels of both IL-33 and 
sST2 in the serum of patients with ER positive breast cancer relative to healthy 
controls [195]. Moreover, administration of IL-33 to breast cancer-bearing mice 
showed accelerated tumour growth and increased metastasis. The proposed 
mechanism responsible for the enhanced tumour growth was the increase in the 
number of infiltrating immunosuppressive immune cells and innate lymphoid cells, 
providing further evidence of the role of IL-33 in driving carcinogenesis [196].  
Since the link between IL-33/ST2 in carcinogenesis was first identified in breast 
cancer, this pathway has now been examined in numerous cancer types. Consistent 
with a role for IL-33 and ST2 in promoting tumour metastasis and invasion, 
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inhibition of IL-33 and ST2 in glioma cells resulted in reduced tumour growth and 
colony formation in vitro, and reduced tumour size in vivo [197]. In contrast, an anti-
tumorigenic role for IL-33 has been reported in other studies, with IL-33 reduced in 
the serum of non-small cell lung cancer patients relative to controls [198], and 
circulating IL-33 negatively correlating with tumour stage in multiple myeloma 
patients [199]. Over-expression of IL-33 in breast and melanoma tumour cells was 
also observed to result in reduced tumour growth in vivo. Moreover, IL-33 
overexpression induced recruitment of CD8
+ 
cells and NK cells to the site of the 
tumour [200]. Tumour metastasis was similarly attenuated in metastatic models of 
B16 melanoma and Lewis lung carcinoma cells transplanted into transgenic mice 
overexpressing IL-33. The mechanism proposed was through the activation of NF-
κB signalling, which induced the proliferation, activation and recruitment of CD8+ 
cells and NK cells, which in turn attenuated pulmonary metastasis in melanoma and 
lung carcinoma models [201]. 
In relation to CRC, the IL-33/ST2 pathway has recently been investigated in a 
number of studies, with these studies being published during the course of my PhD 
studies. IL-33 was shown to be increased in the epithelium and stroma of CRC as 
compared to adjacent normal tissue and healthy volunteers [147, 202]. Expression of 
both IL-33 and ST2 was increased in intestinal adenomas. However, expression of 
both proteins was lower in the colon tumour cells compared to the intestinal 
adenoma cells [203]. A recent study by Mertz et al. demonstrated that IL-33 and ST2 
expression decreased with increasing tumour grade [202]. In vitro studies have 
demonstrated that IL-33 stimulation enhanced invasion of primary CRC cells [204]. 
Moreover, overexpression of ST2 followed by stimulation with IL-33 further 
increased invasion in a dose dependent manner. Correspondingly, reducing IL-33 and 
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ST2 expression using shRNA targeting both proteins inhibited the increased invasion 
observed upon IL-33 stimulation. Overexpression of IL-33 by SW620 cells in a nude 
mouse model reduced survival time. This was reversed using shRNA targeting IL-33 
[204]. Furthermore, ST2-/- mice treated with AOM and DSS showed a reduced 
tumour load compared to WT mice. This is a model of colitis-associated cancer 
[202]. In an APCMin mouse model IL-33, sST2 and ST2L were increased in polyps 
compared to normal intestinal mucosa of WT mice. Knocking out IL-33 in the APC 
Min model reduced polyp number [147]. Therefore, this data suggests that IL-33 
may be active during polyp development. The majority of studies to date in CRC 
point to a pro-tumorigenic role for IL-33/ST2 signalling in CRC. 
 
1.10 The IL-36 subfamily  
The genes of the IL-36 family members are located in a cluster on chromosome 2 
[205].  All three activating ligands, IL-36α, IL-36β and IL-36γ share the classic IL-1 
β-trefoil structure, and lack a signal peptide. IL-36α, IL-36β, and IL-36γ lack a 
signal sequence, and thus cannot be transported to the endoplasmic reticulum. 
Similar to IL-1β and IL-18, the N-terminus must be cleaved for full agonist or 
antagonist bioactivity of each of the IL-36 cytokines [206]. The protease responsible 
for this cleavage has not yet been elucidated. It is not thought to be a caspase as the 
site does not resemble a caspase cleavage site [207]. These three agonists induce 
proinflammatory cytokines, chemokines and other stimulatory molecules, thus 
promoting the infiltration of many immune cells such as DCs and neutrophils, 
activation of Th1 and IL-17-producing T cells, and keratinocyte proliferation [208, 
209]. 
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1.10.1 Expression and function of IL-36 family members 
 
IL-36R ligands are principally expressed by epithelial cells, keratinocytes, brain 
tissue and macrophages [210-212]. However, T cells have also been shown to 
express IL-36α and IL-36β [27]. Variation in cellular expression of the ligands has 
also been observed. For instance, IL-36α is constitutively expressed by keratinocytes 
while IL-36γ is induced upon stimulation with TNFα [213]. In vitro, monocytes were 
found to specifically express IL-36γ following LPS treatment [214]. IL-36α is 
secreted by BMDMs upon treatment with LPS, indicating that IL-36α can be 
externalized in response to a stimulus comparable to IL-1β [215]. 
IL-36 cytokines can regulate the immune response by influencing antigen presenting 
cells (APCs), such as macrophages and DCs. Indeed, the IL-36R is expressed by 
both monocyte and plasmacytoid derived DCs. Both of these APCs increase 
expression of CD83 in response to IL-36β and IL-36γ stimulation. In particular, IL-
36β can induce secretion of IL-12 and IL-18 production by monocyte derived DCs. 
These cytokines can then activate IFN-γ producing T-cells [216]. CD11+ cells 
stimulated with IL-36α produce TNFα, CD40, CXCL1 and CXCL2 which activate 
proliferation of CD4
+
 T cells. The IL-36R is also expressed on naïve T-cells, 
enabling IL-36 agonists to stimulate the proliferation of T-cells and induce IL-2 
secretion by naïve T cells [217]. Indeed, IL-36R signalling has also been shown to 
activate a Th1 and a Th17 response [209, 212].  
1.10.2 IL-36 regulation 
 
To date, few studies have investigated the regulation of IL-36 signalling. The IL-36R 
and the IL-1RAcP have been shown to be recycled in the absence of agonists. 
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However, in the presence of agonists both receptors accumulated in higher 
abundance in lysosomes [218]. Toll-interacting protein (Tollip) is a protein that is 
central to the regulation of Toll-like receptor (TLR) signalling pathways. Tollip also 
regulates IL-36 trafficking by elevating the levels of IL-36R and IL-1RAcP. In 
addition, Tollip has been shown to stabilise the IL-36R once the agonist has bound. 
This is unlike IL-1R signalling where Tollip has been shown to target the ligand-
bound IL-1R for degradation [218]. Proteases produced by immune cells such as 
lymphocytes and neutrophils have been found to enhance the bioactivity of IL-33 
and may also have similar effects on IL-36R agonists [129, 219]. 
Unlike IL-33, IL-36 cytokines require proteolytic processing to become activated. 
Proteases produced by immune cells such as lymphocytes and neutrophils increase 
the bioactivity of IL-36 cytokines. IL-36α, IL-36β, and IL-36γ are distinctively 
processed and activated by neutrophil granule-derived proteases cathepsin G, 
elastase, and proteinase-3 [220]. In this manner neutrophil-derived proteases can 
increase inflammation through the regulation of IL-36 cytokines. 
 
1.10.3 IL-36 signalling  
 
Few studies to date have investigated the role of the IL-36R signalling axis in the 
intestine. Similar to other IL-1R family members, the co-receptor IL-1RAcP is 
recruited to the IL-36R upon binding by one of the three agonistic ligands. This 
stabilizes ligand binding [207]. Conformational changes are induced in the TIR 
domains of both heterodimers. The IL-36R adaptor protein, MyD88, is subsequently 
recruited. Similar to other IL-1R family members, IL-36R signalling has been shown 
to activate MAPK, ERK1/2, JNK (Figure 9) [221]. Indeed, studies investigating IL-  
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Figure 9: The IL-36 family members and signal transduction. The IL-36R is a 
member of the IL-1R family. IL-36α, IL-36β and IL-36γ exert their actions by binding 
to the IL-36R. Ligand binding enables the recruitment of the IL-1RAcP. This leads to 
signal transduction through MYD88-dependent pathways, and activation of NF-κB and 
MAPKs. The IL-36R antagonist, IL-36Ra, also binds to the IL-36R, but fails to recruit 
the IL-1RAcp. Moreover, it also prevents other agonist ligands from binding to the 
receptor. IL-38 is also thought to act as an antagonist for this receptor. 
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36 signalling in both HT29 and Widr colon cancer cells have shown that stimulation 
with IL-36α and IL-36γ resulted in the recruitment of MyD88, TRAF6, IRAK1 and 
TAK1 adaptor proteins [222]. This adaptor complex induced the activation of NF-
κB, the phosphorylation of the MAPKs and AP-1 activation. Similar to IL-33, 
stimulation of the cells with IL-36 cytokines upregulated CXC chemokines (such as 
CXCL1, CXCL2, CXCL3) in intestinal epithelial cells [222]. Consistent with a role 
for the MAPK pathway and NF-B in IL-36R signalling, activation of the IL-36R by 
IL-36γ was reduced in the presence of MAPK inhibitors and siRNAs specific for 
NF-κB and AP-1 [223]. In addition to the induction of chemokines, IL-6 was 
strongly induced in response to IL-36R stimulation in colonic fibroblasts [224]. IL-6 
has a broad range of functions in the colon. This cytokine has been implicated in a 
pro-inflammatory response, but it is also thought to play a role in mucosal healing of 
mucosal lesions  [225]. The antagonist IL-36Ra shares homology with IL-1Ra. It 
binds to the IL-36R preventing the formation of the heterodimer with IL-1RAcP. 
However, IL-36Ra can induce IL-4 production in glial cells [207]. 
1.11 Physiological functions of IL-36 
 
Similar to IL-33, IL-36R ligands are involved in maintaining intestinal homeostasis. 
Analogous to IL-33, IL-36γ is localised to the nuclei of intestinal epithelial cells 
[226]. The presence of IL-36γ in the nucleus may be due to its role as an “alarmin”. 
In murine models of intestinal damage such as the DSS colitis model and also in 
mechanical mucosal injury model, IL-36γ was released by the intestinal epithelial 
cells and shown to enhance mucosal healing [224]. The effects of IL-36γ on colonic 
fibroblasts have been examined in a recent study [224]. It was demonstrated that IL-
36γ induced proliferation of murine fibroblasts to effect closure of wounds. IL-36γ 
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also promoted mechanical wound repair. This is a complex task in which numerous 
pathways participate including Wnt ligand signals, cytokines and growth factors 
[227-229].  
1.12 Pathophysiological functions of IL-36  
 
Studies to date have demonstrated a role for IL-36 in many diverse diseases with an 
inflammatory component. Given the high expression of these ligands and the 
receptor on keratinocytes, much early work focussed on the role of IL-36 cytokines 
on cutaneous diseases. IL-36 is known to play a pathogenic role in chronic psoriatic 
disorders [208, 217, 230]. IL-36 was demonstrated to mediate crosstalk between 
keratinocytes and DCs that was vital for controlling the IL-23/IL-17/IL-22 axis 
during psoriatic development [231]. IL-36α was also found to be increased in the 
joints of psoriatic and rheumatoid arthritis patients [232]. IL-36 has also been 
implicated in pulmonary diseases such as asthma and chronic obstructive pulmonary 
disease (COPD) [233]. Indeed, plasma from acute COPD patients had lower IL-36α 
and IL-36RN levels than healthy controls [234]. IL-36 may also play a role in joint 
disease, as IL-36β is expressed in human articular chondrocytes and stimulation with 
IL-36β induces proinflammatory cytokine production [235]. The IL-36 family have 
also been implicated in obesity [236]. IL-36α is present in adipose tissue resident 
macrophages, and both IL-36α and IL-36γ promote inflammatory gene expression in 
mature adipocytes [237]. Consistent with this, IL-36Ra was demonstrated to be 
downregulated in pre-adipocytes [236].  
1.12.1 IL-36 in IBD 
 
The role of IL-36 in IBD has recently been the focus of several studies. IL-36 is 
known to be dysregulated in psoriasis and these patients are at increased risk of 
42 
 
developing IBD and vice versa. Therefore, this suggests IL-36 dysregulation may act 
through a common mechanism in these diseases [238, 239].  Some studies suggest 
that IL-36 plays a pro-inflammatory role in IBD, while others have suggested that 
IL-36 promotes wound healing. Initial studies have shown that IL-36α and IL-36γ 
are upregulated in the colonic mucosa of UC patients [222, 240, 241]. IL-36RN was 
reduced in these patients, which may contribute to increased activation of IL-36 
signalling [240]. DSS-induced colitis models have shown delayed wound healing in 
IL-36
-/-
 mice. This was accompanied by a reduction in the barrier protective cytokine 
IL-22 and a reduction in the number of infiltrating neutrophils [241]. Interestingly, 
IL-36γ was found to be the most strongly upregulated gene on inflammatory 
macrophages that infiltrate the colon after DSS treatment [209]. As well as epithelial 
cells and macrophages, human colonic subepithelial myofibroblasts (SEMFs) were 
also shown to express IL-36γ in response to IL-1β [223]. Evidence in support of IL-
36 promoting wound healing was shown in an IL-36R
-/- 
mice, which demonstrated 
delayed wound healing in DSS-induced colitis. This was potentially due to a 
reduction in neutrophil recruitment [241]. This suggests there may be a very fine 
balance required in the level of neutrophils recruited. Low levels of neutrophil 
recruitment may lead to poor wound healing, while high levels of neutrophil 
recruitment may lead to prolonged inflammation and enhancement of IBD. 
1.12.2 IL-36 in cancer  
 
The link between IL-36 and cancer has only recently been investigated. To date two 
papers have investigated the role of IL-36 family members in cancer. IL-36α 
expression was found to correlate with mortality of hepatocellular carcinoma (HCC) 
patients [242]. These authors examined expression of IL-36α in a cohort of 345 
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patients by IHC and found IL-36α was expressed by nearly half of all HCC patients 
examined. IL-36α was found to be predominantly expressed in the cytoplasm of 
normal hepatocytes and well-differentiated HCC cells. Low expression of IL-36α 
was associated with increased tumour volume and increased TNM stage. Survival 
analysis showed that reduced expression of IL-36α was indicative of a poor 
prognosis for HCC patients, suggesting a possible anti-tumorigenic role for IL-36α 
in HCC. Cancers expressing high levels of IL-36α contained higher populations of 
intra-tumoral CD3
+ 
and CD8
+ 
tumour-infiltrating lymphocytes (TILs), but not CD4
+ 
TILs [242]. This suggests that IL-36α can attract CD3+ and CD8+ TILs and promote 
an adaptive T-cell immune response, which can impact the prognosis of HCC 
patients. 
The second study injected B16 melanoma cells and 4T1 breast cancer cells 
overexpressing murine IL-36γ into WT mice and found tumour growth to be reduced 
in both models compared to vector controls. In the B16 melanoma model, the total 
number of CD8
+
 and CD4
+
 TILS and the percentage of NK and γδ T cells were 
increased in IL-36γ-expressing tumours compared to vector controls. Higher 
percentages of Foxp3
+
 CD4
+
 T cells, most likely T reg cells, were also detected in 
the IL-36γ-expressing tumours. Cells which have been shown to promote tumour 
growth such as type 1 lymphocytes and B cells were reduced in B16-IL-36γ 
compared to WT tumours [243, 244]. Overall these results suggest that a type 1 
immune response was activated in B16-IL-36γ. This may have been regulated by the 
increased numbers of T reg cells observed [245]. These studies have identified a link 
between IL-36 agonists and tumorigenesis. Further studies are required to determine 
the role of additional IL-36 family members in other cancer types.  
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1.13 Aims: 
 
Therefore the aims of this study were to; 
1. Characterise expression of IL-33 and ST2 in colon cancer cells in vitro and 
investigate the effect of IL-33 on colon cancer cells in vitro (Chapter 3). 
2. Evaluate the role of tumour cell-expressed ST2 in colon carcinogenesis in 
vivo (Chapter 4). 
3. Investigate the expression and function of IL-36 in colon cancer (Chapter 5). 
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2.0 Material and Methods 
2.1 Materials 
All reagents were stored and prepared according to the manufacturer’s guidelines. 
2.1.1 Cell lines and tissue 
CT26, HT29, HCT116, SW480, THP1s, U266B1, JJN3 and RAW 264.7 cells were 
obtained from the American Type Culture Collection (MD, USA).  
2.1.2 Mice 
Six week old female Balb/C mice were obtained from Harlan (Oxon, UK) and 
maintained in the animal facility of University College Cork. Standard housing and 
environmental conditions were maintained (temperature 21°C, 12 hrs light and 12 
hrs darkness with 50% humidity). Animals were fed a standard pellet diet and water 
ad libitum. Animal husbandry and experimental procedures were approved by the 
University College Cork Animal Experimentation Ethics Committee (AEEC). Prior 
to initiation of experiments, the mice were afforded an adaptation period of at least 7 
days. 
2.1.3 Reagents 
Anti-fade fluorescent mounting media GM-304 (Dako, Glostrup, Denmark) 
Bovine Serum Albumin (BSA) A9418 (Sigma Aldrich, Dublin, Ireland) 
BCA Protein Assay Reagents A and B 23223 and 23224 (Thermo Fisher Scientific, 
MA, USA) 
Dulbecco's Modified Eagle Medium D5796 (Sigma Aldrich) 
Collagenase dispase solution 10269638001 (Roche Diagnostics, Basel, Switzerland) 
Congo red C6277 (Sigma Aldrich) 
Crystal Violet Dye C3886 (Sigma Aldrich) 
Dimethyl sulphoxide D2650 (Sigma Aldrich) 
DPX mounting medium 44581 (Sigma Aldrich) 
Eosin 45260 (Sigma Aldrich) 
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Human recombinant epidermal growth factor 585506 (Biolegend) 
Murine recombinant epidermal growth factor PMG8044 (Thermo Fisher Scientific) 
Normal Goat serum X0907 (DAKO Diagnostics) 
Heat-inactivated foetal calf serum (FBS) F2442 (Sigma Aldrich) 
Haematoxylin 51260 (Sigma Aldrich) 
Human recombinant IL-33 CYT-655 (Prospec, NJ, USA) 
Murine recombinant IL-33 CYT-425 (Prospec) 
Human recombinant IL-36α 551602 (Biolegend) 
Human recombinant IL-36β CYT-159 (ProspecBio) 
Human recombinant IL-36γ 711602 (Biolegend)  
Immobilon Western Chemiluminiscent HRP substrate WBLUF0500 (Merck 
Millipore, MA, USA) 
Ultra-pure LPS tlrl-pb5lps (Invivogen, CA, USA) 
Matrigel® Basement Membrane Matrix 356234 (Corning, NY, USA) 
Thiazolyl blue tetrazolium bromide (MTT) sigma aldrich 
Penicillin/Streptomycin P4333 (Sigma Aldrich) 
Phorbol 12-myristate 13-acetate (PMA) P1585 (Sigma Aldrich) 
Phosphate Buffered Saline D8662 (Sigma Aldrich) 
Polyoxyethylene (20) sorbitan monolaurate (TWEEN) P1379 (Sigma Aldrich) 
Polybrene sc-134220 (Santa Cruz, Heidelberg, Germany) 
Prostaglandin E2 14010 (PGE2) (Cayman Chemical, MI, USA) 
Protease inhibitor cocktail I 539131 (Merck Millipore) 
Puromycin P8833 (Sigma Aldrich) 
Normal rabbit serum R9133 (Sigma Aldrich) 
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Red cell lysis buffer R7757 (Sigma Aldrich) 
Resazurin powder R7017 (Sigma Aldrich) 
RNAlater R0901 (Sigma Aldrich) 
RPMI-1640 R8758 (Sigma Aldrich) 
Tumour necrosis factor alpha 300-01A (PeproTech, NJ, USA) 
Triton X T8787 (Sigma Aldrich) 
2.2 Methods 
2.2.1 Cell culture 
Cells were cultured in 75cm
2
 flasks at 37°C in 5 % C02 in DMEM (Sigma Aldrich) 
supplemented with 10% FBS and 10,000 units/ml penicillin and 10mg/ml 
streptomycin. Cells were routinely grown to 70-80% confluence before being 
passaged three times per week. Passaging involved washing the cells with pre-
warmed PBS and subsequent incubation at 37°C with 3 ml of Trypsin to detach cells 
from the flask wall. 
2.2.1.2 Viability 
10μl of cell suspension was added to 90μl of Trypan Blue (Sigma aldrich) and mixed 
well by pipetting. 20μl was transferred to a haemocytometer. The number of stained 
cells was counted, in addition to the total number of cells and percentage viability 
assessed. 
2.2.2 Western blotting 
2.2.2.1 Preparation of whole cell lysates 
Cells were seeded at 1x10
5
 cells/ml into 6 well plates and then cultured until 70% 
confluent. Cells were then treated as specified in the figure legends. Following 
treatment cells were washed with ice-cold PBS and then lysed on ice for 1 hr with 
100 μl of lysis buffer containing 50 mM Tris-HCl (pH 8.0), supplemented with 1x 
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protease inhibitor cocktail (Merck Millipore). Samples being examined for 
expression of the heavily glycosylated ST2L were lysed in sample buffer containing 
50 mM Tris-HCl (pH 7.5), 150mM NaCl, 0.1% NP40, 0.05% 3-[(3-
Cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPs), 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 1x protease inhibitor cocktail (Merck 
Millipore). Cells were then scraped and transferred to a 1.5ml eppendorf. Lysates 
were centrifuged at 12000 rpm at 4°C for 15 min. The resulting pellet containing 
cellular debris was discarded and lysate was stored at -20°C. 
2.2.2.2 Quantitation of total protein concentration  
Protein standards were prepared using BSA (Thermo Fisher Scientific) (0, 2.5, 5, 
7.5, 10, 15, 20μg/ml) and added to a 96 well plate. 2μl of each sample was added to 
the plate followed by 38μl of distilled H20. Both standards and samples were 
analysed in triplicate. 160μl of BCA Protein Assay Reagent (Thermo Fisher 
Scientific) was added to each well, the plate agitated and then left at 37°C for 30 min 
before the absorbance was read at 560 nm on the Glomax multi-detection system 
(Promega, WI, USA).  
2.2.2.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis and 
Western blotting 
The appropriate amount of cell supernatant containing 50µg of protein was mixed 
with 4 x Polyacrylamide Gel Electrophoresis (PAGE) loading buffer (125mM Tris, 
2% SDS, 20% Glycerol, and 20 mM DTT) and lysis buffer containing 50 mM Tris-
HCl (pH 8.0) to a final volume of 20μl. Lysates were boiled for 5 min before loaded 
onto a separating and stacking SDS gel. A 19-180 kilo Dalton (kDa) molecular 
weight marker (Sigma Aldrich) was run alongside the samples. Proteins were 
separated by electrophoresis at 50 mA. Proteins were then transferred overnight onto 
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an Immobilon–P polyvinylidene diflouride membrane (Merck Millipore) at 40V and 
4°C using a wet transfer method. The following morning, membranes were stained 
with Ponceau to ensure even transfer of proteins. 
2.2.2.4 Immunoblotting 
Ponceau was removed with distilled water and Tris buffered Saline (TBS)-0.1% 
TWEEN (TBST) before membranes were blocked using 5 % (w/v) milk powder or 
BSA in TBST (henceforth referred to as blocking buffer) for 1 hr with rocking. 
Membranes were washed for 5 mins in TBST before the appropriate primary 
antibody was added diluted in blocking buffer and stored overnight at 4°C. 
Membranes were washed 3 times with TBST for 5 mins at a time, and then incubated 
for 1 hr at room temperature with the appropriate secondary antibody. Finally, 
membranes were washed 3 times with TBST for 5 mins at a time before detection 
using an Immobilon Western Chemiluminescent HRP substrate (Merck Millipore) 
according to manufacturer’s instructions. Protein bands were analysed using ImageJ 
(National Institutes of Health, Bethesda, MA, USA, http://imagej.nih.gov/ij/, 1997-
2012.). Changes in protein expression were determined after normalising the band 
intensity of each lane to that of β-actin. 
2.2.3 Quantitative real-time polymerase chain reaction (qRT-PCR) 
2.2.3.1 RNA extraction 
RNA was isolated from cultured cells using the GenElute total mRNA kit (Sigma 
Aldrich). Cells were lysed in 700 μl of RNA lysis buffer and RNA extracted and 
stored at -80
o
C. RNA concentration and quality was determined 
spectrophotometrically using the Nanodrop 1000 (Thermo Fisher Scientific). 
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2.2.3.2 cDNA preparation  
1 µg of total RNA was used as the template for cDNA synthesis using a 
commercially available cDNA synthesis kit according to the manufacturer’s 
instructions (Bioline, UK). This was added to 1μl of Oligo (Dt), and 1μl of 10Mm 
dNTP and heated to 65°C for 10 mins. Following 5 mins on ice, 4μl of 5x Reverse 
Transcriptase Buffer, 1μl of RNase inhibitor, 0.25μl of Reverse Transcriptase, and 
2.75μl of DEPC treated water was added to each sample before incubation at 37°C 
for 30 mins. The reaction was terminated by a final incubation at 70°C for 15 mins 
and chilling samples on ice.  
2.2.3.3 qRTPCR 
1 μl of cDNA template was amplified in a 25 μl total reaction volume as per Applied 
Biosystems standard PCR protocol using appropriate probes and TaqMan Gene 
Expression Master Mix (Applied Biosystems, UK). Thermal cycling was performed 
in a PCR machine (Applied Biosystems), with general conditions as follows: 50 °C 
for 2 mins; 95 °C for 10 mins; 60 cycles at 95 °C and 60 °C for 1 min.  
Other samples were run on the LightCycler® 480 (Roche) in a 10 μl total reaction 
volume. The reaction mix contained a final concentration of 400nM of each primer 
and 200nM of the appropriate Universal Probe Library probe (Roche) and 1x 
Sensifast Probe Lo-Rox kit (Bioline). Conditions for the LightCycler® 480 were 95 
°C for 10 mins; 45 cycles of 95 °C for 10 seconds, 60 °C for 30 seconds, followed by 
a final cooling at 40
oc for 30 seconds. All results were analysed using the ΔΔ ct 
method and the gene of interest was normalized to the corresponding housekeeping 
gene results. Data were expressed as fold induction relative to untreated cells. In the 
case of human tumours versus adjacent tissue, a pool was generated of all samples 
and values were normalised to this pool. Data were expressed as fold induction 
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relative to the pool. Grubbs test was used to remove any outliers and the results 
achieved were then interpreted using GraphPad Prism software. 
2.2.4 Resazurin Assay 
Resazurin powder (Sigma Aldrich) was hydrated with PBS under sterile conditions 
to make a 10 x stock solution (440μM). The solution was filter sterilized using a 
0.22µm filter and stored in a foiled covered container at 4°C until use. The media 
was aspirated from the 6-well plates and each well was washed once with PBS. 2ml 
of prewarmed 1x Resazurin solution was added to each well before measuring 
fluorescence at 535-590nm on a GenIOS fluorometer. Fluorescence readings were 
taken at a variety of time points (5-55 mins) to create a standard curve of 
fluorescence against time. Readings were subsequently taken during the log phase of 
the reaction. 
2.2.5 MTT assay  
The MTT assay depends on the ability of viable cells to reduce MTT to a coloured 
formazan product. MTT was dissolved at a final concentration of 5mg/ml in 
complete culture medium. The solution was then filter sterilized using a 0.22µm 
filter and stored in a foiled covered container at 4°C until use. 100 μl of the MTT 
solution was added per well to a 96-well plate. Cells were incubated at 37
o
C, and 5% 
CO2 for 2 hours. Medium was aspirated and the MTT-formazan precipitate was 
dissolved with 100 μl of DMSO per well. The plate was further incubated for 15 min 
at room temperature and the optical density (OD) of the wells was determined at a 
wavelength of 560nm using the Glomax multi-detection system. Changes in MTT 
reduction were normalised relative to untreated cells. 
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2.2.6 BrdU Assay 
BrdU incorporation assay was performed using a Cell Proliferation ELISA System 
(Roche) according to the manufacturer’s instructions. 2,000 cells per well were 
seeded in a 96 well plate, and serum starved overnight in 0.5% serum. Cells were 
treated with 15, 30 or 60ng/ml IL-33 or 100 ng/ml of EGF for 24 h. Following 
incubation the cells were treated for with 10μM of BrdU labelling solution and re-
incubated in at 37
o
C for 2h. The cells were fixed and denatured in one step using the 
FixDenat solution. An anti-BrdU-POD antibody was then added for 90 mins at room 
temperature. Following three wash steps substrate solution was added for 30 mins at 
room temperature. Stop solution was then added and the BrdU incorporation was 
measured at 450nm using the Glomax multi-detection system (Promega).  
2.2.7 Immunohistochemistry 
Formalin fixed and paraffin embedded human and murine colonic sections were 
deparaffinised and rehydrated using Xylene and an ethanol gradient (100%, 95%, 
70% ethanol and then distilled water). The sections were then boiled with sodium 
citrate (pH 8) in order to induce epitope retrieval. Sections were washed in Tris 
Saline solution (1% Tris Saline (0.05M) and 0.001% Saponin), hereafter known as 
wash solution, and blocked in 3% hydrogen peroxide. Following a further wash in 
1% normal goat serum (NGS) or normal rabbit serum (NRS) Wash solution, a 
blocking step in 5% NGS Tris Saline and a final wash, sections were incubated with 
primary antibody in 1% NGS Tris Buffer over night at 4°C. The following morning, 
sections were washed with wash solution before incubation for 45 mins at room 
temperature with 0.5% biotinylated anti-Rabbit IgG or anti-goat IgG (Vector 
Laboratories, Inc CA, USA). A five minute wash step followed, after which the 
sections were incubated with ABC Elite complex (Vector Laboratories) for 45 mins 
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at room temperature. Sections were then washed and DAB substrate added (Vector 
Laboratories) according to manufacturer’s instructions. Finally sections were washed 
in tap water and counterstained with Mayer’s haematoxylin (Sigma Aldrich), then 
washed in tap water again before being mounted with crystal mount (Sigma 
Aldrich). The specificity of the reaction was proven by staining with a normal rabbit 
IgG or normal goat IgG isotype control. 
2.2.8 Enzyme Linked Immunoassay (ELISA) 
CXCL-1 levels in CT26 cell supernatant treated with IL-33 for 24h were quantified 
using the murine CXCL-1 Quantikine ELISA (R&D Systems (Minneapolis, MN) 
according to the manufacturers’ instructions. Three independent experiments were 
performed.  The concentration of IL-33 and ST2 in serum was determined using 
commercially available IL-33 (Biolegend Inc.,) and ST2 (R&D Systems) ELISAs 
according to the manufacturers’ instructions. All samples were analysed in duplicate.  
2.2.9 Cell migration assay  
HT29, SW480 or CT26 cells were plated in the top chambers of 8μm-pore transwells 
(Merck Millipore) in media containing 0.5% serum at a concentration of 1x10
5
 
cells/insert. Increasing concentrations of IL-33 as indicated in the figure legend were 
added to the cells. DMEM with 10% FCS was added to the lower chamber to serve 
as the chemoattractant. After 16 hrs of incubation, cells in the top chamber were 
removed, and cells at the bottom of the filter were fixed in 100% ice cold methanol 
for 5 min and stained with 0.5% crystal violet for 20 min. The dye was eluted from 
the membrane using 10% acetic acid, and crystal violet absorbance was measured at 
560 nm. Duplicate wells were used per condition in each experiment. A minimum of 
three independent experiments for each cell line was performed. The percentage 
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change in migration was assessed relative to migration of untreated cells towards 
DMEM with 10% serum. 
 
2.2.10 RAW 264.7 migration assay 
For the RAW 264.7 migration assay, 1.2 x 10
5
 cells were plated on the top of 5μm-
pore transwells in media containing 0.5% serum. Supernatant derived from CT26 
cells either untreated or treated with 15ng/ml IL-33 for 24h served as a 
chemoattractant. To block CCL2-induced migration, anti-CCL2 antibody (R&D 
Systems) was added to the lower chamber as indicated. The % change in migration 
was assessed relative to migration towards supernatant derived from untreated CT26 
cells.   
2.2.11 Invasion Assay 
The transwells were coated with 100 μl of Matrigel® (Corning) diluted in serum free 
media to a final concentration of 4mg/ml. The Matrigel® was incubated at 37
o
C for 
45 mins to set. Once the Matrigel® had set, CT26 and HT29 cells were then seeded 
in media containing 0.5% serum +/- IL-33 on top of the Matrigel® at a density of 
1x10
5
 cells/well into the upper chamber of an 8μm pore size transwell. 750μl of 
media containing 10% serum was added to the bottom chamber of the transwell and 
served as the chemoattractant. Following 48 h incubation at 37
o
C, the insert was 
washed twice in PBS and fixed in ice cold methanol for 5 mins. Inserts were then 
stained in 0.1% crystal violet in 0.1M borate pH 9.0 and 2% ethanol for 20 mins. 
Inserts were then washed twice in PBS and membranes removed from the transwell 
and placed into a 24 well plate containing 200μl of acetic acid to elute the stain. 
Absorbance was read at 560nm on the Glomax plate reader (Promega). 
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2.2.12 Caspase 3 and 7 Assay 
HT29 cells were plated in white 96 well plates at 2x10
4
 cells per well. The cells were 
then incubated with 100ng/ml of IL-36α, IL-36β and IL-36γ for 4.5 hours. 
Staurosporine (1μM) was used as the positive control to induce apoptosis (Sigma 
Aldrich). 100 μl of the Apo-One® Caspase 3/7 detection reagent (Promega) was 
added to a final volume of 200μl and the contents were gently mixed using a plate 
shaker. The plate was incubated at room temperature and readings were taken at 1, 2 
and 3 hours. Fluorescence was recorded using a BioTek Flx800 spectrofluorometer 
at an excitation wavelength of 485nm and an emission wavelength of 530nm. 
Background readings were determined from wells containing culture medium 
without cells. 
2.2.13 Generation of ST2 knockdown cancer cells 
Lentiviral particles were used to deliver shRNA encoding plasmids into the cells. 
The lentiviral particles enter the CT26 cells where the shRNA is transcribed. The 
shRNA is then cleaved by the Dicer enzyme into small interfering RNAs (siRNAs) 
which are short duplexes of 19-21 nucleotides, including hairpin, with two 
nucleotide 3’ overhangs on each strand. The siRNAs are then assembled into 
endoribonuclease containing complexes known as RNA induced silencing complexes 
(RISCS), unwinding in the process. Activated RISC’s subsequently bind to 
complementary transcripts by base pairing interactions between the siRNA anti-
sense strand and the complementary mRNA. The bound mRNA is cleaved and 
sequence specific degradation of mRNA results in gene silencing. Control shRNA 
lentiviral particles encode a scrambled shRNA sequence that does not lead to the 
specific degradation of any known cellular mRNA.  
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Prior to transfection with lentivirus, the optimal concentration of the transfection 
reagent polybrene and the selection antibiotic puromycin (Sigma Aldrich) was 
determined for CT26 cells. Polybrene is a polycation that neutralizes charge 
interactions to increase binding between the pseudoviral capsid and the cellular 
membrane. The optimum concentration of polybrene was determined to be 4μg/ml. 
To select for positive clones following transfection with shRNA particles, the 
antibiotic puromycin was used. The lowest concentration of puromycin that resulted 
in 100% cell death was determined to be 6 ng/ml. CT26 cells were seeded 24 hours 
prior to viral infection. Polybrene, at a final concentration of 6 μg/ml was added to 
the media. Cells were transfected with lentiviral particles containing target-specific 
shRNA against ST2 (sc-40036-V) or control lentiviral particles containing scrambled 
shRNA (sc-108080) (Santa Cruz Biotechnology), according to the manufacturers’ 
instructions. Cells were seeded in 12-well plates at a concentration of 7.5 x104 
cells/ml. Cells were infected 24hrs later with lentiviral particles in the presence of 4 
µg/ml polybrene and cultured in selection medium containing 6-8 μg puromycin 
until resistant clones could be identified. Resistant clones were selected by limiting 
dilution. Knockdown of ST2 expression was determined by Western blotting and 
functional analysis. 
2.3 In vivo studies 
For tumour induction 2x10
5
 cells in 200ul of PBS was injected subcutaneously into 
the flank of the mice. For the initial in vivo study, female Balb/c mice were injected 
with either CT26
scrshRNA#
1 (n=4) or CT26
ST2shRNA#1 
cells (n=4) and tumour growth 
monitored over a period of 21 days. A separate control group were injected with PBS 
only (n=3). The subsequent investigation compared two CT26
ST2shRNA
 groups each 
with a control CT26
scrshRNA
 group and again another control group were injected with 
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PBS only (n=3). The viability of cells used for inoculation was more than 95% as 
determined by Trypan Blue Dye Exclusion. Following tumour establishment, the 
health parameters which can lead to the endpoints were carefully monitored three 
times per week: cachexia (acute weight loss), lack of activity and loss of appetite. 
Weight was measured and general behaviour as well as body condition was assessed. 
Tumour size was carefully monitored to ensure that it doesn’t exceed maximal 
allowed sized of 2 cm
3
. Tumour volume was measured using Vernier calipers and 
calculated according to the formula 1/2 (length x width
2
). At the end of the 
experiment animals were euthanized by CO2 inhalation. 
2.3.1 Treatment groups and ear marking 
Female mice weighing 18-25g and 6 weeks of age were randomly divided into 
experimental groups. Mice were ear clipped for identification purposes. 
2.3.2 Monitoring body weight 
Mice were weighed thrice weekly to monitor changes in body weight. 
2.3.3 Tumour formation 
Mice were subcutaneously injected into the right flank with CT26 cells suspended in 
200μl of PBS. Tumour formation was monitored thrice weekly by palpation at the 
site of injection. The width (w) and length (l) of the tumours was measured using 
Vernier calipers and the mean tumour volume calculated using the formula: 
½ (l x w
2
). 
2.3.4 Tumour sampling 
Following euthanasia by CO2 inhalation and cervical dislocation, tumours were 
excised from mice and dissected for subsequent analysis using the clock face 
dissection method. This method ensured that all stored tissue incorporated tumour 
tissue from the core to the leading tumour edge. Tissue was stored in liquid nitrogen, 
formalin and RNAlater (Sigma Aldrich). In addition, tissue was placed in an 
69 
 
eppendorf containing 1 ml of a working solution of collagenase/dispase (Roche) in 
PBS on ice. 
2.3.5 Single cell suspension of tumour cells for flow cytometric analysis 
Tumours in collagenase/dispase solution were incubated at 37
o
C for 1hr with 
shaking. Tumour tissue was placed into a petri dish, 10ml of serum free DMEM was 
added and cells were then passed through a cell strainer (Fisher). Cells were pelleted, 
washed in PBS and resuspended in 2ml of Red Cell Lysis Buffer. Following 
incubation at room temperature for 10 mins, 10% FCS DMEM media was added to 
stop the lysis reaction. Finally, a cell count was performed to obtain a final 
concentration of 1 x 10
6
 cells/ml. 
2.3.6 Flow cytometry 
Single cell suspensions from tumour tissue were prepared. 200,000 cells per tumour 
were re-suspended in 200μl of cell staining buffer and samples were incubated with 
antibodies to LY6G, CD4, CD8, CD25, CD49b, Siglecf or F4/80 for 30 minutes at 
4
o
C in the dark.  Cells were washed with cell staining buffer, centrifuged at 350 x g 
for 5 min and resuspended in 0.5ml of cell staining buffer. 2.5ug/ml of 
ViViD viability staining solution (Life Technologies) was added per million cells 
and samples were incubated on ice for 15 min in the dark. For each sample, 10,000 
to 20,000 events were recorded. The percentage of cells labelled with each antibody 
was calculated in comparison with cells stained with the isotype control antibody. 
Analysis gates for each antibody were set by using FMO (fluorescence minus one) 
controls with a threshold below 1%. The results represent the percentage of 
positively stained cells in the total cell population with a signal exceeding the 
background staining signal. Relative fluorescence intensities were measured using a 
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FACSLSRII 5 laser (UV/violet/blue/yellowgreen/red) cytometer and BD Diva 
software (Becton, Dickinson). 
2.4 Statistical analysis 
Experiments were performed a minimum of three times in triplicate. Results were 
statistically evaluated using One-way Anova with Tukeys post-test, or by students 
paired t test. Values of p < 0.001 are indicated by three asterisks (***). Values of p< 
0.01 are indicated by two asterisks (**). Values of p < 0.05 are indicated by one 
asterisk (*). Grubbs test was used to detect outliers.  
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Chapter 3 
 
 
Characterisation of IL-33 and ST2 
expression, signalling and function in colon 
cancer cells in vitro. 
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3.1 Introduction 
 
Expression of both IL-33 and ST2 has been examined in many cell types, both in 
vitro and in vivo. IL-33 is known to be robustly expressed by high endothelial 
venules in human tonsils, lymph nodes and Peyer’s patches [246]. Its ligand, ST2L, 
is expressed on the surface of macrophages, mast cells and Th2 cells [122, 247, 248], 
while sST2, in turn, is expressed by fibroblasts and both endothelial and epithelial 
cells [106, 249]. In terms of expression in the colon, in vivo studies have found both 
IL-33 and ST2L to be expressed by intestinal epithelial cells [177, 181], as well as 
macrophages and lymphocytes infiltrating the intestine [173, 177]. More specifically, 
IL-33 was shown to be localized to both the nucleus and cytoplasm of intestinal 
epithelial cells [177]. The decoy receptor, sST2, was found to be particularly 
strongly expressed in intestinal stromal cells and infiltrating regulatory T-cells [173, 
250]. Consistent with the in vivo findings demonstrating epithelial expression of IL-
33, HT29 colon cancer cells were shown to express IL-33 mRNA, although the 
transcript was not detected in CaCo2 colon cancer cells. Subepithelial 
myofibroblasts were also shown in in vitro studies to have low basal levels of IL-33, 
with expression enhanced by TNFα stimulation [178]. In contrast, few, if any studies 
have examined ST2 expression in intestinal cells in vitro. 
Studies investigating the physiological functions of the IL-33/ST2 signalling axis 
demonstrated that IL-33 plays a key role in maintaining the mucosal barrier in the 
gut. Under healthy conditions, constitutively produced, intracellular IL-33 
participates in maintaining barrier function by regulating gene expression as a 
nuclear factor. Upon damage to the barrier, for instance as a result of helminth 
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infection, nuclear IL-33 is released and functions as an “alarmin”, promoting the gut 
inflammatory response to induce parasitic clearance [251]. Once released, IL-33 has 
dual roles, initially functioning as a potent driver of Th2 immunity at the site of 
infection, and later as a T-cell-independent proinflammatory cytokine [252]. A 
second immune related pathology associated with the intestine that, in turn is also 
associated with increased IL-33 expression, is Inflammatory Bowel Disease (IBD). 
IBD encompasses two main disorders, ulcerative colitis (UC) and Crohn’s disease 
(CD). Studies examining expression of IL-33 and ST2 showed that IL-33 expression 
is upregulated in active UC and CD patients [177, 178]. In severe UC, as the 
epithelium becomes damaged and mucosal lesions form, IL-33 is secreted, and 
functions as an alarmin [179]. The pattern of ST2 expression is also altered in IBD. 
ST2 becomes depleted in intestinal epithelial cells, and is prominent in the lamina 
propria of IBD patients. Not only is the pattern of expression changed, but the 
expression of the ST2 isoforms is also modified in UC; ST2L is reduced [177], while 
sST2 is increased compared to CD and control tissue [177, 181]. The increased 
levels of IL-33 are thought to contribute to the sustained inflammatory state present 
in active IBD. SAMP1/YitFc (SAMP) mice are a murine model of CD used to 
investigate the pathogenesis of chronic intestinal inflammation. In SAMP mice IL-33 
expression was found to positively correlate with the severity of disease [177]. 
Inflammation has recently been described as an emerging hallmark of cancer. 
Consistent with this, individuals with IBD are at increased risk of developing 
colorectal cancer. This risk is specifically linked to the duration and extent of the 
inflammation [253]. However, whether IL-33 and ST2 signalling promotes 
inflammation and colon carcinogenesis is unclear.  
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Colon cancer represents the third most common cancer type worldwide, and is a 
major cause of morbidity and mortality. Thus, identifying factors that promote colon 
cancer is important. Whilst IL-33 and ST2 are known to be expressed by IECs, no 
studies to date have comprehensively investigated their pattern of expression in 
malignant IECs or colon cancer cells, nor have they characterised their cancer 
promoting abilities (e.g. capacity to induce migration and invasion), or factors that 
regulate or alter their expression in colon cancer cells. As there is an emerging focus 
on these proteins in cancer, with pro-tumorigenic roles for IL-33/ST2 reported in 
breast cancer in vivo [196], and IL-33 shown to promote migration and invasion of 
gastric cancer cells in vitro [254], the aim of this chapter is to investigate the 
potential role of IL-33 and ST2 in colon carcinogenesis. 
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3.2 Results 
3.2.1 LPS induces ST2L expression in a murine macrophage cell line  
 
Prior to investigating expression of the membrane bound form of ST2 (ST2L) in 
colon cancer, endogenous ST2L expression was examined in RAW 264.7, a murine 
macrophage cell line. This cell line was selected as a positive control, as 
macrophages are known to express high levels of ST2L in response to LPS 
stimulation [255]. Whilst ST2L expression was not observed at basal levels, it was 
seen to be upregulated upon stimulation with LPS (Figure 1). 
3.2.2 Human colon cancer cell lines express both sST2 and ST2L. 
 
As the ST2 antibody appeared to be able to detect ST2L, I subsequently examined 
expression levels of both the transmembrane (ST2L), and the soluble (sST2) forms 
of ST2 in human colon cancer cells. For this, the cell lines HT29 and SW480 were 
selected. These cells were stimulated with the pro-inflammatory stimuli LPS, TNFα 
and PGE2, for 24, 48 and 72 hours. Basal expression of ST2L was observed to be low 
in both cell lines examined, but was upregulated in response to pro-inflammatory 
stimuli, LPS, TNFα and PGE2 (Figure 2 and 3). In contrast, sST2 levels remain 
unchanged by pro-inflammatory stimuli in both of the human colon cancer cell lines 
(Figure 2 and 3).   
3.2.3 Murine colon cancer cells express both sST2 and ST2L. 
 
As I had shown that human colon cancer cells express both sST2 and ST2L (Figure 2 
and 3), protein levels of both of these ST2 variants was next examined in murine 
colon cancer cells. Similar to findings in human colon cancer cell lines, both ST2L 
and sST2 were detected in resting CT26 cells (Figure 4), with sST2 expression  
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Figure 1: Murine macrophage cell line RAW 264.7 express ST2L in response 
to LPS stimulation. Macrophages were treated for 24h with 100ng/ml LPS, prior 
to being lysed and probed with anti-ST2 antibody or anti-β-actin specific 
antibodies as indicated. Images shown are representative of three independent 
experiments. 
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Figure 2: ST2L expression was increased in HT29 colon cancer cells 
stimulated with pro-inflammatory stimuli. Colon cancer cell lines HT29 were 
stimulated with (a) LPS (100ng/ml), (b) TNFα (10ng/ml) and (c) PGE
2
 (1μM) 
for 24, 48 and 72h. Cell lysates were separated by SDS-PAGE and probed with 
anti-ST2 or anti-β actin specific antibodies as indicated. Images shown are 
representative of three independent experiments. 
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Figure 3: ST2L expression was increased in SW480 cells stimulated with 
pro-inflammatory stimuli. SW480 cells were stimulated with (a) LPS 
(100ng/ml), (b) TNFα (10ng/ml) and (c) PGE
2
 (1μM) for 24, 48 and 72h. Cell 
lysates were separated by SDS-PAGE on a 10% gel and probed with anti-ST2 or 
anti-β actin specific antibodies as indicated. Data shown are representative of 
three independent experiments.  
79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: ST2L expression was increased in CT26 cells stimulated with pro-
inflammatory stimuli. CT26 murine colon cancer cells were stimulated for 24, 48 
and 72 hours with (a) LPS (100 ng/ml), (b) TNFα (10ng/ml) and (c) PGE
2
 (1μM) 
for 24, 48 and 72h. Cell lysates were separated by SDS-PAGE and probed with 
anti-ST2 or anti-β actin specific antibodies as indicated. Data shown are 
representative of three independent experiments.  
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unchanged by stimulation with LPS, TNFα or PGE2 (Figure 4). Similarly murine 
ST2L was upregulated by LPS, TNFα or PGE2 (Figure 4). However, in murine cells 
the induction of ST2L expression by TNFα and PGE2 occurred slightly later (48h), 
than in the human colon cancer cell lines (24h) (Figure 3).  
3.2.4 Colon cancer cell lines and macrophages express IL-33 mRNA, the ligand 
for ST2L 
 
As both human and murine colon cancer cells were found to express the ST2L 
receptor, the expression of its ligand, IL-33, was subsequently investigated in these 
cell lines. Similar to experiments performed in 3.1, the murine macrophage cell line 
RAW 237.4 was initially used as a positive control for confirmation of detection of 
IL-33 expression (Figure 5a), as macrophages have previously been shown to 
produce IL-33 [256]. Expression of IL-33 mRNA was seen to be increased 5000-fold 
in RAW 264.7 cells, following LPS stimulation and 22-fold in RAW 264.7 cells 
following PGE2 stimulation (Figure 5a). IL-33 mRNA expression in both human 
colon cancer (HT29) and murine colon cancer (CT26) was also examined. Basal 
levels of IL-33 mRNA were detected in human and murine colon cancer cells. In 
HT29 cells, IL-33 expression was increased 2-fold in response to LPS and 1.5-fold 
by PGE2 stimulation (Figure 5b). In CT26 cells, IL-33 was upregulated 1.5-fold in 
response to LPS, and 1.8 fold upon stimulation with PGE2 (Figure 5c). Basal levels 
of IL-33 in all three cell lines were compared. Expression was similar in HT29 and 
RAW 237.4, while IL-33 expression in CT26 was higher ~10 fold (Figure 5d). 
3.2.5 IL-33 protein expression was not effected by pro-inflammatory stimuli in 
colon cancer cells.  
 
As IL-33 mRNA expression had been detected in colon cancer cells (Figure 5), with 
no significant changes observed upon stimulation of cells, the induction of IL-33  
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Figure 5:  Stimulation with pro-inflammatory stimuli induced the expression of  
IL-33 mRNA in colon cancer cells and macrophages.  IL-33 mRNA expression in 
(a) RAW 264.7, (b) HT29, and (c) CT26 cell lines (d) shows basal IL-33 expression 
levels in unstimulated cells. Colon cancer cells were stimulated for 4 hours with 
100ng/ml of LPS or PGE
2
 at 1μM.  Total RNA was extracted and IL-33 mRNA levels 
were measured by qPCR.  Data shown are the mean +/- SEM. Statistical analysis was 
carried out using a student t test, n=3.  
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Figure 6:  IL-33 expression was unchanged in colon cancer cells stimulated with 
pro-inflammatory stimuli. IL-33 expression was examined in (a) HT29, (b) 
SW480 and (c) CT26 cells by Western blotting analysis. Colon cancer cells were 
stimulated for 24, 48 and 72 hours with pro-inflammatory stimuli as indicated. Cell 
lysates were separated by SDS-PAGE and probed with anti-IL-33 or anti-β-actin 
specific antibodies.  Data shown are representative of three independent 
experiments.  
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protein was next determined by Western blot analysis. Western blotting for IL-33 
confirmed that HT29, SW480 and CT26 cells express basal levels of IL-33 (Figure 
6). These levels were unchanged by treatment with LPS, TNFα or PGE2, in all cell 
lines (Figure 6). 
3.2.6 IL-33 inhibits proliferation of colon cancer cells 
 
As I had demonstrated that colon cancer cells express sST2, ST2L and IL-33, I next 
wished to determine the functional role of these proteins in colon cancer cells. I 
initially investigated cellular proliferation, as sustained proliferative signalling is a 
key hallmark of cancer progression, which increases tumorigenicity [2]. Four colon 
cancer cell lines, HT29, SW480, HCT116 and CT26, were stimulated with 
increasing concentrations of IL-33 for 24, 48 hours, and changes in proliferation 
detected using the MTT assay. IL-33 was seen to suppress proliferation of all of 
these cells, with the exception of SW480 cells at 24h (Figure 7). As IL-33 did not 
increase cellular proliferation, cells were stimulated with epidermal growth factor 
(EGF), a growth factor known to increase tumour cell growth. Consistent with its 
ability to increase tumour cell growth, HT29 cells showed a 75% increase in 
proliferation when stimulated with EGF (Figure 8). SW480 cells showed a 30% 
increase in proliferation (Figure 8), while CT26 cells showed a 25% increase in 
cellular proliferation (Figure 8). This indicated that although the colon cancer cells 
did not proliferate in response to IL-33, they do proliferate in response to EGF.  
Although the MTT assay can be used as an indicator of proliferation, this assay 
specifically detects changes in the metabolic activity of the cell. Therefore, any 
impact on metabolism such as cytotoxicity, apoptosis or necrosis can also influence 
the assay. Thus, it can be difficult to distinguish between cell viability and  
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Figure 7: IL-33 suppressed proliferation of human colon cancer cells. 
Thiazolyl Blue Tetrazolium Bromide (MTT) analysis was used for evaluation of 
cell proliferation. (a) HT29, (b)  SW480 (c) HCT116 and (d) CT26 were stimulated 
with  increasing concentrations of IL-33 as indicated. After 24hr or 48hrs MTT 
solution was added to each well, 2hrs later, the media was removed, and dimethyl 
sulfoxide was added to each well to dissolve the MTT formazan crystals. Data 
shown are mean +/- SEM (n=3).  
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Figure 8: EGF induced proliferation of human colon cancer cells. Thiazolyl 
Blue Tetrazolium Bromide (MTT) analysis was used for evaluation of cell 
proliferation. HT29, SW480 and CT26 cells were stimulated with EGF 10 ng/ml as 
indicated, for 24 hrs. MTT solution was added to each well, 2hrs later, the media 
was removed, and dimethyl sulfoxide was added to each well to dissolve the MTT 
formazan crystals. Data shown are mean +/- SEM (n=3).  
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Figure 9: IL-33 does not induce proliferation of  colon cancer cells.  
Cellular proliferation was assessed by BrdU incorporation with EGF used as a 
positive control. (a) HT29, (b) SW480 and (c) CT26 cells were stimulated with 
varying  concentrations of IL-33 as indicated, and 24 hrs later the cells were labelled 
with BrdU after 2hrs of incubation, the media was removed and the cells were fixed 
and denatured, and absorbance was measured. Data shown are mean +/- SEM (n=3).  
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proliferation using this assay. To ensure that results I have observed using the MTT 
assay were truly a measurement of proliferation, I verified these results by doing a 
second specific proliferation assay, examining BrdU incorporation into cellular DNA 
during cell proliferation. The results were similar to those observed with the MTT 
assay. Incorporation of BrdU was seen to be suppressed by IL-33 stimulation in 
HT29 (Figure 9a), SW480 (Figure 9b) and CT26 (Figure 9c). Overall, the data 
suggests that IL-33 may suppress colon cancer cell proliferation.   
3.2.7 IL-33 induces migration, but not invasion of colon cancer cells 
 
As IL-33 had no effect on cellular proliferation, the ability of IL-33 to effect cellular 
migration, invasion was next investigated. Indeed the main cause of cancer death is 
due to metastasis of the primary tumour to a new site. Most commonly colon cancer 
metastasizes to the liver [257], and as such cellular migration is an important pro-
tumorigenic mechanism, required by cancer cells for sustained growth and 
progression. Cells were stimulated with increasing doses of IL-33 as indicated and 
changes in migration assessed using a modified Boyden chamber assay (Figure 10a). 
IL-33 significantly enhanced migration of HT29 cells, in a dose dependent manner, 
towards media containing 10% serum above migration observed by unstimulated 
cells, p value >0.01 (Figure 10b). IL-33 also increased migration of SW480 cells, but 
this was not significant (Figure 10c). Finally, migration was also significantly 
increased by IL-33 in CT26 cells, p-value >0.01 (Figure 10d).  
As IL-33 increased the migration of colon cancer cells towards 10% serum, in a dose 
dependent manner, the ability of IL-33 to induce invasion in colon cancer cells was 
next investigated. Invasion is an essential function underlying cancer cell metastasis. 
Invasive cells travel through basement membranes and extracellular matrices into  
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Figure 10:  IL-33 induced migration of colon cancer cells towards 10% serum 
at increasing doses. (a) Changes in cellular migration were assessed using a 
modified Boyden chamber assay. (b) HT29, (c) SW480 and (d) CT26 cells were 
stimulated with increasing doses of  IL-33 (0, 15, 30, 45 and 60 ng/ml). Data 
shown are mean +/- SEM (n=3). Statistical analysis were determined using a one-
way ANOVA 
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Figure 11:  IL-33 did not induce cellular invasion of colon cancer cells towards 
10% serum.  (a) HT29 and (b) CT26 cells were stimulated with 60ng/ml of IL-33. 
Changes in cellular invasion were assessed using a modified Boyden chamber 
coated with 100 μl of 4mg/ml Matrigel. The cells were incubated for 48 hours at 
37
o
C.  Data shown are mean +/- SEM (n=3).  
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neighbouring tissues in a complex process that involves adhesion, extracellular 
matrix degradation, proteolysis and migration. To assess the ability of IL-33 to 
induce cellular invasion, colon cancer cells were seeded on Matrigel coated 
transwells. As seen in Figure 13, IL-33 did not affect invasion of HT29 (Figure 11a) 
or CT26 cells (Figure 11b). 
3.2.8 IL-33 induces limited expression of cytokines/chemokines in colon cancer 
cells. 
The link between colon cancer and chronic inflammation is well established. 
Communication between the immune system and malignant cells can play an 
important role in tumorigenesis. This cell to cell interaction is usually via cytokines 
or chemokines, and can have far reaching effects, from recruiting immune cells that 
supply growth factors or pro-angiogenic factors, to increasing proliferative signalling 
and limiting cell death. To date, the effect of IL-33 stimulation on colon cancer cells, 
in terms of cytokine production, has not been comprehensively investigated. To 
address this, and to further our extensive characterisation of IL-33 and ST2 in colon 
cancer cells, a number of cells were stimulated with IL-33, and a panel of cytokines 
and chemokines examined (i.e. TGF-β, LTα, COX-2, IL-6, IL-8, IL-13, CXCL-8, 
VEGF, CCL2 and CXCL-1). This panel was selected for a number of reasons; TGF-
β expression is indicative of poor prognosis in CRC [258], while increased COX-2 
expression is associated with poor survival in CRC [259]. IL-6 is a key regulator in 
CRC development [260], while IL-8 is associated with migration and angiogenesis 
of colon cancer cells [261] and both have previously been shown to be activated by 
IL-33 [262, 263]. A number of chemokines were also selected (i.e. CXCL-1, CXCL-
8, IL-13 and CCL2), as IL-33 has been shown to recruit immune cells [264]. 
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In HT29 and SW480 cells, CCL2 was the only cytokine/chemokine to be induced. 
CCL2 was induced 7 fold in HT29 (Figure 12a), and 70 fold in SW480 (Figure 12b). 
Whilst several genes were not induced in the CT26 cells (i.e. IL-13, TGF-β and 
LTα), a slightly broader number of genes were found to be induced by IL-33 in these 
cells. IL-33 induced a 2 fold induction of VEGF, a 10 fold induction of CXCL1 and 
a 40 fold induction of CCL2 in CT26 cells (Figure 13). The CXCL-1 induction was 
further confirmed using increasing doses of IL-33, and was seen to occur in a dose 
dependent manner at both the mRNA (Figure 14a) and the protein level (Figure 14b).  
To ensure that the lack of changes in the transcription of the selected panel of 
cytokines and chemokines was due to the concentration of IL-33 used being too low, 
a dose response of 0 to 60 ng/ml was employed. TGF-β was selected as the output, 
as this had previously shown a lack of induction in response to IL-33 stimulation at 
15ng/ml in HT29 cells (Figure 12a). IL-33 did not increase transcription of TGF-β in 
HT29 (Figure 15a) or CT26 cells (Figure 15b) at any dose, indicating that the lack of 
transcription of the panel seen in (Figure 12 and 13) was unlikely due to the dose of 
IL-33 being too low.   
3.2.9 IL-33 activates MAPK, NFκB and AKT signalling pathways  
 
Whilst the majority of cytokines were not activated by IL-33 stimulation, CCL2 was 
activated in all cell lines. As such, I hypothesized that the activation of signalling 
pathways downstream of IL-33 may be responsible for the restricted cytokine 
induction observed. To examine this, I next investigated the ability of IL-33 to 
activate the canonical transcription factors and kinases, activated by other IL-
1R/TLR superfamily members in colon cancer cell lines, such as NF-κB and 
MAPKs. Phosphorylation of the AKT pathway was also examined, as AKT is  
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Figure 12: Stimulation of human colon cancer cells with IL-33 increased 
expression of CCL2. (a) HT29 and (b) SW480 cells were stimulated with 15ng/ml 
of  IL-33 for 4 hours . CCL2 was induced by IL-33 stimulation, while it had no 
effect on transcription of a panel of other factors (i.e. TGFβ, VEGF, LTα, COX-2, 
IL-6, IL-8, CXCL-8 or CXCL-1). Data shown are mean +/- SEM (n=3).  
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Figure 13: IL-33 induces the expression of VEGF, CXCL-1 and CCL2 in 
murine cancer cells. CT26 cells were stimulated with 15ng/ml of IL-33 for 4 
hrs. RNA was extracted and changes in cytokine/chemokine expression were 
detected by qRT-PCR. RNA was extracted and changes in expression of VEGF, 
CXCL-1, and CCL2 were detected by qRT-PCR. Data shown are mean +/- 
SEM (n=3). 
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Figure 14: CT26 murine colon cancer cell produce CXCL-1 in response to IL-
33 in a dose dependent manner.  CT26 cells treated with IL-33 for 4 hours (a) 
and IL-33 mRNA expression was examined. CT26 cells were treated with IL-33 
for 24 hours, (b) supernatants were removed and examined for CXCL-1 expression 
by ELISA. Data shown are mean +/- SEM (n=3). Statistical analysis was 
performed by one way ANOVA. 
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Figure 15: Increasing doses of IL-33 did not increase expression of TGF-β 
expression. Cells were stimulated with increasing doses of IL-33 as indicated. 
TGF-β mRNA expression was examined in (a) HT29 and (b) CT26. Data shown 
are mean +/- SEM (n=3). 
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strongly activated in many human cancers [265]. To investigate whether IL-33 was 
able to induce activation of NF-κB, phosphorylation of the NF-κB subunit p65 was 
examined in HT29 cells. p65 phosphorylation was observed 30 minutes after IL-33 
stimulation, and this was sustained until the final time point of 60 minutes (Figure 
16a), with no change in total p65 observed. To investigate MAPK activation, 
phospho-specific antibodies to JNK, ERK and p38 were used, with IL-33 stimulation 
seen to phosphorylate all of these. Phospho-ERK was observed at all-time points, 
however, the greatest phosphorylation of ERK was observed between 30 and 60 
mins (Figure 16b). Maximal phosphorylation of p38 was observed between 30 and 
60 mins (Figure 16b). IL-33 stimulation caused phosphorylation of JNK between 5-
30 mins (Figure 16b). AKT phosphorylation in response to IL-33 treatment was 
observed at 45 and 60 min (Figure 16c). These results indicate that IL-33 can 
activate NFκB, MAPK and AKT subfamilies.  
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Figure 16: HT29 cells phosphorylate the NFκB p65 subunit p65 at 30 to 60 
minutes.  HT29 cells were treated for between 0-60 mins with IL-33. Cell lysates 
were separated by SDS-PAGE and probed with anti-Phospho-65 anti-p65, anti-
Phospho-ERK, anti-ERK, anti-Phospho p38, anti-p38, anti-phospho Jnk, anti-Jnk 
and anti Phospho-Akt or anti-Akt specific antibodies as indicated. Data shown are 
representative of three independent experiments. 
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3.3 Discussion: 
 
Here I have demonstrated that colon cancer cells express ST2L, sST2 and IL-33 in 
vitro. In terms of tumorigenic processes, stimulation with IL-33 suppressed cellular 
proliferation, increased migration, but did not affect invasion of colon cancer cells. 
IL-33 induced a very limited number of cytokines and chemokines in colon cancer 
cells, in particular only inducing expression of CCL2 in human cells, and CXCL-1, 
VEGF and CCL2 in murine cells. However, IL-33 activates multiple signalling 
pathways such as AKT, MAPK and NF-κB in colon cancer cells. 
3.3.1 sST2 expression was increased in colon cancer cells compared to ST2L 
expression 
 
In this chapter, I have comprehensively examined the expression of key components 
of the IL-33/ST2 axis in colon cancer cells. I have shown that colon cancer cells 
express both sST2 and ST2L isoforms. The basal level of sST2 was observed to be 
generally higher than that of ST2L in these cells. Both ST2 isoforms are transcribed 
from the same ST2 gene (IL1RL1). However, unlike ST2L, sST2 lacks the 
transmembrane and cytoplasmic domains [71, 72, 98]. ST2 gene expression is 
controlled by two discrete promoters, a distal and a proximal promoter [104]. 
Promoter usage is cell type specific, not transcript specific, as fibroblasts initiate 
transcription of ST2 (both sST2 and ST2L) at the proximal promoter, while acute 
myeloid leukemic cells are dependent on the distal promoter mainly for ST2L, with 
less sST2 transcribed [105].  Thus, the variation in the levels of ST2 isoforms that I 
have observed in colon cancer cells is unlikely to be due to differential promoter 
usage, with the exact mechanism responsible for variation between ST2L expression 
and sST2 expression being unclear. One possibility  is  that the different levels of 
ST2 isoforms detected are due to various regulatory processes, such as 
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transcriptional regulation [114]. In a study investigating the raised levels of sST2 
produced by cardiac cells following myocardial infarction, stress or stress-activated 
cytokine release were found to be responsible for the sST2 induction [266]. 
However, further studies are required to clarify the exact mechanism of regulation of 
ST2 isoforms in colon cancer cells. 
3.3.2 IL-33 suppressed cancer cell proliferation 
 
IL-33 is an important mediator of intestinal barrier homeostasis. IL-33 is thought to 
maintain a quiescent state in barrier cells, as it is only produced when cells are 
senescent. Downregulation of IL-33 has been linked to initiation of cell proliferation 
in intestinal epithelial cells [145]. Here, I have shown that IL-33 stimulation did not 
enhance cellular proliferation of colon cancer cells in vitro. Indeed, similar to the 
findings for IL-33 in the normal intestine, these data demonstrate that IL-33 may, in 
fact, play an inhibitory role in colon cancer cell proliferation and may be 
downregulated during cellular proliferation, although changes in IL-33 expression 
during proliferation were not examined. Differences in the ability of IL-33 to 
suppress proliferation were observed between the cell lines examined, with HCT116 
cells showing less suppression of proliferation by IL-33 than HT29 cells. HT29 cells 
are isolated from a stage II adenocarcinoma, while HCT116 are stage IV. This 
suggests that cancer cells may become less responsive to the anti-proliferative effects 
of IL-33, as they increase in cancer stage. Other studies investigating the ability of 
IL-33 to alter cell proliferation demonstrated that IL-33 played opposing roles in 
cellular proliferation depending on the confluency of the cells. When IL-33 was 
added to confluent murine embryonic fibroblast cells (NIH-3T3), proliferation of the 
cells was suppressed. Conversely, when IL-33 was added after the start of cellular 
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proliferation, it enhanced cellular growth [267]. The opposing effects observed may 
be due to the role that IL-33 plays in maintaining intestinal homeostasis. When cell 
density is low, IL-33 enhances cellular proliferation, while when cells are confluent 
IL-33 suppresses proliferation. The effect of IL-33 on cell proliferation has been 
examined in other cancer cell types. In pancreatic stellate cells, IL-33 stimulation did 
not induce proliferation  [268]. Although, in contrast to this, in ovarian cancer cells, 
IL-33 stimulation increased cellular proliferation in vitro, whilst in vivo IL-33 
expression positively correlated with Ki-67 expression [269]. The variation in IL-33-
induced-proliferation between cancer cells suggests that the function of IL-33 may 
vary depending on the cancer type [269].  
3.3.3 IL-33 increased migration of colon cancer cells 
 
In contrast to the inhibition of proliferation, IL-33 was seen to enhance cellular 
migration of colon cancer cells in vitro, in a dose dependent manner, in all three cell 
lines examined. This ability of IL-33 to induce cellular migration in vitro suggests 
that IL-33 may play a role in metastasis in vivo. However, we only observed robust 
migration of colon cancer cells at very high doses of IL-33, which may not be 
physiologically relevant, as IL-33 levels in the serum of cancer patients is typically 
in the low pg/ml concentration [270]. Similarly, IL-33 induced migration of gastric 
and ovarian cancer cells [254, 269]. Furthermore, migration of ovarian cancer cells 
was reduced in response to transfection with IL-33 siRNA [269]. Contrastingly, 
transgenic expression of IL-33 was shown to attenuate tumour metastasis in the B16 
melanoma and Lewis lung carcinoma metastatic models [201]. However, the amount 
of IL-33 produced by these cells was not quantified and therefore it is difficult to 
determine if the differences observed were due to large variations in IL-33 
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concentration. Therefore, this suggests, that similar to the differences we observed in 
the role of IL-33 in colon cancer cell proliferation, IL-33 may play a dichotomous 
role in cancer cell migration depending on the origin of the cancer.   
Distinct from migration, I found that IL-33 did not promote invasion of colon cancer 
cells in vitro. In contrast to our findings in colon cancer cells, IL-33 has previously 
been shown to enhance the invasion of gastric cancer cells [271]  and human CRC 
primary cells. Following transfection with either an IL-33 or an ST2 expression 
vector, human CRC primary cells extracted from surgical samples showing enhanced 
invasion compared to untransfected cells [204]. One explanation for the differences 
seen may be due to variations in the concentration of IL-33. Transgenic ST2 
expression may also have increased the responsiveness of the cells, which could also 
account for the increase in invasiveness observed in the primary cells. The overall 
contribution of IL-33 to tumour progression remains to be directly assessed, and the 
mechanisms by which IL-33 contributes to tumour initiation and progression remain 
unexplored. 
3.3.4 IL-33 activated chemokine production by colon cancer cells 
 
Cytokines allow the rapid dissemination of signals between cells. However, 
cytokines produced in the tumour microenvironment can influence tumour 
development and progression in a number of ways, one of which is through the 
recruitment of immune cells to the tumour site. Most tumour associated macrophages 
are derived from monocytes recruited from the blood by the chemokine CCL2 [272]. 
Of the cytokines and chemokines examined, CCL2 was the only one consistently 
induced across all cell lines by IL-33. CXCL-1, a neutrophil chemotactic factor, was 
also induced by IL-33 in murine colon cancer cells. It is well established that IL-33 
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has the ability to promote inflammation, through the recruitment of immune cells 
[264]. Thus, it was not surprising that IL-33 induced the production of two immune 
cell chemoattractants. This profile of chemokine induction has also been 
demonstrated in other disease models. In a murine model of mucositis, IL-33 
treatment combined with a chemotherapeutic agent (CPT-11), increased CCL2 and 
CXCL-1 expression in WT mice, above levels seen in ST2-/- mice [273]. Similarly, in 
a fibrosis mouse model, ST2-/- mice showed decreased levels of CXCL-1 and CCL2 
in lung tissue compared to WT mice [274]. CXCL-1 is a known neutrophil 
chemoattractant and indeed, mice treated with IL-33 displayed neutrophil and 
eosinophil infiltration in the colonic mucosa [153]. In primary lung endothelial cells, 
CCL2 was also produced in response to IL-33 stimulation, sustaining chronic 
inflammation of the asthmatic airway [112]. Therefore, the increased production of 
CCL2 by colon cancer cells in response to IL-33 may lead to increased recruitment 
of macrophages to the tumour site. Macrophage infiltration is generally considered to 
be a poor prognostic indicator in cancer, although this can vary widely depending on 
the cancer types. For instance, increased macrophage recruitment is indicative of a 
poor prognosis in breast cancer [275]. However, in colon cancer it is currently 
unclear whether high macrophage infiltration is beneficial to the patient, as some 
studies have reported that TAMs appear to have anti-tumour activity and are 
associated with improved disease free survival  [45], while other research has shown 
that increased macrophage infiltration positively correlates with tumour progression 
and aggressiveness of this disease [25, 276]. Similarly, neutrophils can also 
significantly influence the tumour microenvironment in a pro-tumorigenic manner, 
as they have been shown to induce angiogenesis and metastasis [277]. However 
other reports suggest an anti-tumour neutrophil phenotype can be generated in vivo 
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[278]. Therefore, further investigation is required to determine the downstream 
effects of increased chemokine production, activated in response to IL-33 
stimulation, in the tumour cells. 
3.3.5 IL-33 activates signalling pathways common to other IL-1 family members 
 
As I have shown that IL-33 activates CCL2 and CXCL-1, I next sought to determine 
how these chemokines were activated. The CCL2 promoter contains binding sites for 
multiple transcription factors such as NF-κB subunits, AP-1, Sp-1 and the STAT 
family [279]. The CXCL-1 promoter is also regulated by numerous factors, e.g. NF-
κB subunits, poly (ADP-ribose) polymerase (PARP) and  CCAAT displacement 
protein (CDP) [280].  While selecting which signalling pathways to examine, I 
considered that, as IL-33 is a member of the IL-1 receptor family, and common to 
other family members, IL-33 signalling occurs through dimerization of the TIR 
domain of the receptor (i.e. ST2L in this case) with the co-receptor IL1RAcP. 
MyD88 is then recruited and IRAK1/2 activates TNF receptor associated factor 6 
(TRAF6), leading to activation of the MAPK pathways [281]. Therefore, I examined 
the ability of IL-33 to activate the following pathways; the MAPK pathways, due to 
the IL-1 family connection; NF-κB, as this is known to activate both CCL2 and 
CXCL1; and the PI3K/AKT pathway, due to its increased activation in human 
cancer. I observed activation of multiple signalling pathways by IL-33 in colon 
cancer cells, including activation of the PI3K/AKT and MAPK pathways (JNK, 
ERK and p38). Similar to my findings, JNK was also found to be activated by IL-33 
in gastric cancer cells [271], while both ERK and JNK were activated in ovarian 
cancer cells. P13K/Akt signalling was not investigated in that study [271]. Although 
IL-33 has previously been shown to activate PI3K/AKT signalling in endothelial 
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cells [282], this has not been shown to date in cancer cells. I have also demonstrated 
that IL-33 activated the NF-κB subunit, p65. There have been contrasting findings in 
the literature regarding the ability of IL-33 to activate NF-κB, with some studies 
showing that IL-33 can drive NF-κB activation [283, 284], while others have shown 
that IL-33 dampens NF-κB activity. For instance, nuclear IL-33 was shown to 
sequester nuclear NF-κB and suppress NF-κB activity, thereby reducing pro-
inflammatory signalling [285]. NF-κB activation has previously been shown to 
mediate expression of CXCL1 and CCL2 in ovarian cancer cells [286, 287]. 
Similarly, CCL2 was upregulated via NF-κB and JNK pathways in prostate cancer 
cells [288]. Therefore, a combination of the pathways I examined may be responsible 
for activation of CXCL-1 and CCL2, i.e. MAPK, NF- κB and Akt/P13K.  
Interestingly, I found very few other cytokines were induced by IL-33. We 
investigated a panel of ten cytokines, of which only three were seen to be robustly 
induced by IL-33. A similar absence of cytokine induction by IL-33 was observed in 
pancreatic and cardiac cells. In particular there was a lack of IL-6, IL-8 or CCL2 
induction [249, 268]. Moreover, in a murine model of sepsis, treatment with IL-33 
lowered the levels of the  pro-inflammatory cytokines, TNF-α, IL-6 and CXCL2 in 
the blood, while no increase in IL-4, IL-10 or IL-13 was detected in lung tissue post 
IL-33 treatment [289]. In the intestine, IL-33 is a known regulator of barrier function 
and homeostasis. Under homeostatic conditions IL-33 is localized to the nucleus of 
epithelial cells and has been shown to suppress pro-inflammatory gene expression 
[285]. IL-33 is thought to maintain intestinal homeostasis by limiting inflammation 
[290]. However, upon cellular damage or necrosis IL-33 is released from the nucleus 
and functions as an alarmin, inducing a pro-inflammatory response. Therefore, IL-33 
can have both pro- and anti-inflammatory functions. Indeed, under the conditions 
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examined in this chapter IL-33 may be acting to limit inflammation and this may 
explain the lack of cytokine induction observed. Given the ability of IL-33 to 
activate the MAPK, AKT and NF-κB pathways in colon cancer cells, the lack of 
cytokine induction is unclear. One possible explanation is that IL-33 also activates 
the transcription of inhibitors, such as SIGGIR [291], which may in turn dampen IL-
33 signalling, reducing cytokine output. This is a potential mechanism whereby such 
limited cytokine expression may be accomplished, although such specificity being 
achieved through targeted inhibition has not been extensively reported. Another 
possible mechanism whereby limited cytokine expression could occur in colon 
cancer cells in response to IL-33 is through modification of the genes by epigenetic 
mechanisms. IL-33 expression is linked to histone deacetylase 3 (HDAC3) enzyme, 
which regulates gene expression [139]. IL-33 was also shown to be specifically 
regulated by HDAC inhibitors compared to other IL-1 members [139]. Epigenetic 
modification may explain why so few cytokines were produced in response to IL-33 
stimulation, especially as transcription factors and pathways examined (i.e. NF-κB, 
MAPK, and AKT), were activated by IL-33. Therefore, it seems likely that the level 
of repression of transcription in response to IL-33 may be occurring through direct 
modification at the epigenetic level of inflammatory genes.  
In conclusion, this chapter has characterised expression of IL-33 and ST2 in colon 
cancer cells, identifying an anti-proliferative role for IL-33/ST2 in colon cancer, and 
showing IL-33 enhanced migration while invasion was unaltered. Furthermore, this 
research has identified that colon cancer cells stimulated with IL-33 produce potent 
chemokines and angiogenic factors, which could recruit immune cells, specifically 
macrophages and neutrophils, which can influence the immune infiltrate in the 
tumour microenvironment and the vascularisation of the tumour. Therefore, further 
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studies are required to determine whether manipulation of this pathway represents a 
potential therapeutic target in colon cancer. 
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Chapter 4 
 
The IL-33/ST2 axis modulates tumour growth and 
the tumour microenvironment in vivo 
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4.1 Introduction:  
Current research has primarily focused on the role of IL-33 and ST2 in 
chronic disorders, with IL-33 and ST2 playing a role in the pathogenesis of 
several human inflammatory diseases including IBD [177]. On commencing 
this thesis there were only two papers pertaining to the role of the IL-
33/ST2 axis in cancer, both of which examined this signalling axis in breast 
cancer [193, 194]. The first study utilised ST2
-/-
 mice and demonstrated that 
deletion of ST2 suppressed breast cancer progression and metastasis, and 
increased the number of activated natural killer (NK) cells. Furthermore, 
ST2 deletion increased the cytotoxic activity of NK cells and CD8
+ 
T cells 
and systemic Th1/Th7 cytokines [193]. A second study specifically 
implicated sST2 in metastasis, as knocking down sST2 reduced ErbB2-
induced cell motility in breast cancer cells, while cells from metastatic 
breast tumours secreted increased levels of sST2 relative to cells from 
primary tumours. Moreover, the authors demonstrated that patients with 
metastatic breast cancer had higher levels of serum sST2 compared to 
patients with primary tumours, leading to the conclusion that in breast 
cancer ST2 may serve as a biomarker of disease severity or progression 
[194].  Therefore, in breast cancer the IL-33/ST2 pathway appears play a 
pro-tumorigenic role. Subsequent studies in breast cancer also showed 
significantly higher levels of both IL-33 and sST2 in the serum of patients 
with ER positive breast cancer relative to healthy controls [195]. Moreover, 
administration of recombinant IL-33 to breast cancer-bearing mice resulted 
in accelerated tumour growth and enhanced metastasis. This was thought to 
be due to increased accumulation of immunosuppressive immune cells and 
innate lymphoid cells within the tumours, further supporting a role for IL-33 
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in promoting tumorigenesis [196]. More recently, the role of the IL-33/ST2 
signalling axis has been investigated in other cancer types. Consistent with a 
role for IL-33 and ST2 in promoting tumour cell invasion and metastasis, 
inhibition of IL-33 and ST2 in glioma cells resulted in reduced tumour 
growth, migration and colony formation in vitro, and smaller tumours in 
vivo [197].  
Other studies, however, have shown somewhat divergent effects, with IL-33 
reduced in the plasma of non-small cell lung cancer patients relative to 
controls [198], and IL-33 negatively correlating with tumour stage in 
multiple myeloma patients [199]. Furthermore, over-expression of IL-33 
potently inhibited tumour growth and metastasis in both B16 melanoma and 
4T1 breast cancer models. NK cells and CD8
+
 T cell numbers were 
increased [200]. Similarly, transgenic expression of IL-33 reduced tumour 
metastasis in a Lewis lung carcinoma and B16 melanoma model. Both the 
number and the cytotoxicity of CD8
+
 T cells and NK cells were increased in 
response to IL-33 expression [201]. 
In the previous chapter, I demonstrated that stimulation of colon cancer 
cells with IL-33 induced the expression of the chemokines CCL2 and 
CXCL-1. Thus, IL-33/ST2 signalling in colon cancer may contribute to the 
chronic inflammatory microenvironment thereby promoting tumorigenesis. 
CXCL-1 is a neutrophil chemotactic factor, while CCL2 is a macrophage 
chemotactic factor. Recruitment of such immune cells can have a potent 
influence on the tumorigenic process. For instance, depending on activating 
signals, macrophages can be polarised towards either an anti-tumorigenic 
M1 phenotype or a tumour-promoting M2 phenotype. Consistent with 
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tumour-associated macrophages (TAMs) being skewed towards an M2 
phenotype, increased numbers of macrophages can indicate a poor 
prognosis in certain cancers such as breast [292], gastric [293] and ovarian 
[293]. However, the role of TAMs in colon cancer seems to be more 
complex, with both tumour-suppressive and tumour-promoting effects being 
reported. Similarly, both pro- and anti-inflammatory effects have been 
described for tumour-associated neutrophils. Therefore, a cytokine such as 
IL-33 with the ability to influences immune cell recruitment may 
powerfully influence tumorigenesis.  
Given the variation in the expression levels of IL-33 and ST2 in CRC 
reported in the literature, combined with the IL-33 induced chemokine 
production we had observed in colon cancer cells, the aim of this chapter 
was to characterise IL-33 and ST2 expression in CRC. Furthermore, I 
wished to specifically examine expression of the different isoforms of ST2 
in human colon cancer tissue. 
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4.2 Results: 
4.2.1 Generation of stable cell lines with suppressed ST2 expression by 
stable transfection with short hairpin RNA (shRNA) encoding plasmids. 
In order to further investigate the role of ST2 in colon cancer, stable cell 
lines with suppressed ST2 expression were generated (Figure 1). CT26 
mouse colon cancer cells were selected as these cells grow in immune 
competent BALB/c mice. Moreover, I had previously shown that these cells 
express ST2L, sST2 and IL-33 (Chapter 3, figure 4 and 6). CT26 cells were 
transfected with lentivirus particles containing shRNA encoding plasmids 
designed to target the murine ST2 gene (Figure 2). In parallel, CT26 cells 
were transfected with lentiviral plasmids containing a scrambled sequence 
showing no homology to any known mammalian gene. As can be seen in 
Figure 2a, a CT26 clone transfected with shRNA against ST2, hereafter 
referred to as CT26
ST2 shRNA#1
 was generated that showed a significant 
reduction in ST2 expression (*** P < 0.001) relative to cells transfected 
with the scrambled control, CT26
scr shRNA#1
 cells, by Western blot. Although 
a number of clones were generated, this clone was selected as it showed the 
lowest expression of ST2 by Western blot. To further characterise knock 
down of ST2 expression, a functional assay was performed. In chapter 3, I 
showed that CXCL-1 is produced by CT26 cells in response to IL-33 
stimulation. Thus, CXCL-1 production in response to IL-33 stimulation was 
selected to confirm that the ST2 receptor was knocked down. IL-33 
stimulation led to a 27-fold increase in CXCL-1 production in CT26
scr 
shRNA#1 
cells (Figure 2b). In contrast, there was approximately a 4-fold 
reduction in CXCL-1 production by CT26
ST2 shRNA#1
 cells upon IL-33 
stimulation, relative to CT26
scr shRNA#1 
cells (Figure 2b). To determine  
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Figure 1: Experimental outline of the generation of CT26 stable cell lines with 
suppressed expression of ST2. CT26 cells were stably transfected with lentiviral 
particles containing either ST2-specific or scrambled control shRNA expressing 
plasmids. ST2 knockdown cells were characterised by Western blot and qRT-PCR. 
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Figure 2: Characterisation of stable cell lines generated following transfection of CT26 
cells with shRNA targeted against ST2 or scrambled control. CT26 cells were transfected 
with lentiviral particles containing either ST2-specific or scrambled control shRNA 
expressing plasmids in the presence of polybrene. Following puromycin selection, stable 
clones were generated and knockdown of ST2 expression was determined by (a) Western 
blotting with subsequent quantification by densitometry. (b) Changes in CXCL-1 production 
were determined by qRT-PCR. (c) Cell proliferation was measured by resazurin reduction. 
DMSO was added to ensure the assay could detect changes in proliferation. Values are plotted 
as Mean +/- S.E.M. n=3. *** P < 0.001. Results were statistically evaluated using One-way 
Anova with Tukeys post-test, or by students paired t test. 
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whether knocking down ST2 affected cellular proliferation, a resazurin 
reduction assay was utilised to examine the proliferation of the CT26 cell 
lines generated. Suppression of ST2 in CT26 cells (CT26
ST2 shRNA#1 
cells) did 
not alter the proliferation of these cells relative to control cells (CT26
ST2 scr 
shRNA#1 
) (Figure 2c). This indicated that reducing ST2 expression in murine 
colon cancer cells does not affect the proliferation of these cells in vitro. In 
contrast, when treated with DMSO, an amphipathic molecule, that is known 
to induce apoptosis [294], cell proliferation was substantially reduced 
(~75%), relative to untreated cells. 
4.2.2 Knocking down ST2 expression in CT26-derived tumours 
increases tumour formation and growth in vivo. 
 
In order to assess the biological effect of reducing ST2 expression on 
tumour growth, we utilised the well-characterised murine model of CT26 
colon cancer cells subcutaneously injected into the right flank of BALB/c 
mice. I first performed a preliminary study, whereby immunocompetent 
female Balb/c mice were subcutaneously injected with either CT26
scr shRNA#1
 
cells (n=4) or CT26
ST2 shRNA#1
 cells (n=4), and tumour growth was 
monitored over a period of 20 days. A separate control group were injected 
with PBS only (n=3) (Figure 3a). To determine whether tumour cell 
injection or cancer growth impacted on feeding capability, body weight and 
food consumption were measured throughout the course of the experiment. 
No differences in food consumption were observed between the CT26
scr 
shRNA#1
 and CT26
ST2 shRNA#1
 groups (Figure 4a). Moreover, no significant 
differences in body weight were detected between the groups (Figure 4b).   
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Group name Number in 
group 
Cell type inoculated 
1 4 CT26
scr shRNA#1
 
2 4 CT26
ST2 shRNA#1
 
3 3 PBS 
a) 
Figure 3: Outline of preliminary in vivo study design and tumour 
dissection. (a) Balb/c immunocompetent female mice were 
subcutaneously (s.c.) injected with 4 x 10
4 
cells in 200μl of PBS in the 
right flank.  The control group were injected with 200μl of PBS only. (b) 
Animals were sacrificed after 20 days, and harvested tumours were 
dissected as illustrated. 
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Figure 4: Food consumption and body weight was monitored, with no differences 
observed between the groups. (a) Food consumption for each group was measured twice 
weekly post injection of tumour cells. Values are displayed as average food consumption 
per mouse. (b) The weight of each animal in the study groups was monitored three times 
per week. Values are plotted as Mean ± S.E.M. 
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Tumour development was monitored over the course of the investigation. By 
day 12, all eight mice injected with either CT26
ST2 shRNA#1 
or CT26
scr shRNA#1
 
cells had developed palpable tumours (Figure 5a). However, in contrast to the 
in vitro findings, whereby suppressing ST2 expression did not alter tumour 
growth (Figure 2c), in vivo tumour growth was increased when ST2 
expression was suppressed. The cancer cells with suppressed ST2 expression 
formed tumours that grew at a faster rate in mice, than those injected with 
CT26
scr shRNA#1
 cells. Once the tumours had reached the maximum size 
(2cm
3
), all mice were sacrificed. On the day of termination, the final tumour 
volume was increased by ~85% in tumours derived from CT26
ST2 shRNA#1
 
cells relative to those derived from CT26
scr shRNA#1
 cells (p=0.026) (Figure 
5b). 
4.2.3 Ki67 expression was unchanged in CT26
ST2 shRNA#1
 tumours 
compared to CT26
scr shRNA#1
 tumours. 
  
Tumour tissue was excised and dissected according to figure 3b. Formalin-
fixed paraffin-embedded tissue sections were stained using haematoxylin 
and eosin (Figure 6a). General tumour morphology was examined and no 
differences in tumour architecture were observed. As larger tumours 
resulted from CT26
ST2 shRNA#1 
cells, compared to CT26
scr shRNA#1
 cells, 
sections were also immunostained with a Ki67 antibody, a marker of 
cellular proliferation. Ki67 staining was unchanged in CT26
ST2 shRNA#1
 
compared to CT26
scr shRNA#1
 (Figure 6b). Therefore, from these results I can 
conclude that both groups contained actively proliferating tumour cells. 
4.2.4 Generation and functional assessment of additional ST2
-/- 
CT26 
cells in vitro and in vivo. 
In order to confirm the findings of the initial study and to power the study  
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Figure 5: Suppression of ST2 expression in colon cancer cells results in increased tumour 
growth in vivo. (a) Female Balb/c immune-competent mice were s.c. injected with 4 x 10
4
 
cells into the right flank. The appearance of palpable tumours was determined by monitoring 
tumour development. Tumour growth was monitored at least twice weekly by measurement of 
tumour length (a) and width (b) using Vernier calipers. Tumour volume was calculated as ½ 
(axb
2
). (b) 20 days after tumour injection, animals were sacrificed and the final tumour 
volume recorded. Values plotted as mean +/- S.E.M. n =4. * P < 0.5,  ** P < 0.01. Results 
were statistically evaluated using a students paired t test. 
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Figure 6: Ki67 expression was unchanged in CT26
ST2 shRNA 
tumours compared to 
CT26
scr shRNA 
tumours.  Tumour tissues were excised, formalin-fixed, paraffin-
embedded and stained with (a) haematoxylin and eosin or (b) Ki67 antibody for 
histochemical analysis. Scale bar = 100μm. Images shown are representative of the 
findings obtained. 
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Figure 7: Characterisation of ST2 suppressed stable cell lines generated following 
transfection of CT26 cells with shRNA targeted against ST2 or scrambled control. (a) 
CT26 cells were transfected with lentivirus containing plasmids encoding ST2 or scrambled 
control shRNA. Knockdown of ST2 expression was determined by Western blotting and 
quantified by densitometry. (b) Changes in CXCL-1 production were determined by qRT-
PCR. Values are plotted as Mean +/- S.E.M. n=3. *** P < 0.001. 
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sufficiently for statistical analysis, a second in vivo investigation using the 
same subcutaneous murine model of colon cancer was employed. To ensure 
the results observed in the preliminary in vivo study were not just a clonal 
effect, two new stable ST2 suppressing clones were generated (CT26
ST2 
shRNA#2
 and CT26
ST2 shRNA#3
) in parallel with CT26
scrshRNA#2 
cells. Similar to 
the preliminary study, ST2 knockdown clones were selected using 
puromycin. A number of clones were generated. CT26
ST2 shRNA#2 
and 
CT26
ST2 shRNA#3
 clones were selected as they showed a significant reduction 
in ST2 expression, as assessed by Western blot analysis (p<0.001), relative 
to CT26
scr shRNA#2
 cells (Figure 7a). Knock down of ST2 expression was 
further characterised by a functional assay. IL-33 treatment led to ~30-fold 
increase in CXCL-1 production in CT26
scr shRNA 
cells (Figure 7b). In 
contrast, IL-33 stimulation of CT26
ST2 shRNA#2
 and CT26
ST2 shRNA #3 
cells led 
to just a 2 and 4-fold increase in CXCL-1 production, respectively (Figure 
7b). 
As tumour growth of CT26 cells was enhanced following suppression of 
ST2 expression in vivo in the preliminary study, and IL-33 suppressed 
proliferation in vitro in colon cancer cells (Chapter 3, figure 9), basal 
cellular proliferation was examined in the freshly generated clones. BrdU 
incorporation was measured and no significant changes were observed in 
the basal level of proliferation between the CT26
scr shRNA#2
, CT26
ST2 shRNA#2 
and CT26
ST2 shRNA #3
 cells over a 48-hour period (Figure 8a). As I had 
previously shown that migration was enhanced by IL-33 stimulation of 
CT26 cells (Chapter 3, figure 10), migration of the freshly generated clones 
towards 10% serum was also examined. However, no significant changes in  
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Figure 8: Suppressing ST2 expression did not alter proliferation or migration of colon 
cancer cells in vitro. (a) Cell proliferation of CT26
scr shRNA#2
,
 CT26
ST2 shRNA#2
 and CT26
ST2 
shRNA#3
 cells was measured by BrdU assay. (b) Migration of stably transfected cells was 
measured using a modified Boyden Chamber assay. Values are plotted as Mean +/- S.E.M. 
n=3. Results were statistically evaluated using One-way Anova with Tukeys post-test. 
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basal migration were observed between the CT26
scr shRNA#2
, CT26
ST2 shRNA#2 
and
 
CT26
ST2 shRNA #3 
cells towards 10% serum (Figure 8b). 
In order to confirm the findings of the initial study, a second in vivo study 
using the same murine model of CRC was performed. Immunocompetent 
BALB/c mice were injected subcutaneously with CT26
ST2 shRNA#2
 CT26
ST2 
shRNA#3 
and CT26
scr shRNA#2
 cells. To sufficiently power the study for 
statistical analysis, a larger number of animals were required in each group, 
i.e. n=6, except for the PBS injected control group, which contained n=3 
(Figure 9a). To investigate if tumour cell injection and growth impacted on 
feeding capability, food consumption was measure twice weekly throughout 
the course of the experiment, and remained constant among all groups 
(Figure 10a). Each mouse was weighed twice per week and no significant 
difference in body weight was detected between the tumour cell injected 
groups and those animals injected with PBS alone (Figure 10b). Tumour 
development was monitored over the course of the investigation and by day 
13, palpable tumours began to appear in all groups (Figure 11a). CT26
ST2 
shRNA#3 
derived tumours grew at a fastest rate than the other two groups and 
resulted in the largest tumours. CT26
ST2 shRNA#2 
and CT26
scr shRNA#2
 showed 
similar growth rates up until day 20, at this point tumour growth continued 
to increase in CT26
ST2 shRNA#2 
tumours, while CT26
scr shRNA#2
 tumours 
remain static (Figure 11a). The final tumour volume was two-fold greater in 
tumours derived from CT26
ST2 shRNA#2 
cells and three-fold greater in 
CT26
ST2 shRNA#3 
(p=0.0425) derived tumours, relative to those derived from 
CT26
scr shRNA#1
 cells (Figure 11b). This second independent study using two 
newly generated clones was consistent with the findings of the preliminary  
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a) 
Figure 9: Outline of second in vivo study design. (a) Immunocompetent 
female Balb/c mice were s.c. injected with 4x10
4 
tumour cells in the right 
flank. The control group were injected with 200μl of PBS only. (b) 
Tumours were dissected using a “clock” dissection method for subsequent 
processing as indicated. 
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Figure 10: Food consumption and body weight was monitored, with 
no change observed between groups.
 
(a) Food consumption for each 
group was measured twice per week. (b) The weight of each animal in the 
study groups was also monitored twice per week. (a) Values are plotted as 
g per mouse. (b) Values are plotted as mean +/- SEM. 
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Figure 11: Suppression of ST2 expression in colon cancer cells results in increased 
tumour growth in vivo. (a) Female Balb/c immunocompetent mice were s.c. injected 
with 4 x10
4 
cells into the right flank. The appearance of palpable tumours was 
determined by monitoring tumour development. Tumour growth was monitored at least 
twice weekly by measurement of tumour length (a) and width (b) using Vernier 
calipers. Tumour volume was calculated as ½(axb
2
). (b) 24 days after tumour injection, 
animals were sacrificed and the final tumour volume recorded. Values plotted as mean 
+/- S.E.M. n =6. * p < 0.05. Results were statistically evaluated using One-way Anova 
with Tukeys post-test. 
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study, suggesting that a reduction in ST2 signalling leads to increased 
tumour growth in vivo. 
Upon completion of the study, the murine tumour tissue was excised, and 
dissected as indicated in Figure 9b. As the ST2 suppressed tumours were 
increased in size compared to the scrambled control, Ki67 expression was 
also examined. This was found to be unchanged in CT26
ST2 shRNA #2 
and
 
CT26
ST2 shRNA #3 
tumours 
 
compared to CT26
scr shRNA#2 
tumours (Figure 12a), 
indicating that all tumours contained cells that were actively proliferating. 
In addition, expression of IL-33 was examined in the murine tumours. IL-33 
was found to be markedly reduced in the CT26
 ST2 shRNA#2
 and CT26
 ST2 shRNA 
#3
 tumours compared to CT26
scr shRNA#2
 tumours (Figure 12b). While the 
underlying mechanism for this decrease in IL-33 expression in vivo is 
unclear, it may be caused by a lack of positive regulation of IL-33 by ST2L 
signalling. 
In the previous chapter I had observed that IL-33 stimulation can alter 
VEGF expression in CT26 cancer cells in vitro (Chapter 2, figure 13). 
Therefore, I wished to examine if differential expression of the pro-
angiogenic factor, VEGF, was responsible for the alterations observed in 
tumour growth following suppression of ST2 expression. Expression of the 
pro-angiogenic mediator VEGF was found to be increased in CT26
ST2 
shRNA#3
 cells both in vitro (Figure 13a) and in vivo (Figure 13b) as compared 
to CT26
scr shRNA #2
 cells. However, this was not significant. Moreover, 
although, CT26
ST2 shRNA#2
 cells also showed increased tumour growth VEGF 
expression was unchanged compared to CT26
scr shRNA #2 
cells.  This suggests 
that increased VEGF expression is not responsible for the increased tumour  
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Figure 12: IL-33 expression is reduced in colon cancer tumours with reduced 
ST2 expression, while Ki67 expression is unchanged by suppressing  ST2 
expression. Tumour tissues were excised, formalin fixed and paraffin embedded. 
Murine tumour sections were immunostained using (a) anti-Ki67 or (b) anti-IL-33. 
(c) Primary antibody was omitted in the negative control. Scale bar: 100 μm. Images 
shown are representative of the findings obtained. 
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Figure  13: VEGF expression is increased in CT26
ST2 shRNA #3
 cells in vitro and in 
vivo. (a) Total RNA was extracted from CT26
scr
 
 shRNA #2,
 CT26
ST2 shRNA #2
 and CT26
ST2 
shRNA #3
 cells and changes in VEGF were examined by qRT-PCR. Data shown are mean 
+/- SEM (n=3). (b) Total RNA was extracted from excised tumours and expression of 
VEGF was examined by qRT-PCR. Results were statistically evaluated using One-way 
Anova with Tukeys post-test. 
130 
 
 
growth seen following suppression of ST2 expression. 
4.2.5 Suppression of ST2 expression does not alter colon cancer cell 
proliferation in vitro in response to pro-inflammatory stimuli. 
 
Suppression of ST2 in colon cancer cells did not alter the proliferation of 
unstimulated cells in vitro (Figure 2c and 8a), but did result in increased 
tumour cell growth in vivo (Figure 5 and 11). To investigate if pro-
inflammatory factors in the tumour microenvironment may be driving 
proliferation of the ST2 suppressed cells, cells were stimulated with PGE2, a 
pro-inflammatory prostaglandin that is commonly upregulated in colon 
cancer (Figure 14a), and LPS (Figure 14b), a potent pro-inflammatory 
cytokine that has been shown to activate MAPK pathways, which in turn 
influences proliferation [295]. Changes in proliferation were assessed by 
BrdU incorporation. No significant differences were observed between the 
CT26
ST2
 
shRNA#2
 and CT26
ST2 shRNA#3
 cells and the CT26
scr
 
shRNA#2
 control 
cells, indicating that neither of the pro-inflammatory stimuli examined were 
responsible for the increase in proliferation observed in vivo. 
4.2.6 Suppression of ST2 expression in tumour cells results in reduced 
macrophage and CD8
+
T cell recruitment in vivo. 
 
As ST2 suppressed cells did not show an increase in proliferation in 
response to pro-inflammatory mediators in vitro. I next examined the 
immune infiltrate in ST2 suppressed tumours. Tumours were excised and 
immune cell infiltration analysed by flow cytometry. Representative dot 
plots for the FACS analysis are shown in Figure 15. A number of immune 
cell populations were examined, including macrophages, neutrophils,  
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Figure 14: Suppression of ST2 expression in colon cancer cells does 
not alter their proliferation in vitro in response to pro-inflammatory 
stimuli. Cells were stimulated with (a) PGE
2 
and (b) LPS as indicated 
and changes in proliferation assessed by BrdU incorporation. Data shown 
are mean +/- SEM (n=3). Results were statistically evaluated using One-
way Anova with Tukeys post-test. 
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LY6G F4/80 CD8 
LY6G F4/80 CD8 
CT26
scrshRNA#2
 b) 
a) 
c) 
d) 
CT26
ST2shRNA#2
 
CT26
ST2shRNA#3
 
Figure 15: Tumour cells were stained with fluorochrome-labelled mAb and 
analysed by flow cytometry. (a) Dotplots showing the fluorescence minus one 
controls, which were used to set the threshold gates for the data presented in (b-d). 
Representative dot plots showing the percentage of LY6G
+ 
neutrophils, F4/80
+
 
macrophages and CD8
+
 T cells in the viable tumour cell population from (b) CT26
scr 
shRNA#2
, (c) CT26
ST2 shRNA #2
, and (d) CT26
ST2shRNA #3 
derived  tumours. 20,000 to 
50,000 events were recorded,  
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Figure 16: F4/80
+
 cells and CD8
+
 cells were decreased in the CT26
ST2 shRNA#2 
and
 
CT26
ST2 shRNA#3
 tumours compared to the CT26
scr shRNA#2 
tumours, while 
the level of CD4
+
CD25
+
 cell infiltration is unchanged. Tumours were excised and 
digested by collagen/dispase. Single cell suspensions were isolated from each 
tumour and surface stained with antibodies against (a) F4/80, (b) CD8, (c) CD4 and 
CD25.  The percentages of each cell subset were assessed by gating on forward 
scatter (FSC) populations using an Accuri C6 Flow Cytometer, and analysis was 
carried out using CFlow software. Values are plotted as Mean ± S.E.M. Each point 
represents tumour cells isolated from a single mouse. * P < 0.05. Results were 
statistically evaluated using One-way Anova with Tukeys post-test. 
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Figure 17: Eosinophils are increased in CT26
ST2 shRNA#3 
tumours compared 
to the CT26
scrshRNA#2
, with no change seen in Ly-6G
+
 and CD49b
+
 cells. 
Tumours were excised and digested with collagen/dispase. Single cell 
suspensions were isolated from each tumour and surface stained with 
antibodies against (a) CD49b, (b) Ly-6G, (c) SiglecF. The percentages of each 
cell subset were assessed by gating on FSC populations using an Accuri C6 
Flow Cytometer, and analysis was carried out using CFlow software. Values 
are plotted as Mean ± S.E.M. Each point represents a single mouse. * P < 
0.05. Results were statistically evaluated using One-way Anova with Tukeys 
post-test. 
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eosinophils, CD8
+
 T cells and NK cells. Macrophage recruitment was 
reduced in CT26
ST2 shRNA#2 
and CT26
ST2 shRNA#3
 tumours compared to 
CT26
scr shRNA#2
 tumours, with a significant reduction seen in CT26
ST2 
shRNA#3
-derived tumours, p<0.05 (Figure 16a). Suppressing ST2 also led to a 
decrease in the recruitment of CD8
+
 T-cells (Figure 16b), while CD4
+
 
CD25
+
 cell infiltration was unchanged (Figure 16c). NK cell infiltration was 
also unchanged (Figure 17a). Although I had previously shown that IL-33 
stimulation increased the neutrophil chemokine CXCL-1 (Chapter 3, figure 
13) suppressing ST2 did not affect neutrophil recruitment (Figure 17b). In 
contrast, eosinophil infiltration was increased in tumours derived from 
CT26
ST2 shRNA#3 
cells, but not in CT26
ST2 shRNA#2
-derived
 
tumours, compared 
to the CT26
scr shRNA#2
 tumours (Figure 17c). 
4.2.7 Migration of macrophages towards tumour cell supernatant is 
increased by IL-33 stimulation of the tumour cells. 
 
Given the reduction in macrophage infiltration observed in tumours derived 
from CT26
 ST2 shRNA#2 
and
 
CT26
 ST2 shRNA#3
 cells, and the ability of IL-33 
stimulation to induce CCL2 production (Chapter 3, figure 13), I next 
investigated whether there was an increase in macrophage migration 
towards supernatant from IL-33-stimulated tumour cells, relative to 
untreated tumour cell supernatant. This experiment was performed using the 
modified Boyden chamber assay, as illustrated in figure 18a. There was 
~25% increase in migration of macrophages as compared to unstimulated 
CT26 cell supernatant (Figure 18b). Consistent with the induction of CCL2 
by IL-33, a blocking antibody to CCL2 reduced macrophage migration 
towards the supernatant of IL-33-stimulated CT26 cells (* P < 0.05) (Figure  
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Figure 18: Supernatant from IL-33-stimulated tumour cells enhances 
macrophage migration, relative to supernatant from unstimulated cells.  CT26 
colon cancer cells were stimulated for 24hrs with IL-33 (15ng/ml). (a) The 
supernatant was isolated from unstimulated or IL-33-stimulated CT26 cells and 
placed in the lower chamber of the modified Boyden chamber assay. (b) Migration of 
RAW 264.7 macrophages towards the cell culture supernatant was assessed. 
Neutralising CCL2 antibody was added to the supernatant as indicated. Data shown 
are mean +/- SEM (n=3). Results were statistically evaluated using One-way Anova 
with Tukeys post-test. 
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Table 1. CRC cohort 1 patient demographics. A cohort of 24 patients with 
CRC was recruited from the Mercy University Hospital Cork. The study 
protocol, including all procedures and study populations was approved by the 
University College Cork Clinical Research Ethics Committee of the Cork 
Teaching Hospitals (ECM (3) P 3/9/2013). All samples were collected with 
patients’ informed consent.  
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Figure 19: IL-33 serum levels were lower in CRC patients than in healthy 
controls, while sST2 was unchanged. Serum was obtained from healthy 
individuals and patients with CRC, and (a) IL-33 and (b) sST2 levels determined 
by ELISA. Statistical analysis was determined using a Students paired t test. * P < 
0.05. 
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18b).  
4.2.8 Serum levels of IL-33 are slightly decreased in CRC patients 
compared to healthy controls, while sST2 levels are unchanged. 
 
As a clear biological effect was observed by suppressing ST2 in murine 
tumours, I next wished to determine if there was a correlation between the 
murine findings and human patient samples. A cohort of 24 patients with 
CRC was recruited from the Mercy University Hospital Cork in 
collaboration with my clinical collaborators, Dr. Amr Mahmoud and Dr. 
Michael Bennett. The demographics pertaining to these patients are 
contained in Table 1. Eight of these patients had received chemotherapy 
prior to surgery. I first measured the level of IL-33 and sST2 in the serum of 
CRC patients (n=24) and healthy individuals (n=15) by ELISA. There was a 
slight reduction in the level of IL-33 in the serum of CRC patients 
compared to the controls, (* P=0.0252) (Figure 19a), with no alteration seen 
in the circulating sST2 levels (Figure 19b).  
4.2.9 Expression of ST2L in CRC is lower compared to adjacent non-
tumour tissue 
 
Although serum IL-33 and sST2 levels were not vastly altered in CRC 
patients, I next wished to examine expression of both IL-33 and its receptor 
ST2L in human CRC. Initially, I examined expression of IL-33 and ST2 by 
qRT-PCR. Similar to most previous reports examining expression levels of 
ST2 at the mRNA level, I initially utilised a qRT-PCR primer to the 
extracellular region of ST2, which detects both the soluble (sST2) and the 
transmembrane (ST2L) form of the receptor. There was no change in the 
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level of transcription of either IL-33 or total ST2 between CRC and paired 
adjacent non-tumour tissue (Figure 20a and b). I subsequently utilised a 
primer specific to the intracellular portion of ST2 to examine changes in 
expression of ST2L in colon cancer. The level of ST2L mRNA was 
significantly reduced (** P=0.0067) in CRC tissue as compared to adjacent 
non-tumour tissue (Figure 20c). Alterations in expression were confirmed at 
the protein level by IHC, using antibodies directed against IL-33 and both the 
extracellular portion of ST2 (total ST2) and the intracellular region (ST2L).  
ST2L was consistently decreased in the CRC tumours compared to the 
adjacent non-tumour (Figure 21c). There was no change in the levels of either 
IL-33 or total ST2 between CRC and adjacent non-tumour tissue (Figure 21a and b).  
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Figure 20: ST2L expression is lower in colorectal cancer tissue relative to 
adjacent non-tumour tissue. Total RNA was extracted and changes in (a) IL-33, (b) 
total ST2 and (c) ST2L were detected by qRT-PCR. Statistical analysis were 
determined using a Students paired t test. ** P < 0.01. 
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Figure 21: ST2L expression is lower in colorectal cancer tissue relative to adjacent 
non-tumour tissue, while IL-33 and total ST2 expression were unchanged. 
Immunohistochemical staining for (a) IL-33, (b) total ST2 and (c) ST2L was performed 
on paraffin-embedded tumour sections, (d) Primary antibody was omitted as a negative 
control. Original magnification: 20X. Images shown are representative of the findings 
obtained. 
143 
 
4.3 Discussion 
 
In this chapter, I have shown that suppressing ST2 expression in murine 
colon cancer cells resulted in significantly increased tumour growth in 
BALB/c mice in vivo. This was associated with alterations in immune cell 
infiltration, in particular a reduction in macrophage and CD8
+
 T cell 
infiltration. Furthermore, migration of macrophages towards tumour cell 
supernatant was increased by IL-33 stimulation of the tumour cells in vitro, 
while macrophage migration was reduced by antagonising CCL2 in vitro. 
These findings were consistent with the induction of CCL2 by IL-33 in 
colon cancer cells in vitro and the reduction in macrophage populations 
observed in ST2 suppressed tumours in vivo. In human CRC patient 
samples, ST2L expression by neoplastic cells was reduced in human colon 
tumours in vivo, as compared to adjacent non-tumour tissue. Working 
concurrently, my clinical collaborator Dr. Amr Mahmoud found that protein 
expression of ST2L was lower in human tumours relative to adjacent non-
tumour tissue, and that the higher the grade of the tumour, the lower the 
expression of ST2L. Taken together this data suggests an anti-tumorigenic 
role for the IL-33/ST2 axis in colon carcinogenesis.  
4.3.1 A potential anti-tumorigenic role for IL-33 in cancer: 
 
In line with findings in this chapter, numerous recent reports have revealed 
an anti-tumorigenic role for IL-33 and ST2. In these studies, IL-33 was 
shown to promote the recruitment of immune cells known to activate an 
anti-tumorigenic immune response, such as CD8
+
 T cells [118, 200, 201]. 
CD8
+ 
T cells mediate a vital role in the defence against cancer by targeting 
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cells compromised by oncogenic transformation, as well as targeting virally 
infected cells [296, 297]. IL-33 has been observed to be increased in 
response to viral infection and to be important for the eradication of a viral 
insult, as it can differentiate CTLs into anti-viral CD8
+
 T cells [298]. IL-33 
has also been shown to synergize with IL-12 to promote CD8
+ 
T cell 
effector function, thereby protecting the host [118]. Additional evidence 
supporting a pro-tumorigenic role for IL-33 has been shown utilising both 
the B16 melanoma and the 4T1 breast cancer models. In these models, 
overexpression of IL-33 potently inhibited tumour growth and metastasis 
through the recruitment of increased numbers of NK cells and tumour 
antigen specific CD8
+
 T cells. These NK and CD8
+
 T cells showed 
increased IFN-γ production [200]. IFN-γ and perforin were important in the 
anti-tumorigenic effect, as they were increased in B16 tumours 
overexpressing IL-33. In addition, when cells overexpressing IL-33 were 
transplanted into IFN-γ-/- mice, growth inhibition was partially reversed 
[200]. In a further study utilising both lung and melanoma tumour models, 
both the number and the cytotoxicity of CD8
+
 T cells and NK cells were 
increased in response to transgenic IL-33 expression in both a Lewis lung 
carcinoma and a B16 melanoma model [201]. These authors again reported 
that the increased number of CD8
+
 T cells and NK cells was associated with 
reduced tumour metastasis [201]. Moreover, depletion of CD8
+
 T cells and 
NK cells reversed the suppression of metastasis that was observed in 
response to transgenic IL-33 expression [201]. Thus, an increase in IL-33 
either systemically, or directly in the tumour cells, resulted in decreased 
tumour growth and metastasis. Therefore, from these studies, it appears that 
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IL-33 influences tumour growth and metastasis by altering the tumour 
microenvironment, in particular by increasing CD8
+
 cell and NK cell 
infiltration. This is consistent with my findings in which I observed a 
reduction in CD8
+
 cell infiltration and increased tumour growth in ST2 
suppressed tumours. 
Similar to our findings, a recent publication demonstrated that both IL-33 
and ST2 expression were decreased with increasing tumour stage, in a large 
cohort of 713 CRC patients [202]. Other cancer types have shown similar 
patterns of circulating IL-33, as IL-33 was reduced in the plasma of non-
small cell lung cancer patients relative to controls [198], and IL-33 
negatively correlating with tumour stage in multiple myeloma patients 
[199]. Our data suggests that ST2 expression may be lost as colon cancer 
progresses. If ST2 plays an anti-tumorigenic role as the data suggests and 
promotes anti-tumour immunity, loss of ST2 as the tumour progresses may 
result in increased growth and tumorigenesis. 
4.3.2 The role of TAMs in tumorigenesis: 
 
Tumour associated macrophages (TAMs) have been shown to increase the 
proliferation of tumour cells through the secretion of growth factors and by 
promoting neovascularization [299]. In vitro findings presented here 
(Chapter 3) show that IL-33 induces CCL2 expression in colon tumour 
cells, which is a known macrophage chemotactic factor. We also 
demonstrated that suppressing ST2 expression by tumour cells results in 
decreased macrophage infiltration associated with a concomitant increase in 
tumour size. These findings suggest that a reduction in CCL2 production in 
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the ST2 suppressed cells could be responsible for the reduction in 
macrophage recruitment seen in vivo. To date three studies have reported on 
the impact of the IL-33/ST2 signalling axis on tumour-associated 
macrophage populations in tumour-bearing mice [196, 200, 300]. Similar to 
my findings, overexpression of IL-33 by fibrosarcoma cells resulted in an 
increase in F4/80
+
 TAMs in vivo. These TAMs were further classified and 
M2 subpopulations were significantly increased in IL-33 overexpressing 
tumours compared to cells containing the vector alone. Indeed, the same 
study went on to examine TAM polarization of IL-33 positive cells on an 
ST2
-/- 
background. Tumours from ST2
-/-
 mice showed reduced M2 markers 
compared to tumours grown in WT mice [300]. Although I attempted to I 
was unable to assess the phenotype of the TAMs in our studies, 
unfortunately this did not prove possible due to the low numbers of TAMs 
isolated from excised tumours. However, in contrast to our findings, two 
studies have reported that infiltration by TAMs was unchanged by 
manipulation of the IL-33 and ST2 pathway. The first study overexpressed 
IL-33 in melanoma cells and reported that TAM numbers were unaltered 
compared to WT [201]. In a breast cancer model, the number of TAMs was 
also unchanged by systemic IL-33 administration. However, these tumours 
had increased numbers of alternatively activated M2 macrophages [196]. 
This correlates with IL-33 being a known inducer of macrophage 
polarization, promoting the development of alternatively activated M2 
macrophages [301]. Unlike our study, which suppressed ST2, these studies 
either overexpressed IL-33 or administered exogenous IL-33. Therefore, the 
levels of IL-33 present could vary quite significantly. This may be an 
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important factor as other models examining immune responses induced by 
IL-33, particularly in hepatitis, have shown that higher doses of IL-33 
induced strong type 1 immune responses, while reduced IL-33 doses have 
led to immune tolerance [302, 303]. Therefore, the immune phenotype 
induced by IL-33 may be influenced by the dose or level of IL-33 present. 
Overall, these findings suggest that suppressing ST2 signalling alters the 
tumour environment through the loss of cells that promote tumour 
eradication, such as macrophages and CD8
+
 T cells. It has also been 
suggested that IL-33 could be potentially useful in immunotherapy, by 
initiating anti-tumorigenic inflammation at the tumour site to enhance the 
response rate of therapy in colon cancer by increasing the immunogenicity 
of the tumour [304]. 
4.3.3 Alternative pro-tumorigenic role for IL-33/ST2 axis: 
 
To date, most studies investigating the role of IL-33 in tumorigenesis have 
focused on breast cancer. In contrast to our findings in the colon, the IL-
33/ST2 signalling axis has been shown to promote breast cancer, as deletion 
of ST2 in BALB/c mice reduced tumour growth in a 4T1 breast cancer 
model [305]. Necrosis of the tumour was increased upon ST2 deletion and 
associated with a reduction in VEGF and was, therefore, proposed as the 
mechanism responsible for suppressing tumour growth. Necrosis may be 
associated with an increase in the anti-tumour immune response as necrotic 
cells facilitate maturation of antigen presenting cells. Consistent with this, 
administering IL-33 to mice accelerated the growth of 4T1 breast cancer 
cells by suppressing anti-tumour immunity and promoting angiogenesis 
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[193]. A pro-tumorigenic role for IL-33 was also recently reported in lung 
cancer. IL-33 was shown to enhance lung carcinogenesis by promoting cell 
death in low metastatic cells in vitro, thus, favouring the growth of more 
metastatic cells that did not express ST2L [304]. The differences between 
these findings and my results may potentially be explained through the 
different models employed, as these studies focused on IL-33 whereas our 
study did not look at IL-33 directly. Therefore, as IL-33 was not suppressed 
in my model and could still function as nuclear factor. It may be through 
this function as a nuclear factor that IL-33 exerted its pro-tumorigenic 
effect.   
The role of IL-33/ST2 in CRC is an area of ongoing research, which has 
resulted in several reports being published during the course of my PhD 
studies. Certain of these have yielded conflicting findings to our data, and 
have indicated a pro-tumorigenic role for this axis in the development of 
CRC [147, 202-204]. Some of the contrasting findings concern the 
expression levels of IL-33 and ST2 being reported in CRC. In our study, 
expression of total ST2 was unchanged compared to adjacent non-tumour 
tissue, while ST2L expression was significantly lower in human tumours 
P=0.01 (n=24). Cui et al. reported however, that total ST2 expression was 
shown to be higher in adenoma samples relative to normal control samples 
[203]. These levels then decreased from adenoma to tumour, as detected by 
both qRT-PCR and IHC. However, these authors investigated total ST2 
expression, and did not distinguish between the different ST2 variants 
[203]. Therefore, although we did not examine ST2 levels in adenoma 
patients, the CRC data presented by Cui et al. are in agreement with our 
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findings, whereby total ST2 expression was unaltered between normal 
adjacent tissue and CRC tissue. Also, similar to our findings, a second study 
showed no increase in total ST2 expression in CRC compared to normal 
tissue [147]. In contrast a third study, reported total ST2 to be increased in 
CRC samples relative to adjacent normal tissue [204]. The differences 
observed between this study and ours may be due to sample ethnicity or 
lack of discrimination between ST2 isoforms, as our observed decrease in 
ST2 expression was confined to the transmembrane bound signalling active 
L-isoform (ST2L). Indeed, to the best of my knowledge, no other study has 
distinctly examined the expression of ST2L in CRC. 
I found that the level of IL-33 expression was low in both CRC tissue and 
non-tumour tissue (n=24). Similarly, my clinical collaborator, Dr. Amr 
Mahmoud examined IL-33 expression in a cohort of 66 CRC patients and 
found IL-33 expression to be low in tumour and adjacent non-tumour tissue. 
In contrast, all of the CRC studies published to date have reported an 
increase in IL-33 levels in CRC as compared to adjacent normal tissue and 
healthy volunteers [147, 202-204]. However, between these publications 
there were variations in the level of IL-33 being reported in CRC. IL-33 
expression levels were low in two of the studies [203, 204], with any 
differences in IL-33 levels predominantly due to alterations in the level of 
IL-33 in the tumour stroma. In contrast to the low expression levels reported 
in the first two studies, further studies detected high levels of IL-33 
expression [147, 202]. It is worth noting that, one of these consisted of a 
cohort of patients that were receiving 5-FU-based chemotherapy [147]. IL-
33 is well known to be released upon cellular damage. It is possible that the 
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chemotherapeutic regimes directly affected the levels of IL-33 in these 
patients. Indeed, the low level of IL-33 seen in my study may be reflective 
of the lack of prior chemotherapy in our cohorts. A second study (n=713) 
found that IL-33 was highly expressed in low-grade tumours compared to 
high-grade tumours. Indeed, numerous studies have reported that IL-33 
expression is low in healthy colonic tissue [178, 306], consistent with its 
role as an alarmin IL-33 only induces robust inflammation when released by 
necrotic tissue [307].   
Using the AOM/DSS model of intestinal tumorigenesis, Mertz et al. 
reported that tumour growth was decreased in ST2
-/-
 mice compared to WT 
[202]. Tumour load, tumour grade and the number of tumours were also 
reduced in the absence of ST2. The combination of AOM with DSS is used 
as a model of colitis-associated cancer. DSS damages the intestinal 
monolayer inducing intestinal inflammation creating an inflammatory 
environment. This model examines the early development of adenoma 
through to carcinoma. The use of this highly inflammatory AOM/DSS 
model of colon cancer may account for some of the differences in these 
results, as our model shows much lower levels of inflammation by 
comparison. An additional study demonstrated that inhibition of the IL-
33/ST2 signalling pathway in the APC
Min/+
 mouse model of intestinal 
tumorigenesis inhibited tumour growth, induced apoptosis and suppressed 
angiogenesis in adenomatous polyps. Inhibition of the IL-33/ST2 axis 
reduced both tumour number, tumour size and mast cell infiltration into 
polyps and suppressed the expression of mast cell derived cytokines and 
proteases that promote polyposis. The authors propose that IL-33 derived 
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from the tumour epithelium promotes polyposis through the activation of 
stromal cells and the formation of a protumorigenic microenvironment 
[147]. The APC
MIN
 mouse develops polyps in the intestine and these benign 
growths transform and become malignant. These studies suggest that IL-33 
and ST2 may play a role during the initial oncogenic transformation of cells 
which would have been an event excluded from our choice of tumour 
model. An additional CRC study, in nude mice, demonstrated that 
overexpression of IL-33 in human CRC cells increased tumour growth, 
while reducing IL-33 expression inhibited growth [204]. However, as nude 
mice are unable to mount a T-cell mediated response, this suggests that T-
cells could be an important factor in our model to reduce tumour growth. T-
cells can be either tumour suppressive or tumour promoting, as determined 
by their effector functions [308]. Many factors can affect the polarization of 
Th1/Th2 cells, including the cytokine milieu in the local environment. Th1 
cells can directly kill tumour cells, while Th2 cells can promote tumour 
growth [309]. BALB/c mice are known to generate strong Th2, but weak 
Th1 responses [244]. Therefore, if a Th1 response induces the pro-
tumorigenic IL-33 response, but is absent in our model this could explain 
the variation observed between results. Other possible explanations for the 
disparity between results may be due to the specific levels of these proteins 
present in the microenvironment. In the current study, I suppressed ST2 
expression in cancer cells, while other studies employed knockout mice, but 
then introduced tumours cells expressing IL-33/ST2. IL-33 has been 
described as a double-edged sword; as it is known to have dual pro- and 
anti-inflammatory functions and therefore, at different levels it may drive 
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either pro- or anti-inflammatory immunity.  
Taken together, this chapter has shown a potential anti-tumorigenic role for 
the IL-33/ ST2 pathway in colon cancer. The data suggests that IL-33 
mediates tumour growth through the recruitment of immune cells into the 
tumour microenvironment, in particular through recruiting CD8
+
 T cells and 
macrophages. Therefore, targeting ST2L could provide potential therapeutic 
benefit for the treatment of colon cancer by priming the anti-tumour 
immune response. However, given that IL-33 and ST2 appear to have 
diverging and opposing effects, depending on the cancer type examined 
further research investigating the role of IL-33 and ST2 in cancer is 
required.  
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Chapter 5 
 
Characterisation of the role of IL-36 in colon cancer 
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5.1 Introduction 
 
The IL-36 cytokines are a recently described subset of the IL-1 family of cytokines. 
The three agonistic members of the IL-36 family, IL-36α, IL-36β and IL-36γ, all 
share a common receptor complex, which is composed of the IL-36 receptor 
(IL36R/IL1RRP2/IL1RL1) and the IL1 Receptor accessory protein (IL1RAcP). A 
biological inhibitor to this complex has also been identified, the IL-36R antagonist 
(IL-36RN). Similar to other IL-1 family members, IL-36 cytokines are important 
activators of the immune response. Recent emerging evidence has demonstrated a 
role for these cytokines in autoimmunity with dysregulated responses indicated in 
the pathogenesis of psoriasis [310], asthma [311] and obesity [236]. 
 
The function of IL-36 family members in intestinal pathogenesis was, until recently, 
largely unknown. However, it has lately become the focus of many studies and is 
currently an area of active research. Numerous studies have recently identified IL-36 
cytokines as being upregulated in IBD [222, 224, 240]. In particular, IL-36α and IL-
36γ have been highlighted as being increased in active IBD [222, 224, 240]. The 
expression pattern of these cytokines differed as IL-36γ was expressed in the nucleus 
of intestinal epithelial cells and IL-36α was expressed in the cytoplasm of CD14+ 
macrophages [224]. The IL-36RN was also found to be decreased in UC patients 
compared to normal tissue [240]. Additional evidence for a novel role for IL-36 
family members in the intestine has been demonstrated in various murine models. In 
a DSS-induced model of acute colitis, IL-36R
-/-
 mice showed reduced disease 
severity and decreased innate inflammatory cell infiltration to the colonic lamina 
propria compared to WT mice [240]. In the absence of the IL-36R, however, 
bacterial colonization by the pathogenic strain Citrobacter rodentium was increased 
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and a reduced Th1 response was observed. This suggests that IL-36 signalling is 
required for protection against pathogenic invasion, but that this response may be 
skewed in intestinal pathogenesis such as IBD.  
Recent investigations have shown that the IL-36R exerts its effect in colonic 
fibroblasts by inducing cytokine and chemokine activation which regulates the 
recruitment of immune cells to the inflamed colon [224]. Consistent with a role in 
maintaining barrier function, an additional study demonstrated that DSS-treated IL-
36R
-/- 
mice showed diminished wound healing [224]. IL-22, the barrier protective 
cytokine, was also decreased in the colon of IL-36R
-/-
 mice. This was accompanied 
by a reduction in IL-22 producing colonic neutrophils at the wound site. This 
suggests that signalling through the IL-36R promotes wound healing of the intestinal 
mucosa via IL-22 production and neutrophil infiltration [241]. While some papers 
suggest that IL-36 plays a pro-inflammatory role in IBD as IL-36 ligands are 
increased in IBD, others suggest that IL-36 promotes wound healing, as IL-36R
-/- 
mice show delayed wound healing due to reduction in neutrophil recruitment. Thus, 
this normally protective response may be skewed in intestinal pathogenesis such as 
IBD, and therefore may also be implicated in colon carcinogenesis. 
Given the involvement of other IL-1 family members in the tumorigenic process, it is 
highly likely that these novel IL-36 cytokines also play a role in cancer. A recent 
study investigating the role of these proteins in cancer identified a potential anti-
tumorigenic role for IL-36γ in breast and melanoma tumorigenesis [244]. Tumoral 
expression of IL-36γ reduced tumour growth and metastasis in both a 4T1 breast 
cancer model and a B16 melanoma model. The proposed mechanism responsible for 
this anti-tumorigenic effect was through the activation of a potent type 1 immune 
response, as increased infiltration of CD8
+
 T-cells, NK cells, γδ T-cells and T-regs 
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cells were observed in the tumour microenvironment. Both IL-12 and IFN-γ were 
also greatly increased in the IL-36γ expressing tumours. Therefore, it was proposed 
that these cytokines worked in combination with IL-36γ to induce the anti-tumour 
response observed. Moreover, IL-36γ expression was shown to inversely correlate 
with the progression of melanoma. These authors, however, did not examine the 
involvement of the other IL-36 cytokines in tumorigenesis. A second study identified 
a positive correlation between IL-36α expression and the mortality of hepatocellular 
carcinoma patients (HCC) [242]. These authors demonstrated that low expression of 
IL-36α was associated with increased tumour volume and increased TNM stage. 
Survival analysis showed that reduced expression of IL-36α was indicative of a poor 
prognosis for HCC patients. Increased tumoral expression of IL-36α was associated 
with higher infiltration of CD3
+
 and CD8
+
 T cells [242]. Given the recent 
identification of a role for IL-36 in IBD, and the recently described link between IL-
36 agonists and cancer, the aim of this chapter is to investigate the role of the IL-36 
family in colon cancer.  
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5.2 Results 
5.2.1 IL-36α and IL-36γ expression were increased in tumour tissue compared 
to adjacent tissue, while IL-36R expression was unchanged.  
 
In order to investigate the role of the IL-36R in CRC, IL-36 mRNA expression was 
initially examined by qRT-PCR in the same cohort of CRC patients utilised in the 
previous chapter. The demographics pertaining to these patients (termed CRC cohort 
1) are contained in Chapter 4 Table 1. IL-36α expression was detected in 4 out of the 
24 adjacent non-tumour tissue samples, while 11 out of 24 CRC tumours expressed 
IL-36α. Of those samples that expressed IL-36α, expression was significantly higher 
in tumour tissue compared to adjacent non-tumour tissue (p=0.0112) (Figure 1a). 
Alterations in IL-36α expression was further validated using a second cohort of 46 
patients (Table 1). IL-36α expression was investigated at the protein level and was 
found to be low in adjacent healthy tissue, but was increased in the tumour cells of 
CRC (Figure 1b). IL-36α expression was further analysed in this second cohort 
(n=46) and samples were stratified according to cancer stage by IHC (Figure 2). 
Representative images are shown in Figure 2a. A scoring system was developed, 
with the staining intensity of IL-36α in tumour epithelium categorised as negative, 
weak, moderate or strong. No correlation was observed between IL-36α expression 
and tumour stage (Figure 2b).  
IL-36β expression was next investigated and quantitative qRT-PCR analysis showed 
that IL-36β was expressed in colon cancer tissues and normal adjacent tissue. IL-36β 
was also found to be significantly increased in tumour tissue compared to adjacent 
non-tumour tissue (p=0.0474) (Figure 3a). These changes in IL-36β mRNA 
expression were not replicated at the protein level as both adjacent non-tumour tissue  
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Table 1. CRC cohort 2 patient demographics. A cohort of 46 patients with CRC was 
recruited from the Mercy University Hospital Cork. The study protocol, including all 
procedures and study populations was approved by the University College Cork 
Clinical Research Ethics Committee of the Cork Teaching Hospitals (ECM (3) P 
3/9/2013). All samples were collected with patients’ informed consent.  
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Figure 1: IL-36α expression was significantly higher in human CRC, compared to 
adjacent non-tumour tissue. (a) IL-36α mRNA expression was higher in human CRC 
tumours compared to adjacent non-tumour tissue. Total RNA was extracted and 
changes in  expression were detected by qRT-PCR. Statistical analysis was carried out 
using a student t test. P=0.0034. (b) IL-36α protein expression was examined by 
immunohistochemistry. Immunohistochemical staining was performed on paraffin-
embedded human tumour sections. Primary antibody was omitted as a negative 
control. Scale bar = 100μm. Images shown are representative of the findings obtained. 
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Figure 2: No correlation between IL-36α expression and tumour stage was observed. 
(a) Stage I to IV paraffin-embedded human CRC tumours were examined for IL-36α 
expression by immunohistochemistry No correlation was observed between IL-36α protein 
expression and CRC stage. Primary antibody was omitted as a negative control. Scale bar = 
100μm. Images shown are representative of the findings obtained. (b) Table of IL-36α 
expression by CRC stage. Tumour sections were scored as negative, weak, moderate or 
strong, according to the intensity of IL-36α staining. No correlation was observed between 
IL-36α protein expression and CRC stage.  
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Figure 3: IL-36β mRNA expression was significantly higher in human CRC, compared 
to adjacent non-tumour tissue. However, IL-36β protein expression was unchanged. (a) 
IL-36β mRNA expression was higher in human CRC tumours compared to adjacent non-
tumour tissue. Total RNA was extracted and changes in expression were detected by qRT-
PCR. Statistical analysis was carried out using a student t test, P=0.0474. (b) IL-36β protein 
expression was examined by immunohistochemistry. Immunohistochemical staining  was 
performed on paraffin-embedded human tumour sections. Scale bar = 200μm. Images shown 
are representative of the findings obtained. Primary antibody was omitted as a negative 
control. (c) The majority of tumours were negative for IL-36β expression, however 2 tumours 
showed strong IL-36β expression in the epithelium and stromal cells. 
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and tumour tissue showed no positive staining (Figure 3b). There were some 
exceptions to this, as 2/46 tumours showed strong stromal expression and some 
epithelial expression of IL-36β (Figure 3c). However, there was no unifying link 
between these tumours as they were different stages, and one patient had received 
chemotherapy while the other had not.  
IL-36γ expression was also examined, with transcription of IL-36  significantly 
increased in CRC tumours compared to adjacent non-tumour tissue (p=0.0056) 
(Figure 4a). Alterations in expression were confirmed at the protein level by IHC, 
using an antibody directed against IL-36γ (Figure 4b). IL-36γ was found to be 
strongly expressed in the colonic tumour cells of CRC tumours compared to adjacent 
non-tumour tissue. We further analysed IL-36γ expression in relation to CRC stage 
in our second cohort of patient samples and did not observe any correlation between 
IL-36γ expression and CRC stage (Figure 5). Representative images are presented.  
We also investigated expression of the IL-36 receptor antagonist (IL-36RN), which 
showed significantly higher mRNA expression in tumour tissue compared to 
adjacent non-tumour tissue (p=0.0034) (Figure 6a). Similarly, the IL-1RAcP was 
also significantly increased in tumour tissue compared to adjacent non-tumour tissue 
(Figure 6b). However, it is worth noting that the IL-1RAcP is also an accessory 
protein for other members of the IL-1R family such as ST2L. I subsequently 
examined IL-36R mRNA expression. Transcription of the IL-36R was unchanged in 
tumour tissue compared to adjacent non-tumour tissue, as determined by qRT-PCR 
(Figure 7a). Consistent with the detection of expression of IL-36R mRNA, IL-36R 
protein was expressed in epithelial tumour tissue and expression was unchanged 
between tumour tissue and adjacent non-tumour tissue (Figure 7b). Similar to the  
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Figure 4: IL-36γ expression was significantly higher in human CRC, compared 
to adjacent non-tumour tissue. (a) IL-36γ mRNA expression was higher in human 
CRC tumours compared to adjacent non-tumour tissue. Total RNA was extracted and 
changes in expression were detected by qRT-PCR. Statistical analysis was carried 
out using a student t test p=0.0056. (b) IL-36γ protein expression was higher in 
tumour tissue compared to adjacent tissue. Paraffin-embedded human CRC sections 
were immunostained with anti-IL-36γ antibody. Primary antibody was omitted as a 
negative control.  
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Figure 5: IL-36γ expression was increased in tumour tissue compared to 
adjacent tissue, but did not correlate with tumour stage. (a) Paraffin-
embedded human CRC tumours, stage I to IV were immuno-stained with IL-36γ. 
No correlation between CRC grade and IL-36γ expression was observed. (b) 
Tumour sections were scored as negative, weak, moderate or strong, according to 
the intensity of IL-36γ staining. 
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Figure 6: IL-36Ra and IL-1RAcP mRNA expression was significantly higher 
in human CRC, compared to adjacent non-tumour tissue. (a) IL-36RN and 
(b) IL-1RAcP mRNA expression was significantly higher in human CRC 
tumours compared to adjacent non-tumour tissue p=0.0034 and p=0.0001 
respectively. Total RNA was extracted and changes in expression were detected 
by qRT-PCR. Statistical analysis was carried out using a student t test. 
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Figure 7: IL-36R expression was unchanged in human CRC tissue compared to adjacent 
tissue. (a) IL-36R mRNA expression was unchanged in human CRC tumours compared to 
adjacent non-tumour tissue. Total RNA was extracted and changes in expression were detected by 
qRT-PCR. Statistical analysis was carried out using a student t test. p=0.0474. (b) IL-36R protein 
expression was unchanged in CRC compared to adjacent tissue. Immunohistochemical staining 
for IL-36R, in human CRC was performed on paraffin-embedded tumour sections. Primary 
antibody was omitted as a negative control. Scale bar = 100μm. Images shown are representative 
of the findings obtained. 
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Figure 8: IL-36R expression was unchanged in tumour tissue compared to 
adjacent tissue. IL-36R expression did not correlate with changes in tumour 
grade (a) Paraffin-embedded human CRC tumours, stage I to IV were immuno-
stained with IL-36γ. No correlation between CRC grade and IL-36R expression was 
observed. (b) Tumour sections were scored as negative, weak, moderate or strong, 
according to the intensity of IL-36R staining. 
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findings obtained with IL-36α and IL-36γ, expression of the IL-36R did not alter 
with tumour stage when assessed in 46 patients (Figure 8). Collectively, these 
findings suggest that although the IL-36R is not increased in tumour tissue, two of its 
agonistic ligands (IL-36α and IL-36γ) and the IL-36RN are significantly upregulated 
in tumour tissue, indicating that the IL-36R pathway may be relevant in colon 
cancer. 
5.2.2 Characterisation of IL-36R
+ 
cells in colonic tumours.  
 
Unlike IL-36α and IL-36γ, which showed localization to the tumour cells in the 
tumour tissue, the IL-36R was also strongly expressed in other cells in the tumour 
microenvironment. To identify and characterise these cells that strongly expressed 
the IL-36R, consecutive tissue sections were stained initially for CD45 (a protein 
marker common to all immune cell subtypes) to determine whether these cells were 
of immune origin. Positivity for both CD45 and IL-36R expression was observed in 
overlapping areas of tissue (Figure 9a). This confirmed that the IL-36R positive cells 
in the tumour microenvironment were immune derived. Macrophages have been 
shown to express the IL-36R [312]. I next examined expression of CD68, a human 
macrophage marker (Figure 9b). Indeed, some overlap in staining patterns was 
observed, indicating that some of the IL-36R positive cells in the tumour were 
macrophages. However, some cells that were IL-36R positive did not stain positive 
for CD68 expression, indicating that these IL-36R positive cells were not just 
macrophages.  
I next investigated expression of CD4 and found a significant overlap between IL-
36R positive immune cells and CD4
+
 cells (Figure 9c). Although I had initially 
suspected macrophages to be the enlarged IL-36R positive cells present in the  
169 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: IL-36R+ cells also stain positive forCD45, CD68 and CD4  
expression in human CRC tissue.  Consecutive CRC tissue sections were stained  
for the IL-36R and (a) CD45+, (b) CD68, (c) CD4, (d) CD20, (e) CD8 expression. 
Immunohistochemical staining was performed on paraffin-embedded human 
tumour sections. Areas of common staining are highlighted in red, areas of no co-
expression are labelled in yellow. Scale bar = 100μm. Images shown are 
representative of the findings obtained.  
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tumour microenvironment, T cells stimulated with IL-36γ have been shown to 
enlarge upon activation, which could explain the larger size of these immune cells 
[244]. To determine if the IL-36R positive cells were B lymphocytes, I next 
examined expression of CD20. Fewer CD20 positive cells were present in the 
tumours than either macrophages or CD4
+
 T cells, and those that were CD20 positive 
did not overlap with those cells that were IL-36R positive, indicating that B cells do 
not express IL-36R, at least in intestinal tissue (Figure 9d). As IL-36γ has been 
shown to activate CD8
+
 cells in a melanoma model, I next examined expression of 
CD8 and found very few CD8
+
 cells present in these tumours (Figure 9e). These data 
suggest that the strongly positive IL-36R cells in the lamina propria comprise both 
CD68
+
 macrophages and CD4
+
 T cells, but not B cell or CD8
+
 T cells. Dendritic 
cells have also been shown to express the IL-36R and may also be positive for IL-
36R expression. However markers for dendritic cells were not examined. 
5.2.3 Colon cancer cells express the IL-36R in vitro. 
 
As IL-36α and IL-36γ were found to be upregulated in CRC tumour tissue, I next 
wished to determine their role in tumorigenesis. Before further investigations were 
performed, I first wished to investigate if colon cancer cell lines expressed IL-36 
family members in vitro. HT29, SW480 and SW620 cells were all found to express 
the IL-36R (Figure 10a), albeit at different levels, while differential expression of IL-
36 cytokines was observed (Figure 10b-d). HT29 cells expressed all three agonistic 
cytokines. SW480 cells expressed IL-36β and IL-36γ, while none of the three 
agonistic IL-36 cytokines were detected in SW620 cells. Caco2 and HCT116 colon 
cancer cells were also examined for IL-36R mRNA expression. However, IL-36R  
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Figure 10: HT29, SW480 and SW620 express IL-36R mRNA,  IL-36α mRNA is 
expressed by HT29 cells , IL-36β and IL-36γ  mRNA is expressed by HT29 and 
SW480 cells.  (a) HT29, SW480 and SW620 cells all express IL-36R. (b) IL-36α mRNA
 
was only detected in HT29 cells. (c) IL-36β and (d) IL-36γ were detected in HT29 and 
SW480 cells. Total RNA was extracted and following cDNA synthesis, expression levels 
of IL-36 family members was determined by qRT-PCR. For comparison ΔCT values 
were normalised to expression in HT29 cells. Data shown are mean +/- SEM (n=3).  
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mRNA was not detected in these cell lines and they were excluded from further 
investigations.  
5.2.4 IL-36α, IL-36β and IL-36γ cytokines induce cellular proliferation in 
SW480 cells, whereas in HT29 cells only IL-36γ increases cellular proliferation. 
 
Once I had determined which colon cancer cell lines expressed the IL-36R, I next 
assessed the ability of IL-36 cytokines to induce cellular proliferation in colon cancer 
cell lines in vitro, using a BrdU incorporation assay. Stimulation with IL-36γ 
increased proliferation of HT29 cells above that seen in untreated cells, while 
stimulation with IL-36α and IL-36β had no effect (Figure 11a). In SW480 cell lines 
all three agonistic IL-36 cytokines strongly increased cellular proliferation in a dose-
dependent manner, with a ~50 fold increase in BrdU incorporation observed for each 
IL-36 cytokine (Figure 11b). SW620 cells are derived from the same patient as 
SW480 cells. SW480 cells are derived from the primary tumour, while SW620 cells 
are their lymph node metastatic derivatives. Unlike SW480 cells, stimulation with 
IL-36 cytokines did not induce an increase in cellular proliferation in the more 
metastatic SW620 cells (Figure 11c).  
5.2.5 IL-36 cytokines did not induce apoptosis in HT29 cells. 
 
As I had observed a reduction in proliferation in response to IL-36α and IL-36β in 
HT29 cells and a reduction in proliferation in SW620 by all three IL-36 cytokines, I 
wished to determine if stimulation with IL-36 cytokines induced apoptosis of cells 
which could account for the reduction in proliferation seen. Therefore, I next 
examined the ability of IL-36 cytokines to induce apoptosis. To this end, I 
investigated the ability of IL-36 cytokines to activate cysteine aspartic acid-specific 
protease (caspase) 3 and caspase 7 activity in HT29 cells. Caspases 3 and 7 play key  
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Figure 11: IL-36γ increased proliferation of HT29 cells. IL-36α, IL-36β and IL-36γ 
increased proliferation of SW480 cells in vitro. In SW480 cells IL-36α, IL-36β and IL-36γ 
did not increase proliferation. (a) Cellular proliferation was assessed by BrdU incorporation 
(a) HT29, (b) SW480 and (c) SW620 cells were stimulated with 25 to 150 ng/ml of IL-36α, IL-
36β or IL-36γ, 24h later the cells were labelled with BrdU. Following 16 hrs of incubation, the 
media was removed and the cells were fixed and denatured, and absorbance was measured. 
Data shown are mean +/- SEM (n=3).  
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Figure 12: Stimulation of HT29 cells with IL-36α, IL-36β and IL-36γ did not 
increase caspase 3 and 7 activity compared to untreated cells. (a) HT29 cells were 
stimulated with IL-36 ligands at 150ng/ml for 4.5 hours at 37
O
C. Staurosporine (1μM) 
was used as a positive control for apoptosis. Caspase activity was measured 
fluorescently and readings were taken at 1hr, 2hr and 3hr. IL-36 cytokines did not 
increase apoptosis of HT29 cells.  This data was obtained from two independent 
experiments. Data shown are mean +/- SEM (n=2).  
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Figure 13: Stimulation of cells with IL-36α, IL-36β and IL-36γ did not 
significantly increase migration of colon cancer cells towards 10% serum. 
Utilising a modified Boyden chamber assay, serum starved HT29 cells were seeded 
in the upper chamber and stimulated with IL-36α, IL-36β and IL-36γ at 150ng/ml for 
16 hours. Cells migrate towards the 8 μm membrane, attracted by the 10% serum 
enriched media. (b) Migration of cells towards 10% serum was utilised as a positive 
control. Data shown are mean +/- SEM (n=2).  
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effector roles in apoptosis in mammalian cell lines [313]. No increase in caspase 3/7 
activity was observed in response to IL-36 stimulation. Staurosporine was utilised as 
a positive control (Figure 12). This suggests that IL-36 does not influence colon 
cancer cell line growth through the induction of apoptosis. 
5.2.6 IL-36 cytokines did not induce migration of HT29 colon cancer cells. 
 
To investigate whether IL-36 cytokines have the ability to promote cell migration, a 
key step in tumour metastasis, I next performed a migration assay to determine 
whether IL-36 cytokines have the ability to promote the migration of colon cancer 
cells in vitro. HT29 colon cancer cells were stimulated with IL-36 cytokines as 
indicated and changes in migration were assessed using a modified Boyden chamber 
assay (Figure 13a). Migration towards 10% serum was examined as a positive 
control (Figure 13b). IL-36 cytokines did not enhance the migration of colon cancer 
cells (Figure 13c). Therefore, it appears IL-36 cytokines do not directly induce 
migration of colon cancer cells. 
5.2.7 Chemokines CXCL-1, CCL2 and CCL20 were produced in response to 
IL-36α and IL-36γ stimulation in HT29 human colon cancer cell lines. 
 
As the immune cells in the tumour microenvironment can be potent drivers of either 
pro-tumorigenic or anti-tumorigenic immune responses, which can either promote or 
inhibit tumour growth, I next wished to investigate whether IL-36 cytokines could 
alter the tumour microenvironment through the recruitment of immune cells. 
Therefore I investigated the ability of IL-36 cytokines to induce chemokine and 
cytokine production by colon cancer cells. As SW480, SW620 and HT29 cells been 
shown to express the IL-36R (Figure 10a), they were stimulated with IL-36α, IL-36β 
and IL-36γ at increasing doses and changes in transcription of cytokines and  
177 
 
 
 
 
Figure 14: Neither IL-36α, IL-36β or IL-36γ increased expression CXCL-1, CCL-
2, CCL-20 or IL-8 in SW480 cells. SW480 cells were stimulated with increasing 
doses of IL-36α, IL-36β and IL-36γ cytokines for 4h. Total mRNA was then extracted 
and following cDNA synthesis expression of the cytokines (a) CXCL-1, (b) CCL-2, 
(c) CCL20 and (d) IL-8 were examined. IL-36 cytokines did not induce CXCL-1, 
CCL2, CCL20 or IL-8 activation in SW480 cells. Data shown are mean +/- SEM 
(n=2).  
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Figure 15: Neither IL-36α, IL-36β or IL-36γ increased production of CXCL-1, 
CCL2, CCL-20 or IL-8 in SW620 cells. SW620 cells were stimulated with increasing 
doses of IL-36α, IL-36β and IL-36γ cytokines for 4h. Total mRNA was then extracted and 
following cDNA synthesis expression of the cytokines (a) CXCL-1, (b) CCL-2, (c) 
CCL20 and (d) IL-8 were examined. IL-36 cytokines did not induce chemokines or IL-8 
activation in SW620 cells. Data shown are mean +/- SEM (n=2).  
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Figure 16: IL-36α and IL-36γ increased expression of CXCL-1, CCL2, CCL20 and 
IL-8 in HT29 cells in a dose dependent manner. HT29 cells were stimulated with 
increasing doses of IL-36α, IL-36β and IL-36γ cytokines for 4h. Total mRNA was then 
extracted and following cDNA synthesis expression of the cytokines (a) CXCL-1, (b) 
CCL-2, (c) CCL20 and (d) IL-8 were examined. Data shown are mean +/- SEM (n=2).  
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chemokines were examined by qRT-PCR. IL-36 cytokines failed to induce 
expression of CXCL1, CCL2, CCL20 or IL-8 mRNA in SW480 and SW620 cells 
(Figure 14a-d and 15a-d). In contrast, IL-36α and IL-36γ, but not IL-36β induced 
CXCL-1 (Figure 16a), CCL2 (Figure 16b), CCL20 (Figure 16c) and IL-8 (Figure 
16d) in HT29 cells. This is similar to findings recently published by Nishida et al. in 
which they found increased secretion of CXCL-1, CXCL-2, CXCL-3, CXCL-6 and 
CXCL-8 by HT29 cells in response to IL-36α and IL-36γ stimulation, but not by IL-
36β stimulation [314]. It is worth noting that although all three colon cancer cell 
lines expressed the IL-36R, SW480 and SW620 cells expressed the receptor at much 
lower levels compared to HT29. Indeed, SW480 cells expressed ~3-fold lower IL-
36R expression compared to HT29 cells, while SW620 cells expressed ~10-fold less 
IL-36R mRNA expression compared to HT29 (Figure 10a). 
Taken together, this data suggests that IL-36α and IL-36γ expression may be 
upregulated in colonic tumours. These ligands in turn may induce chemokine 
production by the tumour cells, thereby recruiting immune cells. This pro-
inflammatory response may alter the immune populations in the tumour 
microenvironment, either promoting or inhibiting tumour growth. 
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5.3 Discussion 
 
The current work was initiated after the recent surge in studies describing the role of 
IL-36 cytokines in IBD. Moreover, a study by Wang et al. has recently shown that 
IL-36γ expression by tumour cells reduces both melanoma and breast tumour growth 
[244]. As no studies to date have investigated the role of IL-36 in CRC, I first 
analysed human CRC tumour samples for expression of IL-36 cytokines. I found 
both mRNA and protein for IL-36α and IL-36γ were increased in CRC compared to 
adjacent normal tissue. In contrast, IL-36R expression was unchanged at both the 
protein and the mRNA level. IL-36R expression was shown to be strongly positive 
on infiltrating CD4
+
 and CD68
+ 
immune cells. To investigate whether IL-36 
cytokines influenced the growth of colon cancer cells, we examined in vitro cellular 
proliferation and found all three IL-36 cytokines increased proliferation of SW480 
cells. In addition, IL-36γ also strongly induced proliferation of HT29 colon cancer 
cells. Finally, we demonstrated that IL-36α and IL-36γ induced strong expression of 
CXCL-1, CCL2, CCL20 and IL-8 in HT29 cells in a dose dependent manner. Taken 
together, these data show that certain IL-36 cytokines are increased in colon cancer 
and that tumour cells may respond to IL-36 ligand stimulation in terms of an increase 
in proliferation and an induction of chemokines. 
5.3.1 IL-36 cytokines are increased in colon cancer: 
 
IL-36 cytokines and IL-36R are expressed by normal epithelial cell types such as 
keratinocytes and bronchial epithelial cells [231, 237, 315], however, they have not 
previously been investigated in colon cancer. Here we have demonstrated that IL-
36α and IL-36γ mRNA expression were increased in tumour tissue compared to 
adjacent non-tumour tissue. Indeed, protein expression of these cytokines was 
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similarly increased in CRC tissue by IHC. Other studies investigating the role of IL-
36α in cancer demonstrated that IL-36α is expressed in hepatocellular carcinoma 
(HCC), but also in normal hepatocytes (n=163). Poorly differentiated tumours 
showed lower IL-36α expression compared to well-differentiated tumours. 
Furthermore, IL-36α expression was shown to significantly correlate with tumour 
size and tumour stage. These authors suggest that decreased IL-36α expression may 
contribute to tumour progression [242]. However, we also examined IL-36α 
expression in relation to tumour stage, and no correlation was observed. The 
variations observed may be due to different tumour types, or the low numbers in our 
cohort.  
I also observed an increase in IL-36β mRNA expression in colon tumours compared 
to normal adjacent tissue. However, when I attempted to confirm the increase in IL-
36β by IHC, I failed to detect IL-36β expression in the majority of CRC tumours. 
There were some exceptions as 2/46 tumour samples which showed IL-36β 
expression in the epithelium and even stronger IL-36β expression was observed in 
surrounding stromal cells. These data confirmed that our antibody was working 
correctly and could detect IL-36β. Other studies have also reported that they were 
unable to detect IL-36β protein expression in colon tissue from IBD patients [224], 
although these studies were also unable to detect IL-36β mRNA [240]. Therefore, 
this data suggests that although IL-36β mRNA is expressed in CRC tumour tissue, it 
is not translated into protein. It is possible that IL-36β mRNA does get translated 
under inflammatory conditions, as a study by Boutet et al. detected IL-36β protein 
expression in patients with Crohn’s disease (CD) [214]. Similarly, elevated levels of 
IL-36β have been detected in mice treated with DSS [224]. However, our data 
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suggest that the low level of inflammation in CRC is not sufficient to induce 
translocation of IL-36β mRNA. 
We also showed that IL-36γ was expressed by the colonic tumour epithelium and 
was increased in tumour tissue compared to adjacent non-tumour tissue. Consistent 
with our findings, data available in online databases reported IL-36γ expression in 
the following cancer types; lung cancer, head and neck cancer, oesophageal cancer 
and CRC (Oncomine database) [244]. We also investigated if IL-36γ expression 
correlated with tumour progression and no association was observed (n=46). 
However, a recent study reported that IL-36γ expression was reduced in later stage 
lung cancer, compared to earlier stages of the disease [244]. Although our study was 
made up of primary tumours, expression of human IL-36γ available online from the 
NCBI GEO database was analysed by Wang et al. They reported that IL-36γ 
expression was lower in metastatic melanoma compared to primary tumours [244]. 
We may need to increase our study numbers and in particular examine IL-36γ 
expression in metastatic samples. However, this research did not compare IL-36γ 
expression levels in healthy tissue compared to tumour tissue as we did. Taken 
together, the two studies to date examining IL-36α and IL-36γ in cancer suggest that 
IL-36 cytokine expression is lost with tumour progression. This may suggest that IL-
36α and IL-36γ expression is important in the early stages tumorigenesis. Further 
studies are required to identify whether IL-36 cytokine expression is also altered in 
other tumour types.  
5.3.2 IL-36R expression on tumour infiltrating immune cells: 
 
Unlike IL-36α and IL-36γ which were predominantly localised to the tumour 
epithelium, the IL-36R was expressed by both tumours cells and immune cells in the 
184 
 
tumour microenvironment. This staining pattern was also observed by Russell et al. 
in IBD where they describe the IL-36R
+
 cells as lamina propria mononuclear cells 
(LPMCs) [240]. I wished to characterise these IL-36R
+
 cells, and demonstrated that 
these (CD45
+
) immune cells also expressed CD4
 
or CD68
 
markers, but not CD20 or 
CD8 protein markers. In support of our findings, Vigne et al. showed that the IL-36R 
was constitutively expressed in CD4
+
 T cells, and macrophages, but not CD8
+
 T 
cells or B cells [211]. Although we did not examine DCs they were also found to be 
positive for IL-36R expression in this study [211]. 
Current research has shown that murine CD4
+
 cells constitutively express the IL-
36R, and IL-36 cytokines have been shown to regulate CD4
+
 T helper responses in 
mice [208, 209].  Macrophages were also found to express the IL-36R [211]. This is 
consistent with current research which demonstrates that macrophages express the 
IL-36R [211]. IL-36 signalling can influence TAMs in different ways depending on 
their phenotype, IL-36R mRNA was higher in M2 than M1, indicating that M2 
polarized TAMs may be more responsive to IL-36 stimulation, with M2 
macrophages shown to produce IL-6, IL-8 and TNF-α in response to IL-36 
stimulation [312]. Our data suggests a subset of the IL-36R positive cells identified 
in our colon cancer sections are macrophages and CD4
+ 
T cells. Ideally to further 
investigate the phenotype of these IL-36R
+
 immune cells I would obtain fresh human 
CRC biopsies to identify the immune cells by flow cytometry. However, as we were 
unable to access fresh human CRC biopsies our only alternative was formalin-fixed 
tissue. Without further analysis it is difficult to determine the exact phenotype of 
these cells. Taken together, this data suggests that CD4
+
 T cells and macrophages in 
the colon tumour microenvironment express the IL-36R. 
5.3.3 IL-36 induces proliferation of colon cancer cells: 
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We showed that IL-36γ induced proliferation of HT29 and SW480 cells in vitro. 
Consistent with this finding IL-36γ has been shown to induce proliferation in other 
cell types including keratinocytes and immune cells such as Th1 cells [209, 316]. Of 
the cell lines examined, SW480 cells were the most responsive to IL-36 cytokines as 
they showed an increase in proliferation in response to all three IL-36 cytokines. 
SW620 cells were the least responsive as cellular proliferation was not increased in 
response to any of the three IL-36 cytokines. SW480 and SW620 cells are derived 
from the same patient; SW480 cells were cultured from the primary tumour, while 
SW620 cells were derived from a lymph node metastasis. Metastatic cells can 
become less reliant on outside influences to induce proliferation as they can make 
many of their own growth factors [3]. It is also possible that genetic mutations and 
other inherent changes from primary to metastatic tumour may be responsible for the 
inability of IL-36 cytokines to induce proliferation in the SW620s. Moreover, 
SW620 cells showed ~5-fold lower IL-36R expression compared to SW480 cells. 
This may also make them less responsive to stimulation with IL-36 cytokines.  
The effect of IL-36 cytokines on tumour proliferation in vivo was investigated in two 
recent studies [242, 244]. Tumours derived from hepatocellular carcinoma cells 
overexpressing IL-36α were shown to grow more slowly compared to controls in 
vivo [242]. Increased IL-36γ expression by both melanoma and breast cancer cells 
also reduced tumour growth in vivo [244]. The proposed mechanism responsible for 
this anti-tumorigenic effect was an increased inflammatory response. Increased 
infiltration of NK cells, γδ T cells, CD8+ T cells and T-reg cells were observed, while 
the number of immunosuppressive MDSCs was reduced. In these studies, 
proliferation of IL-36γ expressing cells was measured in vitro and no alteration in 
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proliferation was observed compared to cells containing the vector alone. This is in 
contrast to our findings in which IL-36γ increased proliferation in two of the three 
colon cancer cell lines examined. Variations in results may be due to the different 
cancer types utilised. Similar to the B16-F10 melanoma cells, SW620 cells were not 
altered in response to stimulation with IL-36 cytokines. Both of these cell lines are 
highly metastatic and this may contribute to the lack of response observed. Our data 
combined with data from Wang et al. suggests that in vitro IL-36 cytokines do not 
directly suppress cellular proliferation [244]. However, in vivo IL-36 signalling may 
suppress tumour cell growth indirectly through the recruitment of anti-tumorigenic 
immune cells.  
5.3.4 IL-36 induces chemokine and cytokine induction: 
 
Studies have shown that IL-36R signalling promotes an inflammatory response 
through the recruitment of immune cells [244]. We showed that IL-36α and IL-36γ 
induced the production of cytokines and chemokines in HT29 colon cancer cells, 
with CXCL-1, CCL2, CCL20 and IL-8 being strongly induced in a dose dependent 
manner. Our findings were confirmed in a recent study by Nishida et al. who showed 
that HT29 secreted increased levels of CXCL-1, CXCL-2, CXCL-3, CXCL-6 and 
CXCL-8 in response to IL-36α and IL-36γ stimulation, but not IL-36β stimulation 
[314]. Stimulation of colonic subepithelial myofibroblasts (SEMFs) with IL-36α and 
IL-36γ also resulted in significantly increased CXCL-1 and CXCL-2 production 
[314]. These data suggest that it is not just tumour cells that respond to IL-36 
cytokines, surrounding tissue can also respond. Intestinal epithelial cells and colonic 
explants stimulated with IL-36γ also induced expression of CXCL-1 and CXCL-2 
neutrophil-recruiting chemokines [241]. This induction of neutrophil chemotactic 
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factors correlates with IL-36R
-/-
 mice showing reduced neutrophil recruitment in 
DSS induced wounds [241]. This is also consistent with an overall reduction in 
immune cells observed in IL-36R
-/-
 mice compared to WT mice [240].  
In the tumour microenvironment increased chemokine production can induce the 
recruitment of immune cells, such as neutrophils by CXCL1, macrophages by CCL2, 
and lymphocytes by CCL20. As IL-36α and IL-36γ expression is increased in the 
tumour epithelium, this may signal through an autocrine loop, resulting in increased 
chemokine production by the tumour cells and increased immune cell recruitment to 
the tumour. However, these infiltrating immune cells, such as macrophages, 
neutrophils and lymphocytes can have both pro-tumorigenic and anti-tumorigenic 
activity as determined by the tumour microenvironment. Thus, the increase in 
immune cell infiltration caused by an increase in chemokines in response to IL-36 
signalling could potentially be beneficial to the host and suppress tumour growth. 
Alternatively, in an immunosuppressive environment the anti-tumour activity of 
immune cells may be inhibited. This is consistent with loss of IL-36 cytokine 
expression as the tumour progresses [242, 244], thereby inhibiting recruitment of 
immune cells to the tumour microenvironment, contributing to an 
immunosuppressive phenotype. 
An in vivo experimental model is essential to further advance our knowledge in this 
field, as this could provide an insight into the role of the IL-36R in colon cancer to 
clearly define whether it has pro- or anti-tumorigenic effects in CRC. It would also 
determine whether IL-36 represents a novel target for therapeutic intervention. To 
investigate the role of IL-36 in the immune cells an AOM/DSS model in IL-36R
-/- 
murine model could be utilised to examine tumour growth in the absence of the IL-
36R. To investigate the role of tumour-expressed IL-36R in tumorigenesis, colon 
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cancer cells in which expression of the IL-36R has been silenced could be injected 
into WT mice and compared to growth of WT cells. These experiments could 
determine if tumour growth is affected by a reduction in systemic IL-36 signalling or 
if tumour mediated IL-36 expression influences tumorigenesis. Alternatively, an 
inducible model could be utilised to show the effects of inhibiting IL-36 signalling 
once the tumour has developed. This model would be more representative of a 
therapeutic intervention. Finally, to characterise the role of the individual IL-36 
cytokines in tumorigenesis, IL-36α, IL-36β and IL-36γ could be silenced 
individually in tumour cells and the growth of these tumour cells investigated. IL-
36α-/-, IL-36β-/- and IL-36γ-/- mice have all been generated and an AOM/DSS model 
in each of these mice could be utilised to identify the role of each of these cytokines 
on immune cell recruitment [317]. These experiments would help to definitively 
clarify the role of IL-36 in colon cancer.  
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6.0 Final discussion and Future Perspectives: 
 
6.1 Alternative roles of IL-1 family members in disease 
IL-1 family cytokines are key pro-inflammatory mediators involved in the activation 
of inflammation, which can eliminate infection and repair damaged tissue. However, 
if this inflammatory response becomes dysregulated, these cytokines can contribute 
to the pathogenesis of many diseases, such as IBD and rheumatoid arthritis [318-
320]. Various studies, however, support protective roles for several IL-1R family 
members in disease. Data presented in this thesis suggest that the cytokine IL-33, 
whilst normally pro-inflammatory and an important initiator of several inflammatory 
diseases, may play a protective role in colon cancer. Indeed, similar to data presented 
here, a divergent protective role for the normally highly pro-inflammatory cytokine 
IL-18 has also been shown in the intestine. IL-18 was shown to be upregulated in the 
intestine of patients with active Crohn’s disease and it was initially suggested that 
blocking IL-18 may be beneficial for intestinal inflammation [321]. However, IL-18 
was later found to be protective in intestinal epithelial cells and involved in 
maintaining epithelial integrity and protecting against bacterial translocation [322, 
323]. Consistent with this, mice deficient in IL-18 and caspase-1 subunits are at 
increased risk of developing colitis in a model of acute experimental colitis [322, 
323]. A protective role for IL-18 in the intestine was further demonstrated by the 
administration of IL-18, which rescued colitis in inflammasome-deficient mice 
[324]. Another IL-1 family member that has been found to display anti-inflammatory 
activity is IL-37. This cytokine has been shown to reduce inflammation associated 
with colitis [325]. This may have therapeutic implications for both IBD and CRC 
patients. In addition to activating an inflammatory response, protective roles for both 
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IL-33 and IL-36 have also been reported in intestinal epithelial repair, mucosal 
wound healing and intestinal homeostasis. IL-33 in particular has been shown to play 
a dual role in the gut, as it can polarize cells towards a Th2 immune response while 
also inducing Th1-mediated inflammation [326]. These studies highlight the 
divergent roles that IL-1 family members play in health and disease, with members 
appearing to mediate alternative functions depending on the system examined, and as 
such may explain why ST2 signalling mediated anti-tumorigenic effects in our colon 
tumour model. 
Another potential explanation as to why we saw an anti-tumorigenic role for ST2 in 
cancer may have been the fact that we examined the role of these proteins in colon 
cancer. Colon cancer differs to most other tumour types, as colon cancer develops in 
the presence of the intestinal microbiota. Indeed, the composition of the intestinal 
microbiome is known to be altered in colon cancer [327]. Whether these alterations 
pre-dispose to the development of colon cancer however is unclear. It was initially 
suspected that intestinal pathogens may play a potential role in colon carcinogenesis 
[328]. These findings were later confirmed in CRC-predisposed mice [329]. This is 
similar to other cancers, such as gastric cancer, which has been linked to exposure of 
the pathogen, Helicobacter pylori [330]. In CRC, dysbiosis of the microbiota may 
promote carcinogenesis through remodelling of the microbiome to become pro-
inflammatory, thereby promoting epithelial transformation and driving 
carcinogenesis [331]. A second theory proposes that intestinal ‘driver bacteria’ cause 
DNA damage and tumorigenesis, which enables the proliferation of ‘passenger 
bacteria’ in the tumour microenvironment [332, 333]. However, to date, it is not 
fully understood whether the dysbiosis observed in CRC is as a result of 
tumorigenesis or the cause of the CRC [331]. 
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Both IL-33 and IL-36 cytokines are expressed at barrier tissues and are important 
factors in regulating the anti-microbial defence in the gut. For instance, IL-33 has 
been shown to be  protective against the pathogen S. typhimurium [334]. This 
suggests that IL-33 and possibly IL-36 may play potential roles in regulating the 
epithelial immune response to specific microbes, thereby impacting on the 
composition of the intestinal microbiota. This could potentially favour the growth of 
specific bacteria that may be either pro- or anti-tumorigenic [335]. The gut 
microbiota in turn, has been implicated in regulating IL-36γ and IL-33 expression. 
Germ-free DSS-treated mice failed to express IL-36γ compared to conventionally-
housed DSS-treated mice [241]. Similarly, the intestinal microbiota is implicated in 
driving IL-33 expression, as IL-33 expression is reduced in germ-free mice 
[336].The role of the microbiota in CRC is becoming an area of intense research and 
in the future may present a novel therapeutic approach for patients with this disease. 
Therefore, the involvement of both IL-33 and IL-36 in the interaction between the 
microbiota and colon tumour cells merits further investigation to determine if their 
manipulation could be of therapeutic benefit to patients. It is possible, therefore that 
interactions between the IL-1 cytokine family and the microbiota may determine 
whether these proteins exert either a protective or an inflammatory response. 
6.2 Development of IL-1 family members as new therapeutic strategies in 
cancer 
The immune system is inextricably linked to the pathogenesis of CRC, as supported 
by the number of retrospective examinations carried out on the immune infiltrates of 
resected CRC tumours [337-339]. Cancer immunotherapy has recently shown great 
potential as a novel anti-cancer therapeutic approach. As IL-1 family cytokines are 
key pro-inflammatory mediators, several studies have investigated whether 
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manipulation of IL-1R family signalling is of therapeutic benefit in inflammatory 
diseases such as cancer. IL-1 has been associated with pro-tumorigenic effects when 
expressed by tumour cells or in the tumour microenvironment [340]. However, 
administration of recombinant IL-1α and IL-1β resulted in anti-tumorigenic effects 
in experimental models [341-343]. This anti-tumour response was observed when 
the recombinant IL-1 was administered during the initial stages of tumour 
development. Both IL-1α and IL-1β reduced metastasis and increased overall 
survival [344]. However, IL-1 treatment resulted in systemic toxic effects in vivo 
[344]. To overcome these side effects other therapeutic approaches have utilised 
encapsulated IL-1α, which forms microspheres which are slowly released. This 
resulted in reduced tumour growth and increased survival [345]. However, as it 
appears there is a short window in which IL-1 can be of therapeutic benefit, this may 
not be clinically relevant to patients presenting with tumours.  
Anti-tumour vaccines developed utilising irradiating tumour cells require an 
adjuvant to enhance a spontaneous anti-tumour response. IL-1α and IL-1β have also 
been investigated as to their efficacy to perform this function and were found to 
function as systemic adjuvants when injected within 10 days of the irradiated tumour 
cells. When IL-1 was administered following tumour cell vaccination, 70-100% of 
mice became tumour free, while mice that had received the vaccination alone were 
0-20% tumour free [346].  IL-18 has also been shown to enhance the activity of 
adjuvants such as IL-12 [347]. 
IL-33 and IL-36 may also prove to have therapeutic potential in the treatment of 
cancer. IL-33 has been shown to be strongly expressed in many tumour types such as 
breast [348], head and neck [349] and colon [350]. However, when further 
investigated, increased IL-33 expression was found to be localised to the tumour 
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stroma in cells such as cancer-associated fibroblasts. Indeed, the cancer cells showed 
lower IL-33 expression when compared to normal tissue [348-350]. However, IL-33 
is an ‘alarmin’, and thus a reduction in its expression in tumour tissue may be in part 
responsible for immune tolerance towards these tumour types [351]. This reduction 
could contribute to lower immunogenicity of cancer cells, while stromal cell 
expression of IL-33 may mediate immune suppression and tumour progression 
through the recruitment of MDSC and T reg cells [352]. This suggests that high 
doses of IL-33 could potentially reverse the immune-suppressive tumour 
microenvironment. This is consistent with our findings, which suggest that 
therapeutically administering IL-33 directly to the tumour cells would drive an anti-
tumorigenic effect. In many cancers, systemic IL-33 is also increased [353-355]. 
Therefore, alternatively, reducing systemic IL-33 levels using anti-IL-33 antibodies 
to reduce systemic IL-33 could also be investigated as an anti-cancer therapy. 
Therefore, the manipulation of IL-33 could potentially vary depending on its 
expression levels in the tumour or systemically.  
 Regarding IL-36, only two studies to date have investigated the role of IL-36 in 
cancer, with both showing that IL-36 promotes anti-tumour immunity. In this study I 
have demonstrated that IL-36α and IL-36γ expression is increased in colon cancer 
compared to adjacent non-tumour tissue. Furthermore, stimulation of colon cancer 
cells in vitro with IL-36α and IL-36γ increased expression of chemokines 
responsible for recruiting immune cells into the tumour microenvironment. Future 
studies examining the role of IL-36 in colon cancer will determine if IL-36 family 
members are targets for future cancer therapy due to their ability to activate an anti-
tumour immune response. As this receptor has three agonistic ligands, IL-36α, IL-
36β and IL-36γ, these individual ligands may have different functions. In particular 
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IL-36β did not induce chemokine expression in colon cancer cells and may have an 
alternate role to the other two IL-36 ligands. 
One of the findings of this thesis was the reduction in CD8
+
 T cell recruitment 
observed in vivo when we suppressed ST2 expression in tumour cells. Other studies 
have shown that overexpression of IL-36α in hepatocellular carcinoma and IL-36γ in 
melanoma resulted in increased numbers of CD8
+
 T cells recruited to the tumour site 
in vivo. T cells are central to anti-tumour immunity as they can recognize and target 
antigens expressed on the surface of tumour cells that have been altered due to 
genetic or epigenetic changes. In CRC tumours, CD8
+
 T cells are associated with a 
better prognosis [356]. Increased numbers of CD8
+
 T cells are strongly associated 
with decreased risk of recurrence of CRC and improved survival
 
[357, 358]. The 
presence of these effector T-cells is more important than naıve T-cells in reducing 
the risk of relapse and improving survival. The prognostic significance of CD8
+
 T 
cells and the ability of both IL-33 and IL-36 to alter the levels of these cells suggest 
that both of these proteins may have potential in future cancer immunotherapies. 
Existing immunotherapy regimens target checkpoint molecules such as PD-1 & 
CTLA4, but this requires a spontaneous anti-tumour immune response. Given the 
potential ability of IL-33 and IL-36 to modulate CD8
+
 T cell levels, they could be 
utilised to increase the immunogenicity of tumours to encourage the breaking of 
immune tolerance to tumour antigens. To do this IL-36γ could be delivered directly 
to the tumour site through antibody-cytokine fusion or the use of an oncolytic virus. 
IL-36γ could also be utilised as an adjuvant to enhance tumour vaccination. 
Therefore, both IL-36 and IL-33 cytokines may represent a mechanism to break 
immune tolerance, reversing the immune suppression observed in many tumour 
microenvironments, thus enabling the hosts’ immune response to target the cancer 
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cells. Further work in this field is necessary, however, to establish the therapeutic 
impact of IL-33 and IL-36. Studies such as these would enhance the findings of this 
thesis, which demonstrated that IL-33 may play a protective role in tumorigenesis 
and that both IL-33 and IL-36 signalling can increase chemokine production, which 
may have therapeutic implications for the treatment of colon cancer. 
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Appendix 
 
A. Table of Primers 
Gene Species Direction Sequence (5’ to 3’) 
β-actin Human F ATTGGCAATGAGCGGTTC 
R GGATGCCACAGGACTCCA 
β-actin Mouse F AAGGCCAACCGTGAAAAGAT 
R GTGGTACGACCAGAGGCATAC 
CCL2 Human F TCAAACTGAAGCTCGCACTCT 
R GTGACTGGGGCATTGATTG 
CCL2 Mouse F TCACTGAAGCCAGCTCTCTCT 
R GTGGGGCGTTAACTG 
COX2 Human F CTTCACGCATCAGTTTTTCAA 
R TCACCGTAAATATGATTTAAGTCC 
CXCL-1 Human F TCCTGCATCCCCCATAGTTA 
R CTTCAGGAACAGCCACCAGT 
CXCL-8 Human F GAGCACTCCATAAGGCAC 
R ATGGTTCCTTCCGGTGGT 
GAPDH Human F AGCCACATCGCTCAGACAC 
R GCCCAATACGACCAAATC 
IL-1RAcP Human F CCCTCTCAGCTTCCCAAGA 
R GGGCAAGAGTGAGGCTTCTA 
IL-6 Human F CAGGAGCCCAGCTATGAACT 
R AGCAGGCAACACCAGGAG 
IL-8 Human F AGACAGCAGAGCACACAAGC 
R ATGGTTCCTTCCGGTGGT 
IL-36RN Human F GAGGAACAGGCAGACTCCAC 
R CAATGCCGAGTCCTTCATTC 
IL-13 Mouse F CCTCTGACCCTTAAGGAGCTTAT 
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 R CGTTGCACAGGGGAGTCT 
IL-33 Human F AGCAAAGTGGAAGAACACAGC 
R CTTCTTTGGCCTTGTGTTGG 
IL-36β Human F TGAAGACATCATGAACCCACA 
R TGTCGAGAATCACGAATAGCA 
IL-36R Human F GCGTGTCAAGCCATACTGAC 
R CCTCCATATCCAGCTCTTTCTG 
IL-36γ Human F AAGTGACAGTGTGACCCCAGT 
R GGATTCTGGATTCCCAAATAAA 
LTα Human F CAGCCCCGACCTAGAACC 
R TTTATAGAGGAAGCGGCAGTG 
LTα Mouse F TTCGACTGAAACAGCAGCAT 
R GGTGGTGTCATGGGGAGA 
ST2 Human F TTGTCCTACCATTGACCTCTACAA 
R GATCCTTGAAGAGCCTGACAA 
ST2L Human F GGGAGAGATATGCTACCTGGAGA 
R CGCCTGCTCTTTCGTATG 
TGF-β Human F ACTACTACGCCAAGGAGGTCAC 
R TGCTTGAACTTGTCATAGATTTCG 
TGF-β Mouse F CTCCGCTGACTCTCTTGG 
R AGGTGGTCGCAAAAACGA 
TNFα Human F CGCTCCCCAAGAAGACAG 
R AGAGGCTGAGGAACAAGCAC 
VEGF Human F TTAAACGAACGTACTTGCAGATG 
R GAGAGATCTGGTTCCCGAAA 
VEGF Murine F AAAAACGAAAGCGCAAGAAA 
R TTTCTCCGCTCTGAACAAGG 
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B. Table of Antibodies 1 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody 
against 
Supplier Cat no. Monoclonal/ 
polyclonal 
Clone Reacts 
with 
WB IHC Migration 
IL-33 Enzo Life Sciences 
(Farmingdale, NY.) 
ALX‐804‐840 M Nessy-1 Human, 
mouse 
1:500   
ST2L Novus (Littleton, CO), NBP1-85251 P  Human    
ST2 Abcam (Cambridge, UK), ab25877 P  Human 
Mouse 
1:500 1:400  
ST2V Millipore 06-1116 P  Human    
CCL2 R&D Systems (Minneapolis, 
MN). 
AF-479-NA P  Mouse   1.5 ng/ml 
Rabbit anti-
mouse Ig/HRP 
Dako Corp (Carpinteria, CA).   P0260 P  Mouse 1:10,000   
Goat anti-rabbit 
Ig/HRP 
Dako Corp (Carpinteria, CA).   P0448 P  Rabbit 1:10,000   
β-actin Sigma Aldrich (St Louis, MO) A5441 M AC-15 Human 
mouse 
1:10,000   
IL-36R Abcam ab180894 P  Human 
mouse, 
rat 
 1:2000  
IL-36α Abcam Ab180909 P  Human  1:2000  
IL-36β Novus NBP1-83892 P  Human  1:100  
IL-36γ LifeSpan BioSciences (Seattle) LS-C338023 M 2F4 Human  1:300  
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C. Table of Antibodies 2 
 
Pre-diluted antibodies 
Antibody targeting Supplier  Catalogue number Specificity 
CD4 (SP35) Ventana (Arizona, USA) 7904423 Human 
CD8 (SP57) Ventana 790-4460 Human 
CD20 (L26) Ventana 760-2531 Human 
CD45(RP2/18) Ventana 760-2505 Human 
CD68 (514H12) Leica (Newcastle Upon 
Tyne, UK) 
PA0273 Human 
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D. Table of Reagents  
Reagent Supplier Catalogue 
number 
Species Concentration 
WB Migration 
TNF-α PeproTech (Rocky Hill, 
NJ), 
300-01A Human 10ng/ml  
LPS Invivogen (San Diego, 
CA 
O111:B4 Human 100ng/ml  
PGE2 Cayman Company (Ann 
Arbor, MI 
14810  Human 1 μM/ml  
IL-33 ProSpec (East 
Brunswick, NJ). 
 
CYT-425 Human  15-60 ng/ml 
IL-33 ProSpec 
 
CYT-655 Mouse  15-60 ng/ml 
IL-36α Biolegend , Inc. (San 
Diego, CA). 
551602 Human 25 -150 ng/ml 100ng/ml 
IL-36β ProSpec CYT-159 Human 25 -150 ng/ml 100ng/ml 
IL-36γ Biolegend 711602 Human 25 -150 ng/ml 100mg/ml 
CCL2 Biolegend 576502 Mouse  40 ng/ml 
 
